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Abstract 
The incidence of CF related diabetes is on the rise as patient life expectancy 
continues to improve. Sugars elevated in diabetics include glucose, fructose, 
and mannose. These sugars, in addition to mannitol (recently approved as an 
inhaled osmolyte) are the basis for this study, aimed at assessing the impact 
these clinically relevant sugars have on virulence in Burkholderia multivorans. 
B. multivorans is a member of the Burkholderia cepacia complex (Bcc), and is 
the most frequent cause of Bcc infection in CF patients.  
Using an exopolysaccharide-deficient knockout in macrophage and 
Galleria mellonella infection models, biofilm formation, and adhesion assays, 
this study has identified exopolysaccharide-dependent and -independent 
phenotypes. Sequencing of B. multivorans C1576, a CF outbreak isolate, 
identified three putative adhesins in clinical isolate C1576 but not present in the 
sequenced environmental strain ATCC17616. Mannitol promoted adhesion and 
enhanced expression of these adhesins. This study characterised these 
adhesins and assessed the distribution within other clinical and environmental 
isolates of B. multivorans and the Bcc.  
Additionally, transcriptomic profiling of B. multivorans assessed the sugar 
response and EPS regulation during growth on clinically relevant sugars. Where 
possible, links were made between phenotypic studies and transcriptome data. 
B. multivorans EPS derived from fructose and mannitol was subjected to 
composition analysis using mass spectrometry, and assessed for biological 
activity.  
Still relevant to CF related diabetes, the ability of some members of the 
Bcc to bind insulin was assessed. Results indicated that a minority of strains 
bound insulin. Furthermore, by using flow cytometry cell sorting and 
fluorescence microscopy, results also showed only a small number of cells 
within a given population that bound insulin. In all, this study has added to the 
knowledge base of B. multivorans but more work is needed to fully understand 
virulence strategies exploited by this CF pathogen. 
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1.1 Cystic Fibrosis  
1.1.1 Epidemiology and distribution 
Over 50,000 individuals world-wide are afflicted with Cystic Fibrosis (CF) 
(81). CF is the most common autosomal recessive heritable disease in 
Caucasians, though it has also been detected in many ethnic groups. In the 
U.K., at least 9,000 people are affected with CF, influenced by a relatively 
isolated population due to ancestry and geography (25,63). The carrier rate for 
the CFTR mutation that causes CF is one in twenty five people in the U.K (81).  
1.1.2 CFTR mutation: disease characteristics and consequences 
The underlying genetic cause for CF is mutation of a large gene located 
on chromosome seven. The gene encodes a protein for an ABC-transporter, 
which forms chloride-ion channels, the Cystic Fibrosis Transmembrane 
Conductance Regulator or CFTR (100,160,163). More than 1,000 CF-causing 
CFTR mutations have been identified. Severity of disease is dependent on the 
type of mutation. The most commonly identified CFTR mutation worldwide, 
found in 70 % of CF patients, is the F508del (a phenylalanine deletion at 
position 508)(81). Variations of CFTR mutations can manifest as protein 
misreads and total or partial loss of CFTR functionality.  
The CFTR gene and encoded CFTR protein were structurally and 
biologically characterised previously (62,147,160). The CFTR protein is 
normally responsible for regulation of chloride. Defective chloride transport in 
CF disease manifests itself as negative impacts on sweat, digestive liquids and 
mucus regulation of sodium and chloride ions across epithelial cells. The 
leading cause of morbidity and mortality in CF patients is respiratory function 
decline and failure caused by chronic lung disease, stemming from thick 
dehydrated mucus obstructing the pulmonary airways and creating an 
environment hospitable to recurrent and chronic bacterial infection.  
Dysfunctional CFTR mis-regulate anion-mediated fluid secretion, 
resulting in significant sodium ion conductance through channel pores in the cell 
membrane. This results in thick and dehydrated airway surface liquid (ASL) and 
mucus, which in turn reduces function of the innate immune system and 
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hydration of the ASL to enable the body to clear away mucus (81). This creates 
a naturally inviting environment for respiratory pathogens and opportunistic 
pathogens to establish infection (82). 
The human body is set up with intrinsic barriers to infection; these 
include the skin, gut, lungs, eyes and nose (224). These built-in barriers prevent 
pathogens from crossing epithelia and colonising human tissue. Surface 
epithelia, such as alveolar epithelia lining the human respiratory tract, provide 
mechanical, chemical and antimicrobial barriers to infection (67,224).Several 
aspects of mucosal immunity have been linked to the dysfunctional CFTR 
chloride channels on the apical surface of epithelial cells in CF patients (194). 
These include the inability to regulate ion flux to sufficiently hydrate the ASL, 
and altered pH of the lung which can impact on the efficacy of the immune 
system such as antibodies, anti-oxidants, and proteases (224). These are 
affected by the inability to hydrate or regulate hydration of the ASL by cilliary 
movement and chloride channel functionality (148). Several components of the 
innate immune system response with particular relevance to CF include 
mucociliary clearance, which in healthy individuals enables grabbing and 
trapping of bacterial pathogens in the airway mucus while epithelial cilia beat 
upwards, resulting in movement of mucus and bacteria out of the body (67). 
Cilliary movement is diminished in CF patients due to the presence of 
dehydrated mucus (188). In addition to mucociliary clearance, antimicrobial 
peptides released by epithelial cells can interact and disrupt bacterial 
membranes (24). Some (but not all) antimicrobial peptides (also found in the 
ASL) are found to be still functional in the CF environment, but a synergistic 
effort of antimicrobials, defensins, lysozymes and other components are key for 
a complete immune response (181). When these and cilliary movement are 
functioning, they can effectively clear potential pathogens from the respiratory 
tract (152). In cystic fibrosis patients, fibrosis of the respiratory tract, along with 
reduced cilliary movement and dehydrated and altered pH of the ASL, leads to 
a decline in pulmonary health and creates an environment that favours chronic 
microbial colonisation of airways (177). Respiratory failure due to long-term 
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microbial respiratory disease is the leading cause of morbidity and mortality in 
patients with CF (31,63).  
Mutated CFTR proteins impact salt absorption in the CF respiratory tract 
(224). This high salt conductance results in a highly electronegative lumen liquid 
with high salt content and ceases transport of useful ASL contents, potentially 
interfering with natural antibiotics, such as antimicrobial peptides, defensins and 
lysozymes (181,182). This is the basis for the CF high salt hypothesis. The high 
salt hypothesis states that normal ASL contains low levels of salt as a result of 
salt absorption in excess of water. Though the airway epithelium is water 
permeable, salt is retained in thin surface films by a combination of surface 
tension and impermeant osmolytes. In CF, salt is poorly absorbed resulting in 
excessively salty ASL that disrupts functionality of mucosal antimicrobial 
peptides and neutrophil functions (78,226,231). Key features of the high salt 
model are the lack of a significant shunt for chloride conductance. Of central 
importance are the CFTR channel role and a switch from isotonic volume 
absorption to hypertonic salt absorption, and no role for the epithelium sodium 
channel  
The contrasting theory to the high salt hypothesis is the low volume 
hypothesis (224). Low volume of the ASL liquid could be linked to the chloride 
ion regulatory role of the CFTR channel. The low volume hypothesis suggests 
the isotonic fluid absorption in the CF airway is decreased due to low chloride 
and high sodium transport (103). This depletes the ASL volume and dehydrates 
the mucus, leading to an infection-prone environment (26). The low volume 
hypothesis suggests normal ASL has salt levels approximately equal to 
blood/plasma and would not inhibit innate immune system components (103). In 
CF, the removal of CFTR inhibition of epithelium sodium channels results in 
abnormally elevated isotonic fluid absorption which depletes the ASL and 
reduces mucociliary clearance. Key features of the low volume model are the 
parallel pathway for chloride ions via shunt pathway(s) and inhibition of 
epithelium sodium channels via mutated CFTR. 
1.2 Cystic fibrosis microbiology 
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As discussed in the previous section, numerous impaired defences exist 
within the CF lung that pre-dispose CF patients to infection, making “The 
microbiology of lung disease in patients with CF is a sub-specialty unto itself” 
(188). Due to the immune compromised environment in CF lungs they are ideal 
locations for numerous different opportunistic microbes to establish chronic, 
debilitating polymicrobial respiratory infections. organisms such as Haemophilus 
influenzae and Staphylococcus aureus, infecting patients with CF first (188), 
followed by the most dominant CF pathogen  Pseudomonas aeruginosa, 
acquired later (188). Fungal infections are also more diverse than previously 
known in CF lung disease, with Aspergillus fumigatus and Candida albicans  
(131) most frequently isolated. It has also been established that viruses such as 
the rhinovirus play a role in the CF respiratory tract (101). Although perhaps not 
the most frequent cause of CF lung disease, the focus of this thesis are 
members of the Burkholderia cepacia complex, a group of organisms found 
ubiquitously in the environment but also cause debilitating and unpredictable 
disease outcomes in CF patients (11,82,108). The polymicrobial nature of the 
CF respiratory tract means that this list of organisms is only the tip of the 
iceberg, and for full discussion on the microbial community-based nature of the 
CF lung, the Sibley et al. review is recommended (177).  
1.2.1 Treatment options for CF lung disease 
Treatments and therapies continue to improve quality and length of life 
for CF patients. Due to the diminished impaired immune response in the CF 
lung, frequent courses of antibiotics and respiratory therapies are key aspects 
of CF respiratory disease treatment. Opportunistic microbial pathogens that 
colonise CF respiratory tracts are treated with inhaled or intravenous courses of 
antibiotics. Antibiotics, drugs aimed to restore the ASL, mucolytics to thin mucus 
and instigate coughing, and/or respiratory therapy are a few of the many 
treatments for CF disease management. These treatments can aid in reduction 
of the bacterial load or infection but often do not eradicate the infecting 
organism completely (136,165). In fact, many CF pathogens are inherently 
resistant to many antibiotics available, adding to the difficulty in eradicating 
infection. 
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1.2.2 CF lung respiratory disease and the Burkholderia cepacia complex 
One group of bacterial opportunistic pathogens that are inherently 
resistant to antibiotics are organisms of the Burkholderia cepacia complex 
(Bcc). Some members of the Bcc are problematic opportunistic bacterial 
pathogens of the CF lung. The Bcc are a group of at least 17 closely related 
species (see Table 1.1) for detailed breakdown of species, identification and 
general characteristics). 
Table 1. 1 Taxonomy of members of Burkholderia  and members of the Burkholderia cepacia 
complex (Bcc). Information gathered from recent relevant reviews summarising most up-to-date 
published information on current Burkholderia species relevant to the cystic fibrosis lung disease 
research undertaken in this thesis. 
Species name Characteristics Characteristics in CF Date 
identified/References 
B. cepacia Environmental Not highly represented in 
CF infections 
1950,1997 (125,207,214) 
B. multivorans Infrequently 
isolated from 
environment 
Most frequently isolated 
from CF patients in most 
record-keeping countries; 
patient-to-patient 
transmission, epidemic 
strains described 
1997 (22,114,125,207) 
B. cenocepacia Commonly found 
in environment 
(rhizosphere) 
Second most frequent 
cause of Bcc CF disease; 
patient-to-patient 
transmission 
1997,2003 
(120,125,128,187,207) 
B. stabilis Infrequently 
isolated from 
environment, 
genome stable 
Important but not 
prevalent in CF patients 
1997,2000 (125,207,208) 
B. vietnamiensis Commonly found 
in environment 
(rhizosphere) 
Infrequent infection of CF 
patients 
 1995,1997 
(114,124,207,207) 
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B. dolosa one isolate from 
environment 
Almost exclusively 
cultured in CF infections;  
2001,2004 (22,48,213) 
B. ambifaria Commonly found 
in environment 
(rhizosphere) 
Infrequent infection of CF 
patients 
2001 (49,125,150) 
B. anthina Environmental 
and clinical 
isolates 
Infrequent infection of CF 
patients 
2002 (206) 
B. pyrrocinia Environmental 
and clinical 
isolates 
Infrequent infection of CF 
patients 
2002 (206) 
B. ubonensis Environmental 
(soil) and clinical 
isolates 
Nosocomial infection 2000,2008 (210,228)  
B. latens  Infrequent infection in CF 
patients, Non –CF 
infections 
2008 (210) 
B. difusa Environment (soil, 
water) 
Infrequent infection in CF 
patients, Non –CF 
infections 
2008 (210) 
B. arboris Environmental 
(soil, water, 
horticulture, 
industrial 
contaminant) 
Infrequent infection in CF 
patients, Non –CF 
infections 
2008 (210) 
B. seminalis Environment 
(Soil, sugar cane, 
rice,  
Infrequent infection in CF 
patients, Nosocomial 
2008 (210) 
B. metallica Few known 
isolates 
Infrequent infection in CF 
patients 
2008 (210) 
B. contaminans Environment 
(Soil) 
Infrequent infection in CF, 
Non-CF (blood)  
2009 (209) 
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B. lata Environmen (Soil, 
flower, river) 
Infrequent infection in CF, 
Non-CF (spinal fluid) 
2009 (209) 
 
 Bcc infections of CF airways is most commonly associated with chronic 
infection and a gradual deterioration in lung function, and are consistently 
identified as an independent risk factor for mortality among CF patients 
(94,95,118). 4-7 % of patients with CF are infected with a species of the Bcc. B. 
cenocepacia and B. multivorans are the most frequently isolated Bcc species 
associated with CF respiratory infections, together accounting for approximately 
70 % of Bcc infections (119). A summary of the significant Bcc infections and 
their ranking order in frequency of isolation from CF patients is listed in Table 
1.2 prevalence of species as presented in recent reviews).  
Table 1.2 Bcc infections and the relative importance/frequency of isolation from CF patients. 
Ranking order of most prevalent Bcc strains known to cause lung disease in CF patients, based on 
current literature available.  
Species  Prevalence of infection in CF patients Reference 
B. multivorans  Most prevalent Bcc species isolated from CF patients 
reported in USA/Europe (e.g. ~65% of Bcc cases in 
U.K.)  
(80,119,143) 
B. cenocepacia  Second most significant cause of Bcc CF infection (e.g. 
~20% of Bcc cases in U.K.) 
(80,119) 
B. gladioli** Primarily a plant pathogen can cause chronic infection in 
CF patients. ~15 % of USA Bcc CF infections; poor 
outcome predictor post lung transplant.  
As above and 
(44,157,223) 
B.vietnamiensis ~5 % of Bcc CF infections reported in the USA; shown to 
clear in Bcc co-infection following antibiotic treatment. 
(80,119,124) 
B. dolosa Rare CF pathogen; known patient-to-patient spread (80,116,119) 
Other Bcc 
species 
 Make up 3 % of recorded Bcc CF infections in USA, 
another 3 % are unidentified Burkholderia.  
(77,111) 
*Percentage of total referred Bcc cases in CF patients ** Not a member of the Bcc complex but closely related to the 
Bcc species, an emerging problem especially amongst CF lung transplant patients (REF).  
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 Until recently, B. cenocepacia was the most commonly isolated species 
associated with epidemic spread among CF patients. As a consequence, B. 
cenocepacia has received the most research attention, resulting in the 
identification of numerous putative virulence determinants (122). However, B. 
multivorans has recently surpassed B. cenocepacia in incidence of respiratory 
infection amongst CF patients in the United States (119) and several other 
countries (30,50,80,143), but in comparison to B. cenocepacia, very little is 
known about the virulence mechanisms and strategies used by B. multivorans 
within the CF host.  
B. multivorans, like B. cenocepacia, can also be associated with patient 
to patient transmission and septic infection (22,222,230), though hospital 
segregation practice has considerably limited transmissible B. multivorans 
infections (14,222).  For the purposes of this study, B. multivorans was used 
throughout as a model organism due to its clinical relevance. 
 
1.3 Cystic fibrosis related diabetes  
CF patients now live longer, with the estimated average life span 
approaching 50 years for infants born in 2000 or after (63). This increased life 
expectancy has resulted in one-third of the CF population now older than 18 
years of age. CF patients are often diagnosed with cystic fibrosis-related 
diabetes mellitus (CFRD) in their late twenties (151). It is unknown precisely 
why the onset of diabetes further immune-compromises the patient, but chronic 
inflammation as a result of long-term infection, such as that in the CF lung, can 
contribute to insulin deficiency and susceptibility to infection. CFRD patients 
have an increased risk of infection and pulmonary decline that ultimately leads 
to drastic respiratory deterioration. CFRD early detection, diagnosis and 
management with insulin injections is crucial to decrease the contribution of 
CFRD to morbidity and mortality (7).  
 29 
 
The onset of CFRD results in sugars elevated in the diabetic blood, urine 
(fructose, glucose and mannose) and airways (glucose) (29,98,153). These 
elevated sugars may effect CF lung microbiology or influence further respiratory 
decline of patients by contributing to acquisition or strengthening of bacterial 
infection (98).  
The present study provides research contributions to the sparse 
knowledge that exists concerning links between CF lung microbiology and 
diabetes, and also adds to understanding the impact clinically relevant sugars 
have on bacterial behaviour. It is important to understand potential impacts of 
elevated sugars relevant to CFRD could have on existing polymicrobial lung 
infections. It is also necessary to understand how insulin administration (aimed 
at controlling elevated blood sugars) could impact on CF lung disease and thus 
the overall health of the CFRD patient (113).  
1.3.1 Sugars, insulin, and insulin binding by the Bcc 
CF and insulin resistance plays an important role in the glucose 
intolerance of CFRD individuals. There are variable levels of insulin resistance 
reported in CFRD patients, depending on their overall health stability (105), and 
researchers report that the bacterial infection within a CFRD patient is 
influenced considerably by the patients‟ diabetic state (104,110). Insulin 
deficiency in CFRD patients could potentially be enhanced by a Bcc infection, 
due to existing reports that members of the Bcc and B. pseudomallei bind 
human insulin (96,141,227). If indeed members of the Bcc bacteria were able to 
sequester insulin making it unavailable to the host, there could be 
consequences for Bcc-infection outcome in CFRD patients. Interestingly, the 
diabetic state is almost a pre-requisite for B. pseudomallei infection, suggesting 
a link with Burkholderia and the immune-compromised diabetic state. The ability 
of members of the Burkholderia to bind insulin appears to be a trait relatively 
unique to few bacteria species, even separating it from Pseudomonas, the 
genus Burkholderia was formerly classified  as (141). 
The diabetic state involves sugars that are elevated, such as fructose, 
mannose and glucose in the blood and urine of patients (98,153). Additionally, it 
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is reported that glucose is elevated in the airways of diabetics (12,29). Onset of 
CFRD and elevated sugars associated with diabetes in CF patients with Bcc 
infections could have potential impacts on lung disease. However, any definitive 
relationship between elevated sugars, CFRD, and the observed overall clinical 
decline associated with a CFRD diagnosis are poorly characterised, and it is 
unknown if CFRD or Bcc infection are linked. Onset of CFRD could impact CF 
lung microbiology and Bcc virulence if elevated airway sugars could induce EPS 
biosynthesis. Fructose and mannitol, among other sugars, induce copious 
amounts of EPS to be produced by members of the Bcc. It has been estimated 
in one study that ~80-90 % of Bcc CF isolates produce EPS (56).  
EPS-production is closely linked to unknown nutritional cues. The switch 
from a non-mucoid to mucoid phenotype, and vice-versa, is not entirely 
understood but several EPS-related biosynthetic operons are present in the 
Burkholderia, and it is likely the mucoid to non-mucoid transition in chronic 
infections may be due to different metabolic needs for survival during long-term 
colonisation (178). It has not been definitively confirmed whether EPS is 
produced in vivo, although attempts have been made to produce definitive 
evidence for EPS from CF sputum samples (88). EPS production in Bcc CF 
isolates is inversely related to respiratory decline (233). If EPS were produced 
in vivo it could act as a virulence factor by masking bacterial cell surfaces from 
neutrophils (51), scavenging reactive oxygen species targeted to kill pathogens 
(33), increase biofilm formation and resistances to antibiotics (56). Interestingly, 
an overall slower clinical decline in CF patients has been observed in patients 
infected with mucoid Bcc isolates (233). Thus, further study is required to fully 
understand the wide-ranging impact of EPS as a putative virulence mechanism 
for B. multivorans. 
 
1.4 Bcc virulence strategies 
1.4.1 Assessing Bcc virulence using plant and animal models of infection 
Acquisition of virulence factors by the Bcc, as well as in vivo evolution 
and adaption of the organism during infection, has been described (32,86,130). 
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One such example is the loss over time of the EPS mucoid phenotype from 
sequential CF isolates (178,234). Several animal models have been utilised to 
study bacterial/host interactions and virulence strategies in vivo for the Bcc. 
These include a rat agar bead model of chronic infection (184), the alfalfa 
seedling infection model (20), a CFTR knockout and F508del CFTR knockout 
mice (183), chronic granulomatous (CGD) mouse (57), a CF piglet model (152), 
the Danio rerio zebra fish model (189,203), the soil dwelling nematode 
Caenorhabditis elegans (35), and the greater wax-moth larva Galleria melonella 
(175). The latter was used in the present study to examine the impact of 
mucoidy on virulence in G. mellonella (Chapter 3). These animal models have 
proven useful for studying Bcc virulence mechanisms in vivo. Additionally, 
tissue culture cell lines with and without CFTR mutations are used to study Bcc 
host cell interactions (47,192). Macrophage and neutrophil studies, as well as 
A549 epithelial cells are also used to study host/pathogen interaction, invasion 
and intracellular survival (32,186). The A549 human lung epithelial and J774.1 
mouse macrophage cell line were used in studies presented in Chapter 3 and 5 
of this dissertation. A broad overall list of virulence traits in the Bcc are listed in 
Table 1.3, and further detail given within the following sections of virulence traits 
particularly relevant to studies in the following chapters. 
Table 1.3 briefly outlines the array of virulence factors known to be part of the 
Bcc virulence armory. As mentioned previously, due it is past dominance B. 
cenocepacia virulence traits have been the best studied and therefore the 
following table and references are biased for more study having been 
concentrated on the most dominant CF species.  
Table 1.3. Virulence traits in the Bcc. Broad overview with some detail of species regarding 
virulence strategies employed by members of the Bcc. 
Virulence factor Presence amongst Bcc 
species 
Characteristics  References 
Antimicrobial 
resistance 
All species  Natural resistance to many 
antibiotics and disinfectants 
(42,145) 
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Biofilm formation All species- but amount 
and ability can be strain 
variable 
Biofilm formation can be 
dependent on quorum 
sensing; provides increased 
resistance to antibiotics 
(34,52,205) 
Cable pili, 22-kDa 
adhesion and other 
adhesions 
B. cenocepacia, B. 
multivorans; 
homologues or other 
types of adhesins 
present in other species 
Cable pilus required for B. 
cenocepacia full adherence 
to mucin and epithelial cells; 
outbreak strain marker.  
(61,168,199) 
Catalse and SOD All species  (112) 
Cenocepacia island B. cenocepacia island  First pathogenicity island 
discovered and described in 
Bcc 
(15) 
Exopolysaccharide All species capable of 
producing EPS –
examined in relation to 
virulence in B. cepacia, 
B. cenocepacia, B. 
multiovorans 
Produced by Bcc isolates in 
vitro; induced after passage 
through murine infection 
model in B. cenocepacia 
(39,45,51,55) 
Extracellular 
proteases 
B. cepacia, B. 
cenocepacia, B. stabilis, 
B. dolosa 
Zinc metalloprotease 
required for virulence in B. 
cenocepacia K56-2 
(21,53) 
Flagella All species Polymorphic flagellin 
subunit; required for cellular 
invasion but not adherence 
(85,202) 
Invasion and 
intraceullar survival 
Variable in species 
tested, can be strain 
dependent 
Some species more 
invasive than others, some 
can survival and replicate in 
macrophages 
(99,130) 
LPS All species;  serotypable Unusual lipid-A structure  (217) 
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O-antigen variation 
Melanin B. cepacia, B. 
cenocepacia, B. 
multivorans 
Scavenges free radicals in 
vitro 
(235) 
Quorum sensing B. cepcia, B. stabilis, B. 
multivorans, B. 
cenocepacia, B. 
vietnamiensis, B. lata, B. 
dolosa, B. pyrocinnia 
All species encode LuxRI 
system and make AHL 
compounds; required for full 
virulence; controls toxins, 
proteases, lipases, 
siderophore 
(173) 
Siderophore 
production 
All species Four different types 
produced – ornibactin 
biosynthesis essential for 
virulence 
(195,218) 
Type III secretion 
system 
B. multivorans, B. 
ambifaria, absent from 
B. cepacia 
Similar inter-species 
genomic organisiation; 
required for B. cenocepacia 
virulence in murine infection 
model 
(76,198) 
Type VI secretion 
system 
B. cenocepacia, B. 
multivorans, B. 
cepacia,B. vientamiensis 
Involved in cell invasion, 
transport of type II secretion 
pathway proteins 
(164,167) 
Haemolysin B. cenocepacia Induces degranulation and 
cell death; haemolytic 
activity observed in many 
Bcc species 
(21) 
 
1.4.2 Exopolysaccharide – sugars elicit different Bcc phenotypes 
Exopolysaccharide (EPS) is a proven virulence factor for P. aeruginosa 
and other bacterial pathogens (190). When grown on certain carbon sources 
such as fructose and mannitol, Bcc species produce EPS resulting in a mucoid 
phenotype (17). This mannitol induced mucoid phenotype is observed in 80- 
90% of Bcc CF isolates (36,234). The most frequently identified Bcc-
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synthesised EPS has been characterised, and named cepacian (142). 
Cepacian is one of several types of EPS known to be synthesised by members 
of the Bcc (88). Whilst clinical B. cenocepacia isolates are frequently non-
mucoid as a result of mutations within EPS biosynthetic or regulatory pathways, 
clinical isolates of B. multivorans frequently retain the capacity for EPS 
production (233).  
EPS production by the Bcc has also been associated with bacterial 
persistence within the lung (51), biofilm formation, resistance to antibiotics (56) 
and inhibition of neutrophil activity (33). Bcc EPS can further restrict the 
diffusion of immune cells and antibiotics by blocking interaction with host and 
bacterial polymers (5,33,36,51). The study included CF Bcc mucoid samples 
from different countries. One study demonstrated that in over two decades 
worth of clinical data and a series of Bcc isolates, Bcc conversion from mucoid 
to non-mucoid  phenotype is associated with worsened clinical status (233,234) 
and persistent infection with poorer clinical outcome (125). If EPS biosynthesis 
impacted on bacterial overall fitness, it would allow the non-mucoid bacteria in 
the population to have a competitive advantage for growth and proliferation. 
EPS production may be metabolically expensive and therefore, selective 
pressure by inhaled mannitol therapy may select against non-mucoid bacteria.  
Structurally similar molecules induce dramatically different phenotypes 
(Figure 1.1). Although glucose, mannose, fructose and mannitol and are 
stereochemically similar, these sugars and sugar alcohol induce EPS profiles 
and support B. multivorans growth in different ways. This may indicate that 
these carbon sources impact on the broader behaviour of the organism in a 
more complex way than as only a carbon source to support growth and 
metabolism. Fructose and mannitol induce EPS production (mucoid phenotype), 
while glucose and mannose do not (non-mucoid phenotype). Media used 
predominantly for the analysis described in the present study contained 0.2 % 
(w/v) yeast extract supplemented with 2 % (w/v) sugar as broth or agar. The 
YEM (mannitol-containing media) is most commonly used to induce the EPS 
mucoid phenotype in the Bcc, and is almost exclusively used in studies of the 
impact of mucoidy on the Bcc (17). 
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Figure 1.1 Structurally similar sugars result in drastically different phenotypes 
Mannose and mannitol are used in the present study for phenotypic characterisation. Chemically 
similar sugar molecules have different impacts on induction of EPS biosynthesis. Although these 
sugars are structurally similar, minor differences in stereochemistry lead to drastically different 
roles in EPS induction. 
 
Recently, the approval of mannitol as an inhaled osmolyte has raised 
questions; the suggested dosage is 800 mg per day inhaled directly into the 
lung. Mannitol induces EPS production, and overall, it is still unknown how EPS 
production impacts on Bcc virulence in the CF lung. Mannitol is a naturally 
occurring sugar alcohol. In plants, mannitol plays a role in osmoregulation and 
stress response within cells. In the CF lung, mannitol acts as an osmolyte by 
drawing liquid towards the epithelial cell layer to rehydrate mucus. The forced 
expiratory volume per second (FEV1), is significantly improved in CF patients 
treated with inhaled mannitol (58). The developers claim sputum microbiology is 
unaltered over a two week period of treatment with mannitol (23,93). However, 
it is common practice to exclude CF patients with Bcc infection from clinical 
trials. This leaves drug developers unaware of effects the drug might have on 
Bcc infections in the CF lung. Treatment of Bcc infections in CF patients are 
notoriously difficult to manage, with some infections ranging from acute „cepacia 
syndrome‟ to long term infections that can be carried with the patient for a life-
time (79,87).  
EPS is a putative virulence factor of the Bcc, and a result of bacterial 
EPS production (induced by mannitol or other sugars) may lead to increased 
viscosity in the lungs. EPS production by the Bcc in the CF lung could thus lead 
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to decreased efficacy of respiratory therapy and antibiotic treatments. Recent 
papers and editorials call for the analysis of the Bcc „sugar response‟ 
(17,83,159), because the impact of mannitol in the CF lung (and other sugars of 
clinical interest in relation to CFRD) is not understood in relation to Bcc lung 
disease. The recent EU approval of mannitol means it could be prescribed 
universally to CF patients, regardless of the patients‟ lung microbiology profile. 
It is necessary to further examine the impact of mannitol and other 
clinically relevant sugars on EPS production and virulence. The average normal 
human lung volume is approximately 4.3 litres (54), and the recommended 
dosage of inhaled mannitol is 400 mg twice daily. If these doses were adhered 
to, the potential (though not documented or reported in the CF literature) 
concentration of mannitol would be ~ 1.02 mM. This concentration of mannitol 
in addition to the CFRD state of elevated sugars in the blood and airways could 
have deleterious effects by strengthening bacterial infection (29). The dispersal 
of an aerosol differs depending on the material size and diffusion, and lung 
volume differs from patient to patient, thus it is difficult to determine actual 
concentrations of mannitol following inhalation into the CF lung. 
 
1.4.3 Genetic basis for Bcc EPS biosynthesis  
EPS is biosynthesised by most members of the Bcc, but the genetic 
basis and regulation that control EPS production are not fully understood. There 
are multiple gene clusters that encode EPS production in the Bcc (17,142). The 
most conserved EPS cluster among the Burkholderia is the bce cluster. The bce 
cluster located on chromosome 2, is 16.2 kb long and includes 12 different 
genes (139). Although the bce I cluster is presented in Figure 1.2, there is also 
an identified bce cluster II (69). Though the bce cluster is well conserved among 
the Burkholderia, the distance between the bce I and II cluster, as well as the 
presence of both, varies from species to species. Interestingly, the greatest 
distance between bce I and II was found in B. multivorans ATCC 17616 (69). 
The bce cluster and associated EPS has been one of the most studied 
virulence factors in the Bcc. Genes within the bce cluster encode proteins 
required for the formation of nucleotide sugar precursors, glycosyltransferases 
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involved in repeat assembly, and other proteins involved in polymerisation and 
export of EPS (Figure 1.2).   
 
 
Figure 1.2 The arrangement of the bce I cluster. 
The bce I EPS gene cluster is conserved amongst Bcc species. The bceB glycosyltransferase is 
assigned to a role involved in repeat unit assembly. This figure based on a figure from Moreira et al. 
(139) and information gathered from burkholderia.com (225). 
 
Within members of the bce cluster, bceB encodes a glycosyltransferase 
that initiates the synthesis of cepacian repeat unit (RU) assembly (139). There 
are also functional equivalents of bce and bceB in other bacteria (see Videira et 
al. for a detailed list of species and loci (216)). The primary structure of the 
cepacian repeating unit is a branched acetylated heptasaccharide repeating unit 
with D -glucose, D -rhamnose, D -mannose, D -galactose, D -glucuronic acid, in a 
1:1:1:3:1 ratio (39). This EPS sugar composition is well conserved within 
cepacian produced by members of the Bcc. Analysis of B. multivorans EPS, 
derived from fructose- and mannitol-induced EPS, is the focus of studies 
presented in Chapter 6 and 7. 
The important role the bce gene cluster plays in Bcc EPS biosynthesis is 
highlighted in the highly transmissible B. cenocepacia ET-12 lineage. Members 
of the ET-12 lineage are predominently non-mucoid. It has been show that this 
lineage contains an 11 base pair deletion within the bceB gene, likely the cause 
of non-mucoid phenotypes in this transmissible lineage, reputed to favour 
aggressive infection and can result in septicaemia termed „cepacia syndrome‟ 
(17). This is in contrast to B. multivorans clinical isolates, which often retain the 
mucoid phenotype and are linked to more chronic infections.  
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1.4.4 Adhesion and biofilms 
Bcc pathogenesis strategies include adherence using cable pilus 
structures and fimbriae. Scanning electron microscopy (EM) shows that 60 % of 
Bcc species express peritricous pili (106). Bacteria use these adhesive 
structures to attach to host tissues and cells to assist colonisation. After initial 
colonisation, biofilms develop and are a recognized virulence factor in the Bcc. 
Biofilms are linked to antibiotic resistant long-term colonisation (95). The most 
commonly isolated CF Bcc bacteria (B. multivorans, B. cenocepacia, and B. 
dolosa) show equal ability to form biofilm, judged by accepted biofilm assays, 
but there is strain to strain variation in the amount of biofilm formed by differing 
Bcc species. A major issue with established bacterial adherence through biofilm 
formation is the effect biofilms have on the host immune inflammatory response, 
causing mis-regulated long term damage by neutrophil influx. Biofilm formation 
led by bacterial communication, also known as quorum sensing (QS) ultimately 
leads to evasion of host response and antibiotic resistance. Biofilm formation 
has been linked to antibiotic resistance because of decreased metabolic activity 
(27,212). There has been research interest in ways to improve drug delivery to 
the CF lung as a means to combat infection and specifically chronic biofilms. 
Some studies have reported that the non-mucoid phenotype results in 
enhanced motility but decreased biofilm formation (178), however EPS-
attributable phenotypes are not clear cut, and further investigations into the 
virulence-relevant phenotypes impacted by EPS production will be discussed 
within the present study. Adhesion and biofilm studies relevant to this 
dissertation are presented and discussed in Chapters 3 and 5.  
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1.5 Aims 
1. Fully characterise the response of B. multivorans to relevant sugars by using 
phenotypic assays that assess virulence associated phenotypes.  
2. Assess the whole genome transcriptional response of B. multivorans to 
clinically relevant sugars. 
3. Compare the composition and functional biological activity of B. multivorans 
ATCC 17616 and C1576 fructose-derived EPS compared to mannitol-
derived EPS.  
4. Investigate insulin binding in the Bcc.    
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A schematic outlining the approach used to address the thesis aims.  
 
 
Figure 1.3 Schematic of the approach to research taken to achieve study aims. Three branches 
of work arise from the main goals of characterising the B. multivorans response to clinically 
relevant sugars and insulin binding; phenotypic analysis, transcriptomic analysis, and assessment 
of insulin binding using microscopy and flow cytometry studies.
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Chapter 2: Materials and Methods 
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2.1 Bacterial strains 
In Table 2.1 are listed the strains used in studies presented in Chapters 3-7. 
Additional information on the strains used in the insulin binding assays for 
Chapter 8 can be found in section 2.23, Table 2.4. Details of the strains used in 
Chapter 5 for Southern hybridisation dot-blot analysis are listed in the appendix, 
Table 9.5.  Table 2.2 provides details of the plasmid constructs and cloning 
vectors used for mutagenesis and complementation. Primer sequences for the 
mutagenesis process can be found in Chapter 9, and Appendix Table 9.1 and 
9.2.  
 
Table 2.1 Bacterial strains used in this study for Chapters 3-7. Tetracycline resistance TetR, 
Trimethoprim resistance,TpR 
Strain Relevant characteristics  Source and/or reference 
B. multivorans strains  
C1576 CF clinical isolate; Index case of outbreak 
strain, ST-27 
(127) 
fim CR  C1576, pGPΩTp::fim, Tp
R
 This study 
hecB CR  C1576, pGPΩTp::hecB, Tp
R
 This study 
hecA CR C1576, pGPΩTp::hecA, Tp
R
 This study 
fim CO  C1576, pGPΩTp:: fim, pDA17:: fim, Tp
R
 Tet
 R 
 This study 
hecB CO  C1576, pGPΩTp::hecB, pDA17::hecB, Tp
R
 
Tet
R 
 
This study 
C1576 bceB 
CR 
C1576,  pGPΩTp::bceB, Tp
R
 This study  
ATCC 17616 Environmental isolate from soil (127) 
ATCC bceB 
CR 
ATCC 17616, pGPΩTp::bceB, Tp
R
 This study 
E. coli strains  
TOP10 F
-
 mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 araD139 
Invitrogen 
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Δ(ara-leu) 7697 galU galK rpsL 
(Str
R
) endA1 nupG λ
-
 
GT115  F
-
 mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 rspL (StrA) 
endA1 ∆dcm uidA(∆MluI)::pir-116 ∆sbcC-
sbcD 
InvivoGen 
 
Table 2.2 Plasmids constructed specifically for this study. Plasmids constructed for mutagenesis 
purposes and complementation are described in detail within this table, and when available a 
reference is made to the original source of the vector.  
Plasmid  Relevant characteristics   Source/reference 
pGPΩTp OriR6K, ΩTp
R 
cassette, mob
+
 (71) 
pRK2013 OricolE1, RK2 derivative, Kan
R
, mob
+
tra
+
 (70) 
pDA17 OripBBR1,Tet
R
, mob
+
, Pdhfr (72) 
pGPΩTp::hecA pGPΩTp; 448 bp internal fragment from C1576 hecA  This study 
pGPΩTp::hecB pGPΩTp; 444 bp internal fragment from C1576 hecB  This study 
pGPΩTp::fim pGPΩTp; 426 bp internal fragment from C1576 gene encoding 
fimbrial usher protein 
This study 
pDA17::hecB pDA17; 1.8 kb fragment encoding the C1576 HecB-like protein  This study 
pDA17::fim pDA17; 2.7 kb fragment encoding the C1576 fimbrial usher 
protein 
This study 
  
2.2 Chemicals, growth media, and culture conditions 
2.2.1 General chemical and media purchasing information 
Unless otherwise stated, all antibiotics, enzymes, solvents and other 
chemicals were purchased from Sigma-Aldrich Inc. (Location), growth media 
from Oxoid (location), amino acids and MOPS from FOREMEDIUM (location), 
mass spectrometry consumables from Agilent, cell culture media, buffers from 
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Gibco, cell culture consumables from Nunc and Corning, and RNA 
consumables from Ambion/ Applied Biosciences.  
2.2.2 General culture conditions 
Strains were stored at - 80° C in Luria-Bertani (LB) broth with no 
antibiotics and 16 % (v/v) glycerol. Bacteria were routinely cultured as follows: 
LB broth cultures inoculated from 3-5 colonies taken from freshly grown agar 
plates (10 ml volumes in 30 ml culture vessels) were incubated at 37° C with 
shaking at 250 rpm unless stated otherwise. Strains were incubated for 16-17 
hours for RNA extraction protocols, 20 hours for phenotypic assays, and 48 
hours for EPS extractions. For routine culture, media were supplemented with 
trimethoprim (100 μg/ml for Bcc; 50 μg/ml for E. coli), tetracycline (100 μg/ml for 
Bcc; 25 μg/ml for E. coli), gentamicin (50 μg/ml for Bcc), or kanamycin (25 μg/ml 
for E. coli) as required (see Tables 2.1, and 2.2). 
2.2.3 Growth media 
LB broth and agar 
LB broth (containing 5 g/litre NaCl – Oxoid) supplemented with 1.5 % (w/v) agar 
as required.  
Sugar media 
Sugar media contained 0.2 % (w/v) yeast extract (Oxoid) supplemented with 
either 2 % (w/v) D-mannitol (for EPS-inducing conditions; YEM media), or 2 % 
(w/v) D-mannose (for non-EPS-inducing conditions) (166). All strains employed 
in this study exhibited comparable growth rates within the media used. All 
sugars used for screening and growth (D-fructose, D-glucose, D-mannose, D-
mannitol, D-Adonitol, D-myoinositol, D-Galactose, D-sucrose, D-inulin) were used 
at 2 % (w/v). Instances where „mannitol‟ or „mannose‟ and other sugars are 
referred to throughout this dissertation, the reader should infer that D-
enantiomer forms of the sugars were used. Agar was added to 1.5 % (w/v) as 
required for sugar agar media.  
Motility agar 
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Swimming agar plates were made as per sugar media but with 0.3 % 
(w/v) agar, to allow the bacteria to swim through the media.  
Synthetic CF sputum medium (SCFM). 
SCFM media was prepared as described in Palmer et al. (149) 
supplemented with either D-mannitol or D-mannose sugars (2 % w/v). Agar was 
added to 1.5 % (w/v) as required. 
SOB broth and agar 
SOB broth and agar used for triparental mating was prepared as follows:  
2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 8.5 mM NaCl, and 250 mM KCl. 
For SOB agar, 1.5 % (w/v) agar was added. The media was sterilised by 
autoclaving, and once cooled, MgCl2 was added to a final concentration of 10 
mM.  
Tryptone soya broth (TSB) 
Gamma-irradiated TSB powder was purchased from Oxoid and 
supplemented with 1.5 % (w/v) agar as required.  
 
2.3 Crude DNA extraction 
Crude DNA preparations were made as follows: 3-4 colonies from an 
overnight growth on an appropriate agar plate were re-suspended in 20 µl of 
alkaline lysis solution (0.25 % SDS, 0.05 N NaOH 92.5 % (v/v) H2O). The 
bacteria–lysis solution suspension was heated for 15 minutes at 95° C to lyse 
the cells, then briefly centrifuged. To this, 180 µl of nuclease-free H2O was 
added, the solutions vortexed, and then centrifuged at full speed on a benchtop 
centrifuge for 5 minutes. Lysates were stored at – 20° C for future use (17). 
 
2.4 Generating crude mutants by insertional inactivation 
2.4.1 Construction of vectors 
Insertional inactivation to create crude mutants of target genes used the 
pGPΩTp suicide vector was carried out as described previously (71). In brief, a 
400-500 bp PCR product mapping within the target gene was cloned into 
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pGPΩTp to facilitate homologous recombination and thus insertional 
inactivation of the target gene. Amplified PCR products and pGPΩTp vector 
were double digested with EcoRI/XbaI restriction enzymes (NEB) overnight at 
37° C. Digests were separated by gel electrophoresis and the required inserts 
and plasmid vectors were gel extracted (Qiagen gel extraction kit), and ligated 
overnight at 16° C with an insert: vector ratio of 1:3 (NEB). For transformations 
of the vectors into E. coli strains, 4 µl of ligation product was used. All primer 
sequences used for insertional mutagenesis are listed in Chapter 9, Appendix 
Table 9.1.  
Transformants were selected using gentamicin in conjunction with 
trimethoprim to select for pGPΩTp integrants. Insertional mutants were 
confirmed by using the pGPΩTp specific RSF1300 primer (71) and appropriate 
adhesion-specific XbaI primer (used for insertional inactivation), additionally 
RSF1300 was used with a forward checking primer, specific to a region of the 
gene upstream of the targeted insertional mutagenesis (primer sequences used 
are available in Appendix Table 9.1).  
 
2.4.2 Conjugation of vectors and validation of resulting insertional mutants 
All plasmids (for mutagenesis and complementation) were mobilised into 
the appropriate B. multivorans recipient strain by triparental mating with the 
helper plasmid, pRK2013 (Table 2.2) (70). Tri-parental mating consisted of 10 
ml overnight SOB cultures with or without antibiotics, as appropriate. Cultures 
were harvested the following day and resuspended in PBS to remove any 
antibiotics present in the growth media. Mating mixtures were combined in a 
1:1:10 helper, donor, recipient ratio, centrifuged, and re-suspended in 2 ml LB 
broth without antibiotics. 200 µl of the mating mixture was plated without 
spreading, onto a SOB agar plate and incubated at 37° C agar side up 
overnight. Growth was then harvested with 1 ml LB broth, and plated onto LB 
agar supplemented with appropriate antibiotics.  
Semi-quantitative RT-PCR was used to validate that insertional 
inactivation did not cause undue disruption of surrounding gene expression in 
crude adhesin mutants. Primers were designed internal to genes up and 
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downstream of the insertional- inactivated targets in adhesin mutants hecA CR, 
fim CR and hecB CR. Strains were grown overnight in LB broths supplemented 
with 100 μg/ml trimethoprim. RNA was extracted using RNA-easy Protect 
Bacteria Mini Kit (Qiagen) per manufacturer‟s guidelines, followed by DNAse 
treatment (1 hour) (Promega). cDNAs were synthesized as described in section 
2.16. Samples alongside positive, negative, and non-RT controls were 
visualised using gel electrophoresis. The sequences of primers for qRT-PCR 
are available in the Appendix Table 9.3.  
 
2.5 Construction of complemented strains 
2.5.1 Construction of complementation vectors 
In trans complementation of mutants was achieved using the previously 
described pDA17 vector (Table 9.2) (72), a broad-host range plasmid that 
drives constitutive expression of the cloned gene from the dhfr promoter. The 
complete genes that had previously been the target of insertional inactivation, 
were amplified by PCR, with the sequence for NdeI and EcoRI restriction 
enzymes added at the start and stop codon respectively. The product was 
inserted directly into the pGEM-T Easy Vector System (Promega) and screened 
using blue/white screening on LB agar supplemented with Ampicillin 100 μg/ml 
and X-Gal 80 μg /ml. Positive (white) colonies were screened with a primers 
internal to the gene of interest and either T7 or SP6 primers, specific to the 
pGEM-T Easy plasmid. PCR-positive clones were sent for sequencing using the 
T7 or SP6 primers. pGEM-T Easy constructs (Table 2.2) containing hecB 
inserts were double-digested with NdeI/EcoRI. The fim complementation 
construct in pGEM-T Easy was digested with ScaI and NdeI/EcoRI. The 
additional ScaI enzyme was included to cut the plasmid backbone enabling 
separation and visualisation of the insert from the plasmid. Digested insert 
fragments were separated by gel electrophoresis, excised, purified, and ligated 
into the vector pDA17 (72) which had been previously digested with NdeI/EcoRI 
(15° C overnight as described in 2.4.1). Ligations were transformed into E. coli 
Top10 (Invitrogen) cells and plated onto tetracycline 50 μg/ml LB agar plates. 
pDA17 constructs were mobilised into the appropriate B. multivorans recipient 
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strain by triparental mating with the helper plasmid, pRK2013 (Table 2.2) as 
described in section 2.4.2 (70). Transformants were selected using gentamicin 
in conjunction with tetracycline for pDA17 complemented strains. 
Complemented strains were confirmed by appropriate PCR validation using 
primers specific to the TetR cassette carried on pDA17 (primer sequences listed 
in Chapter 9 Appendix Table 9.2).  
2.5.2 Validation of complemented strain  
Transformants described in section 2.5.1 were screened by PCR using 
internal primers to the adhesin gene. Phenotypic assays were then utilised to 
confirm the complemented strain had returned to wild-type behaviour.  
 
2.6 Biofilm assay 
Biofilm formation was assessed using the 96-well plate and 
accompanying peg-lid of the MBEC Assay device (Innovotech).  Bacteria were 
harvested from TSB agar and standardized to 107 CFU/ml in 10 ml TSB. Wells 
received either 150 μl of bacterial suspension or an equal volume of un-
inoculated tryptone soya broth (TSB). The peg lid was placed on the plate, 
sealed, and the plate incubated at 37° C with shaking (125 rpm). Following 24 
hours incubation, the peg lid was transferred to a fresh 96-well plate containing 
pre-warmed TSB, and incubated for a further 24 hours (37° C, 125 rpm). The 
peg lid was transferred to a 96-well plate containing 200 µl 1x PBS per well 
(PBS tablets: 0.01 mM Na2PO4-7H2O, 3 mM KCl, 140 mM NaCl, pH 7.4. 
Sigma), and incubated at room temperature for 2 minutes to remove loosely-
attached bacteria. The peg lid was removed and baked (60° C, 20 minutes). 
The peg lid was then transferred to a 96-well plate containing 200 μl of 0.1 % 
(w/v) crystal violet per well, and incubated for 30 minutes at room temperature. 
The peg lid was washed three times (200 μl of PBS per well) following staining, 
and the bound crystal violet was subsequently solubilised with 95 % ethanol (30 
minutes) prior to measuring absorbance at 570 nm. 
2.6.1 Assessing biofilm resistance to tobramycin treatment 
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Bacteria were harvested from yeast extract sugar media agar (section 
2.2.3) and diluted into yeast extract sugar media broths. Biofilms were grown as 
described in section 2.6 with the following alterations: after the initial 24-hour 
incubation pegs were washed twice in PBS, then inserted into a fresh 96-well 
plate containing 200 µl of either 8 μg/ml tobramycin sulphate re-suspended in 
PBS, or PBS alone (control wells). This plate was then incubated a second time 
for 24 hours (37° C static). Sessile cells were sonicated (5 minutes) into a fresh 
96-well plate filled with fresh 200 µl PBS. CFU/biofilm was determined by viable 
counts onto LB agar, and percentage survival was calculated relative to 
untreated biofilms.  
 
2.7 Hydrogen peroxide protection assay 
To assess the in vitro protection of mannitol to oxidative stress, a method 
was adapted from Lefebre et al. (112) and Katsuwon and Anderson (97). 
Overnight cultures of B. multivorans were grown with shaking at 37° C in 
mannitol or mannose sugar broths until late stationary phase. Samples were 
harvested, re-suspended and equalised to an OD590 of 1 (equating to 
approximately 109 CFU/ml) in 1x PBS, and then further diluted to 108 CFU/ml in 
LB broth. Samples were treated with 5 mM H2O2, and incubated with shaking at 
25°C (30 minutes). Control samples were incubated with H2O in place of H2O2. 
Enumeration of viable CFU was carried out by plating serial dilutions onto LB 
agar. After 48 hours of incubation, colonies were counted and percentage 
survival was calculated.   
 
2.8 Swimming motility assay 
Bacteria were sub-cultured from LB plates to grow overnight on TSB 
agar plates at 37° C. Bacteria were harvested from the plates with a sterile 
plastic loop and standardised to an OD590 of 1 in PBS. Cultures were diluted 
1:200 in TSB and used to inoculate swimming agar plates (as described in 
section 2.2.3). A sterile pipette tip was submerged in the 1:200 bacterial 
suspensions in TSB ~10 mm depth and then inserted into the centre of the agar 
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plate. Plates were incubated for 48 hours agar side up at 37° C. Motility was 
quantified at 48 hours by measuring the diameter travelled in mm at the widest 
point from the base of the plate.  
 
2.9 Mucin adherence assay 
Mucin adherence assays were performed as described previously (8), 
with minor modification. In brief, 50 μl aliquots of 50 μg/ml filter-sterilized 
porcine mucin protein (Sigma) were applied to wells of a 96-well polystyrene 
microtitre plate and incubated overnight at 37° C. Bacteria were harvested from 
LB agar plates (for adhesin mutant experiments) or D-mannitol/D-mannose 
sugar broths (for mucoidy-related experiments) following overnight incubation, 
and standardised to 109 CFU/ml in PBS. Mucin-coated wells received either 50 
µl bacterial suspension, or 50 µl PBS, and were incubated at room temperature 
for 3 hours, after which wells were washed ten times with 200 µl aliquots of 
PBS. Bound bacteria were released from mucin with sterile 0.25 % (v/v) Triton 
X-100 and enumerated by plating appropriate dilutions (in triplicate) onto LB 
agar. Six wells were processed per strain in each individual experiment. 
 
2.10 Fibronectin adherence assay 
To assess the involvement of adhesins in interaction with the host 
extracellular matrix (ECM) protein fibronectin, the method from Mil-Homens et 
al. (134), was used, substituting TBS buffer for PBS. Wells of a 96-well 
polystyrene plate were coated with 150 μl of 10 μg/ml fibronectin and incubated 
overnight at 4° C. Strains were grown on LB agar overnight at 37° C and 
standardised in PBS to OD590 of 1. 150 μl of bacterial suspensions were applied 
to fibronectin-coated wells, and the plates were briefly centrifuged at 300 x g for 
3 minutes. Bacteria were left to adhere at room temperature for 2 hours. Un-
bound bacteria were aspirated and wells washed with 200 µl PBS (four times). 
The plate was baked at 60° C (45 minutes) followed by staining (15 minutes) of 
adhered cells with 0.1 % (w/v) filter sterilised crystal violet (CV).,Wells were 
then washed four times with PBS and the stain solubilised in 95 % ethanol (30 
 51 
 
minutes) with rocking. The plate was read at 570 nm on a 96-well plate reader. 
Controls consisted of PBS applied to fibronectin-coated wells. 
 
2.11 Macrophage intracellular survival assay  
2.11.1 Culture of J774 macrophages 
An adherent mouse macrophage cell line (ATCC® number TIB-67™ 
(158)), was cultivated per ATCC guidelines, using high glucose Dulbecco‟s 
modified eagle medium (DMEM) (SOURCE) with 2 mM L-glutamine and 10 % 
heat-treated foetal bovine serum (FBS) (Gibco). Cell layers were cultured in 75 
ml flasks at 37° C, 95 % air, 5 % CO2. Media was renewed 2-3 times per week. 
Growth media was changed prior to harvesting cell layers. Sub-cultivation of the 
cells was carried out by dislodgment from the flask substrate with a cell scraper 
and with a sub-cultivation ratio of 1:6. For freezing working stocks of the cell 
line, cells were suspended in 5 % (v/v) DMSO and DMEM complete growth 
medium and aliquots made at 105 cells per vial. Cells were used in assays 
between passages three and fifteen before a new working stock of the cell line 
was used.  
2.11.2 Intracellular survival assay 
J774 macrophages were cultured as described in section 2.11.1. 
Bacteria were grown overnight in broths or on plates (yeast extract and sugar or 
LB) then harvested and equalised to OD590 of 1 in PBS. Equalised cultures were 
then diluted to an MOI 40 (for 4 x 106 cells/ml to infect 5 x 105 macrophages) in 
pre-warmed L-15 medium (Gibco). Input inoculum was saved to plate out for 
viable counts (T = 0 hours). 24-well plates were seeded with 5 x 105 J774 
macrophages per well and were used within 17 hours (the doubling time of the 
cell line). Cell monolayers were rinsed twice with pre-warmed PBS to remove 
traces of DMEM. Wells were overlaid with 1 ml volumes of L-15 with or without 
bacteria. Plates were incubated statically for 2 hours at 37° C to allow for 
internalization of bacteria by macrophages. Cells were washed once with 1x 
PBS and overlaid with L-15 supplemented with 1mg/ml ceftazidime and 
500μg/ml kanamycin. Plates were incubated for 2 hours, static, at 37° C. 
Monolayers were then washed three times with warmed PBS. To lyse 
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macrophages, 1 ml of 0.1 % (v/v) Triton X-100 was added to all wells prior to 
serial dilution in PBS for viable counts on LB agar. Plates were incubated at 37° 
C for 48 hours.  
To test the efficacy of antibiotic treatment used in the assay, a killing 
curve assay was carried out with ceftazidime and kanamycin which resulted in 
99.6 % C1576 bacteria killed and 100 % ATCC 17616 killed after 2 hours. 
 
2.12 A549 human lung epithelial cell invasion and adherence assays 
2.12.1 A549 culture 
A549 human lung epithelial cell line (ATCC® number CCL-185™) (75) 
was cultured according to the ATCC guidelines. Growth medium was high 
glucose DMEM with L-glutamine supplemented with 10 % (v/v) heat-treated 
FBS. Cell layers were cultured in 75 ml flasks and incubated at 37° C, 95 % air, 
5 % CO2. Media was renewed 2-3 times per week. Monolayers were rinsed prior 
to subcultivation and harvesting with PBS, then 2-3 ml of 0.105 mM trypsin, 
0.53 mM EDTA solution was used to release cells from the flask. Cells were 
sub-cultivated with a ratio of 1:8. Working stocks of the cell line were frozen as 
described for J77.4 cells (section 2.11.1). Cells were used in assays between 
passages three and fifteen before a new working stock of the cell line was used.  
 
2.12.2 A549 invasion assay 
The method for evaluating bacterial invasion of A549 human lung 
epithelial cells for this study was based on previous published protocols (32). 
Plates were seeded as described in 2.11.2. Once seeded, cells were used 
within the doubling time of 22 hours. Bacteria were grown on LB agar overnight 
and then standardised to an OD590 of 1 and diluted to MOI 50 (for a final 
concentration of 5 x 107 CFU/ml) in pre-warmed L-15 medium. DMEM was 
removed from A549 monolayers before the addition of 1 ml L-15 bacterial 
suspension. Bacteria were allowed to invade for 2 hours (37° C static 
incubation) prior to a PBS wash, followed by antibiotic overlay with 1mg/ml 
ceftazidime and 500 μg/ml kanamycin.  
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After 2 hours antibiotics were removed with PBS washing (twice). 200 μl 
of DMEM with 0.105 mM trypsin/0.53 mM EDTA was added to infected 
monolayers and incubated at room temperature for five minutes to release the 
A549 cells from the polystyrene well, followed by 800 μl of 0.25 % (v/v) Triton X-
100. Lysates were serially diluted and plated for CFU/ml onto LB agar and 
incubated for 48 hours. Invasion frequency was calculated as: ((recovered 
average CFU/ml) /input average CFU/mL) x 100 %. 
 
2.12.3 A549 adherence assay 
The method for evaluation of adhered bacteria to human alveolar 
epithelial cells was adapted from Accord et al. (1) and Thomas et al. (196). 24-
well plates were seeded with 5 x 105 A549 cells. Monolayers were rinsed twice 
with PBS, and blocked with 0.5 % (v/v) filter-sterilised heat-treated FBS for 1 
hour to minimise non-specific binding. Bacterial growth was harvested from LB 
agar, resuspended in PBS and standardised to an OD590 of 1, then diluted to 
107 CFU/ml in L-15 media. The monolayers were rinsed again with PBS and 
infected at an MOI 20. Bacteria were allowed to adhere for 2 hours before non-
adhered cells were removed with an aspirator. Monolayers were then washed 
five times with PBS. Infected A549 cells were lysed with 0.1 (v/v) % Triton X-
100 and lysates were serially diluted and plated onto LB agar and the CFU/ml 
enumerated. Controls were monolayers overlaid with un-inoculated L-15 media.  
 
2.13 Galleria mellonella infection model 
Infection of larvae was guided by the specification as described by Seed 
and Dennis (175) with minor modifications as described briefly here. Larvae 
were obtained from LiveFoods U.K. and stored in woodchips at 10° C. A 25 μl 
22s gauge gas-tight high performance Hamilton syringe (Cole-Palmer, location), 
was used to inject 10 μl aliquots of B. multivorans at 106 CFU/ml into G. 
mellonella via the hindmost proleg. Following injection, larvae were placed in a 
static incubator in the dark at 37° C. Control larvae were injected with 10 μl of 
sterile PBS. Per experiment, ten larvae were injected for each strain or growth 
condition of interest, and larvae were scored as dead or alive at appropriate 
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time-intervals post infection (p.i). Larvae were considered dead when they 
displayed no movement in response to touch with a pipette tip. Infection was 
repeated independently five times (for sugar assay work to assess impact of 
mucoidy and for adhesin mutants grown from LB agar plates). Input of bacteria 
was serially diluted in PBS and plated onto LB agar to ensure equal numbers of 
bacteria were inoculated into the larvae.  
 
2.14 RNA extraction 
B. multivorans was cultivated on LB agar growth media from a -80° C 
glycerol stock, and was subsequently plated onto 0.2 % (w/v) yeast-extract agar 
supplemented with 2 % (w/v) D-mannitol (standard YEM), 0.25 % (w/v) D-
mannitol („reduced YEM‟), 2 % (w/v)  D-mannose (YEO), 2 % (w/v) D-fructose 
(YEF), 2 % (w/v) YE + 2 % (w/v)  D-glucose (YEG), or 2 % (w/v) YE + 2 % (w/v) 
D-mannitol („non-mucoid YEM‟).  
After approximately 16-17 hours incubation at 37° C, bacteria were 
harvested from two mannitol and fructose plates, and four mannose and 
glucose plates. Bacteria harvested from multiple plates were pooled together as 
single replicates and re-suspended in ice-cold PBS. 2 ml aliquots of bacterial 
PBS suspension were swiftly pipetted into RNAse-free tubes, chilled in liquid 
nitrogen, and centrifuged at full speed (4° C) for 5 minutes. The PBS was then 
decanted, and any remaining media was removed with a pipette. Pellets were 
immediately frozen in liquid nitrogen and stored at -80° C for up to one week, or 
processed immediately.  
Total RNA extraction was made using the RiboPure kit (Ambion) 
according to the manufacturers‟ instructions. The recovered RNA was treated 
for 1 hour with 10 U of Ambion DNAse, and precipitated with 7.5 mM LiCl 
(Ambion) to concentrate the RNA before finally being re-suspended in 10 μl of 
Nuclease-free water. A diluted aliquot of total RNA sample were set aside for 
nanodrop and RNA quality assessment.  
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RNA quality was assessed upon electrophoretic separation on the 
Agilent Bioanalyzer using the RNA 6000 Nano kit (Agilent). Only samples with 
RNA integrity ratings higher than 7.0 were used for subsequent microarray or 
RNA-seq analysis. 
 
2.15 Microarray analysis 
The custom-made 4 x 44 K microarrays for B. multivorans ATCC17616 
as well as the protocols used for RNA labelling, hybridisation in the microarray 
and fluorescence signal scanning were carried out as described for B. 
cenocepacia (170), and were performed in collaboration with Professor Eshwar 
Mahenthiralingam, Cardiff University. Briefly, 5 μg total RNA from ATCC17616 
(see section 2.14) was labeled with the SuperScript Indirect cDNA Labeling 
System (Invitrogen). 10 μg of total RNA was used per labeling reaction. The 
amount of random hexamers was doubled to 1 μg per reaction and incubation 
time increased to 3 hours. Amino-modified first-strand cDNA was coupled with 
Cy5 dye (GE Healthcare). 
For the Cy3-labeled microarray reference sample, genomic DNA of B. 
multivorans ATCC17616 strain was extracted by mechanical disruption using a 
modified bead-beater protocol (126). 3 ml of an over-night broth culture was 
harvested, mixed with lysis buffer containing pronase and glass beads, and 
beat for 10 seconds on the bead-beater. The lysate was incubated at 37º C for 
1 hour and mixed with saturated ammonium acetate and chloroform. The mix 
was centrifuged, the upper aqueous phase removed and the DNA purified by 
ethanol precipitation. Purified DNA was further treated with RNase. 
The genomic DNA was labeled with the BioPrime DNA Labeling System 
(Invitrogen) at 2 μg genomic DNA per labeling reaction. The dNTP mixture from 
the kit was replaced with a dNTP mixture containing 1.2 mM each dATP, dGTP 
and dTTP and 0.6 mM dCTP. 3 µl of Cy3 dCTp stock solution (GE Healthcare) 
was added per labeling reaction. The reactions were incubated at 37º C for 2 
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hours and then cleaned with the GFX PCR DNA Purification kit (GE 
Healthcare). 
Microarrays were hybridised according to the Two-Colour Microarray 
Based Gene Expression Analysis protocol (version 5.5, Feb. 2007, order no. 
G4140-90050) (Agilent), adjusted for the use of cDNA. The fragmentation step 
was omitted and instead the hybridisation mix was denatured at 98º C for 3 
minutes. Cy5 labeled cDNA was used at 825 ng per sample, and were 
hybridised against the Cy3 labeled genomic DNA, used at 60 ng per sample. 
The washing procedure included the use of Stabilizing and Drying Solution 
(Agilent) to prevent ozone-related degradation of Cy5. All experiments were 
carried out with three biological replicates per growth condition.  
Microarray slides were scanned with a microarray scanner (G2565 BA, 
Agilent) with the Scan Control software (version A.7.0.3 Feb 2007 (Agilent)) and 
a scan resolution of 5 μm. The Extended Dynamic Range function, with 100 % 
and 10 % PMT gain, was enabled. Scanner images were analysed with the 
Feature Extraction (version 9.5.1 (Agilent)) using the FE protocol GE2_v5_95. 
Data was then imported into GeneSpring GX (version 7.3.1. (Agilent)) with the 
Agilent FE data import plug-in switched on to preprocess the data. 
Normalisation was performed with the Agilent FE saved scenario: First every 
spot of the signal channel was divided by the control channel. Each chip was 
then normalised to the 50th percentile of all measurements of that chip followed 
by normalisation of each gene to its median. 
Clustering of samples for quality control and comparisons for statistical 
analysis were carried out using GeneSpring GX (version 7.3.1). As previously 
described by Sass et al.. (171), probe and intergenic (IG) sequences were 
evaluated in Gene Spring by removing unreliable features, removal of results 
with fold changes less than 1.5 in the compared conditions of interest. This was 
followed by 1-way ANOVA statistical tests for significant p-values < 0.05 with a 
parametric t-test with 5 % false discovery rate without multiple testing 
comparison or post-hoc tests. 
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Further details on microarray data quality control, analysis and fold-
change parameters are presented in Chapter 4. Complete GeneSpring 
microarray data can be found on the Appendix CD. 
2.16 Quantitative RT-PCR analyses 
Transcript levels from selected genes were assessed via quantitative RT-
real time PCR (qPCR). RNA was extracted (RiboPure Bacteria Kit, Ambion) 
from bacteria grown in synthetic CF sputum media (SCFM) (149) supplemented 
with either 2 % (w/v) mannitol or 2 % (w/v) mannose. cDNA was synthesized 
from 4 μg of total RNA (SuperScript III reverse transcriptase, Invitrogen), diluted 
1:50 and used as template in qPCR using Platinum SYBR Green qPCR 
Supermix (Invitrogen) on an Mx3005P QPCR system (Agilent).  
Cycling conditions  were as follows: 1 cycle of 95°C (10 min), 40 cycles 
of 95°C (15 seconds) and 55°C (1 minute) with fluorescence measured at the 
55°C annealing step. Then, a denaturation melt curve as follows: 95° C (1 
minute), with fluorescence measured from 55°C (30 s) to 95°C (30 s). The 2(-
∆∆CT) method was used to calculate relative gene expression between the 
mannitol and mannose growth conditions, normalised to gapA expression (121). 
Primers used for qRT-PCR are listed in Appendix Table 9.3. 
 
2.17 RNA-seq analysis  
2.17.1 mRNA enrichment and sample quality assessment 
Ten micrograms of total RNA were subjected to two successive rounds 
of rRNA depletion using MicrobeExpress (Ambion) per the manufacturer 
guidelines. The precipitation step was lengthened from 1 hour at -20° C to 
overnight at -80° C. Resulting mRNA was re-suspended in 25 μl TE buffer and 
frozen at -80° C. An aliquot of mRNA was used for analysis on the Agilent 
Bioanalyzer (RNA Prokaryote Nano kit series). Depletions were deemed 
successful when, compared to the original total RNA, the 16s and 23s peaks 
were eradicated.  
2.17.2 Library preparation 
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RNA-seq analysis libraries were prepared from the resulting mRNA 
(section 2.17.1) using the TruSeq RNA protocol (Illumina). Samples were 
ligated to NEXTflex™ DNA adapters for sample differentiation. Amplified 
libraries were checked using the Agilent Bioanalyzer and concentration was 
estimated and standardised. Concentration of the pooled (8.1 mM) library was 
additionally verified using a qRT-PCR standard curve against a library of known 
concentration. Clustering of samples onto the flow cell was performed by bridge 
PCR using the Illumina cBot prior to sequencing on an Illumina HiSeq2000 
platform.  
2.17.3 RNA-seq data analysis 
Mapping of resultant reads was to the B. multivorans ATCC 17616 
reference genome. Subsequent expression analyses was carried out using the 
CLC Genomics Workbench (CLC bio) to identify differentially-expressed genes 
(two-group pair-wise comparisons), with statistical analysis performed using 
Kals‟ test and with FDR-corrected p- values and post- ests. CLC Genomics 
Workbench was used with default parameters. Further details on sample 
comparisons and quality control are described in Chapter 4.  
 
2.18 EPS extraction 
The method for EPS extractions was modified from Conway et al. (2004) 
(51). B. multivorans was grown on EPS-inducing sugar agar, specifically yeast 
extract and mannitol or fructose for 48 hours at 37° C. After incubation, agar 
plates were flooded with 5 ml of 2 % (v/v) phenol in 0.9 % (w/v) NaCl. The slurry 
was stirred in a glass beaker using a magnetic stir rod at 4° C for five hours at 
150 RPM. The slurry was then pipetted into a phenol-safe plastic centrifuge 
tube with screw-cap lid (Oak Ridge/Nalgene), and spun at 10,000 x g (30 
minutes) to separate cells from the EPS supernatant.  
Supernatant was transferred to a fresh phenol-safe plastic centrifuge 
tube with screw-cap lid, and four volumes of ice-cold 95 % ethanol was added, 
mixed and centrifuged at 9,600 x g (10 minutes). Ethanol was decanted and the 
remaining loose pellet EPS was dissolved in 10 ml de-ionised H2O by mixing 
 59 
 
with a pipette and sitting at room temperature for 15 minutes. Samples were 
dialysed against 1 litre of Milli-Q dH2O at 4° C for 48 hours with water changed 
twice daily. The dialysis tubing was at a molecular weight cut off of 3500 
Daltons.  
The dialysed sample was snap frozen in liquid nitrogen, and then freeze-
dried for 24-36 hours (or until dry). Dry EPS extracts were stored at -20° C for 
short term storage, or - 80° C for long-term storage. EPS samples resuspended 
in water or buffer for use in assays was stored at 4° C (for up to one week) or -
20° C.  
2.18.1 Confirmation of sugars in EPS samples by the Dubois assay 
To verify the presence of sugars within the EPS extracts prior to mass 
spectrometry, the Dubois test (phenol sulphuric acid) was performed (66). This 
method uses colorimetric detection for the determination of sugars. Briefly, 2 
mg/ml of rhamnose, mannose, galactose, and glucose sugar standards were 
prepared in water. This standard mix of sugars was serially diluted in water from 
2 mg/ml to 80 µg/ml. EPS samples of 1mg/ml were serially diluted in water to 80 
µg/ml. 50 µl of EPS sample or standard sugar mix was added to a well of a 
polystyrene 96-well plate in triplicate, followed by the addition of 150 µl of 98 % 
(v/v) sulphuric acid, 30 µl of 5 % (w/v) phenol. The plate was incubated for 5 
minutes at 90° C in a static water bath, cooled to room temp for 5 minutes, and 
absorbance measured in a microtitre plate reader at 490 nm.  
N.B. The phenol sulphuric acid method is reported to be accurate to +/- 2 %. 
 
2.19 Mass spectrometry analysis of EPS  
2.19.1 Acid hydrolysis 
Ten milligrams of freeze-dried EPS extracts were re-suspended into 
HPLC- MS grade H2O. 5mM heavy labelled (D-[1-
13C]) galactose, glucose and 
mannose sugars were added to samples for standard addition quantification 
(spiked). Both spiked and un-spiked EPS samples were then acid hydrolysed 
using 2 M trifluoroacetic acid (TFA). Re-suspended solutions of EPS were 
mixed 50:50 with acid and baked for 1 hour at 110° C in 1 ml Teflon capped 
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ReactiVials (Fisher Scientific). Post hydrolysis, the samples were re-suspended 
in 50 μl HPLC grade H2O and 25 μl was transferred into glass vials. 
 
 2.19.2 Glucose oxidase-treatment of EPS 
Glucose and galactose sugars have the same mass, resulting in difficult 
separation between these two sugars using mass spectrometry. Chemical 
removal of glucose in a given sample using glucose oxidase and comparison of 
this treated sample with an untreated sample allowed for quantitative 
differentiation between the two sugars. Mannose is also of the same mass as 
glucose and galactose but did not co-elute over the same acquisition time 
period on the mass spectrometer. The glucose oxidase was re-suspended in 
sodium acetate buffered to pH 5.1 (0.2 M sodium acetate (Fluka)) in H2O. The 
buffer pH was adjusted using glacial acetic acid to a final concentration, 50mM. 
Freezer stock solutions of glucose oxidase were made at 100 U/ml in 10 % 
glycerol and acetate buffer. Catalase was added to the reaction (in order to 
neutralise H2O2 , a by-product of the reaction). 1,000 U/ml enzyme stocks of 
catalase were made up with 10 % glycerol and acetate buffer, then stored at 4° 
C. The reaction consisted of 2.5 μl of oxidase for 125 μl reaction of EPS and 
acetate buffer, with 500 U catalase. The reaction was allowed to proceed for a 
maximum of 15 minutes to prevent any cross-reactivity with galactose. 
Precipitation of samples to remove protein was carried out following 
glucose oxidase treatment using ice-cold acetonitrile in a 1:3 ratio. Samples 
were gently mixed and centrifuged at 12,000 RPM for 60 minutes (4° C), 
followed by the removal of the supernatant by pipette. The supernatant volume 
was reduced by centrifuging in a speed vacuum to ~ 50 µl. Hydrolysed and or 
glucose oxidase-treated EPS samples were re-suspended in H2O rather than 
acetonitrile prior to running on the mass spectrometer. This was due to an 
observed improvement in chromatography when compared to acetonitrile run 
samples. Post hydrolysis, samples were re-suspended in 50 μl HPLC grade 
H2O and 25 μl was pipetted into glass vials. 
 
2.19.3 Running conditions for Agilent QQQ-ESI-LCMS 
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Quantitative analysis of EPS composition was performed using an 
Agilent 6420B triple quadrupole (QQQ) mass spectrometer (Agilent 
Technologies, Palo Alto, CA, US). The QQQ-ESI-LC mass spectrometer was 
coupled to a 1200 series Rapid Resolution HPLCsystem. Five microliters of 
sample extract was loaded onto a Waters X-Bridge Amide HILIC. The flow rate 
was 0.2 m/min and the column temperature was held at 35 °C for the duration. 
The following gradient was used: 0 min – 0% B; 17 min – 54 % B; 18 min – 0 %; 
9 min post-time. QQQ source conditions were as follows: gas temperature 350 
°C, drying gas flow rate 9 L/minute, nebulizer pressure 35 psig, capillary voltage 
4 kV. The fragmentor voltage and collision energies were optimized for each 
compound. Table 2.3 concisely outlines these mass spectrometry method 
specifications used for detection of rhamnose, glucose, galactose and mannose 
in B. multivorans EPS samples. This method was optimised for hexose sugars, 
including 13C labelled sugars.  
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Table 2.3 QQQ HPLC-mass spectrometry conditions for sugar analysis. *The dwell time 
represents 125 milliseconds the time that the mass spec scans for the sugar of that particular mass 
(e.g. rhamnose 163.3) before it scans the next mass. 
 
Method Sugars SIM amide 
column- 13CHex 
 
Flow rate 
(ml/min) 
0.3  
Injection 
volume 
5 µl  
Gradient* 0 min 0 % mobile phase B 
17 min 54 % mobile phase B 
18 min 0 % mobile phase B 
Stop time 18 min  
Post time 9 min  
Mobile phase A 10 %  acetonitrile, 90 
% H2O 
 
0.1 % ammonia 
 
Mobile phase B 10 % H2O, 90 % 
acetonitrile 
 
0.1 % ammonia 
5 mM ammonium formate 
Column Waters X-Bridge 
Amide HILIC  
3.5µm particle size, 2.1x150mm column 
Column 
temperature 
35 °C  
Acquisition 
type 
Selected ion 
monitoring (SIM) 
Glucose, mannose, 
galactose – 179.1 
Polarity- 
NEG 
Dwell 
time*- 125 
Rhamnose – 163.2 NEG 125 
13
C hexoses – 180.1 NEG 125 
 
Further detail on the method development process from EPS extraction 
to data analysis for EPS composition analysis is described in detail in Chapter 
6.  
 
 63 
 
2.20 Iron toxicity assay 
The protective effect of EPS against iron toxicity was assessed using a 
method previously described (68). Overnight mannose-broth cultures of B. 
multivorans were standardised in PBS and incubated at 30°C in the presence or 
absence of 2.5 g/liter purified fructose- or mannitol- derived EPS and 50 mM 
FeSO4. Percentage survival over three hours was calculated by plating serial 
dilutions of the CFU at T = 0 and hourly time points onto LB agar.  
 
2.21 Desiccation assay 
The protective effect of EPS against desiccation was assessed using a 
method previously described (68). Overnight mannose- broth grown cultures of 
B. multivorans were standardised in PBS, and 10 µl of bacteria suspension was 
air-dried and incubated (30° C) in the presence or absence of 2.5 g/liter of 
purified fructose- or mannitol- derived EPS. Viable CFU were determined by 
rehydration of desiccated wells by the addition of 100 µl PBS. Percentage 
survival over three hours was calculated by plating serial dilutions of the CFU at 
T = 0 and daily time points onto LB agar.  
 
2.22 Xanthine/xanthine oxidase generation of reactive oxygen species  
The xanthine/xanthine oxidase method can be used for in vitro cell-free 
detection of reactive oxygen species (ROS) was modified from Bylund et al. and 
Simpson et al. (33,180). This method uses xanthine as a substrate, and 
xanthine oxidase, an oxidant, used with isoluminol (4-Aminophthalhydrazide) 
provided detection of CL. The reaction reagents were added together, pre-
incubated at 37° C. Every three minutes CL was measured at 37° C using a 
TECAN fluorescent plate reader. Reactions were carried out in triplicate wells of 
a white, clear flat bottom 96-well plate. All reaction constituents were made up 
on the day in Krebs ringer buffer (KRG) as follows: pH 7.3, NaCl (120 mM); KCl 
(5 mM);KH2PO4 (1.7 mM); Na2PHO4 (8.3 mM); D-Glucose (10mM); CaCl2 
dihydrate (1mM);MgCl2 (1.5 mM)). Xanthine was stored in a 10 mM stock in 1 M 
NaOH, wrapped in foil and kept at 4° C for up to three months. The final 
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concentration of xanthine included in the reaction was 6 mM. XO was used to 
start ROS production at 12.5 U. Isoluminol was used at a final concentration of 
0.8 mM. EPS samples were diluted from 50 mg/ml stocks in deionized Milli-Q 
water to 1 mg/ml and 0.5 mg/ml. As a reaction control, 80 U/ml superoxide 
dismutase (SOD) was used. Horse radish peroxidase (HRP) was used in the 
assay at 4 U/ml in KRG. Reaction components were added to the desired final 
concentrations in a final volume of 250 µl in the following order: 0.8 mM 
isoluminol, 1 mg/ml EPS, SOD, or KRG only, 6 mM xanthine, 4 U/ml HRP, 10 
minute static incubation (37° C) to equilibrate, 12.5 U xanthine oxidase. CL 
readings were then taken in 3 minute intervals using the incubation setting at 
37° C, on a TECAN fluorescent plate reader (TECAN Infinite 2000 PRO series). 
Controls were isoluminol in KRG alone, blank wells, and SOD containing wells. 
Further detail on this method is described in Chapter 7 where results and 
reaction schematic are presented.  
2.23 Insulin binding assay 
The ability of a panel of Burkholderia strains to bind insulin was assessed 
with a protocol described previously (141). Table 9.4 in the Appendix lists 
strains used in the insulin binding studies (detailed in Chapter 8). Briefly, cells 
were harvested from an LB overnight culture of strains listed in Table 9.4. Cells 
were centrifuged for 3 minutes at 6,500 x g. Cultures were equalised to 0.7 
OD590. Cells were again pelleted, washed in 500 µl 10 mM MOPS (pH 7) and 
centrifuged again. The pellet was re-suspended in 100 µl MOPS containing 
FITC-insulin at a final concentration of 1μg/μl. Following 20 minutes incubation 
at room temperature in the dark, cells were washed three times in 1 ml PBS and 
re-suspended in 100 μl PBS.  
For purposes of fluorescence microscopy, 20 µl of insulin-exposed 
bacterial culture was added to a microscope slide. The slide was air-dried, heat-
fixed, and a cover-slip mounted with Prolong Gold anti-fade mounting medium 
(Promega).  
For 96-well fluorescent plate reader analysis, after the wash steps, 
insulin-exposed cultures were added directly to wells of a black 96-well plate for 
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quantitative analysis at FITC-wavelength (530 ± 30 nm) with a TECAN 
fluorescent plate reader (TECAN Infinite 2000 PRO series). 
 
2.24 Investigation of insulin binding by flow cytometry 
The flow cytometer used in the present study was a BD FACS Aria II 
(Becton Dickenson), 488 nm excitation laser, Size (Forward scatter) detector 
and Internal Complexity (Side scatter) detector. PBS was used for analysis and 
sheath fluid sorting of all samples. Samples were analysed using a BD FACS 
Aria II Fluorescence Activated Cell Sorter (FACS) equipped with a 100 μm 
sheath fluid nozzle. Particle fluorescence was excited at 488 nm, and 
fluorescence intensity recorded at 530 ± 30 nm. Particle sorting efficiency was 
controlled by routinely calibrating with BD FACS Accudrop beads and enabling 
the „Sweet Spot‟ application. These two measures ensured a steady and 
constant stream of microdroplets through the FACS.  
When possible, at least 10,000 events were recorded for each sample 
and the distribution of the optical properties from each event were used to 
construct areas of interest or „gated‟ populations. FITC-insulin exposed cells 
were sorted using FACS and re-cultured to isolate and enrich the small 
subpopulation of insulin binding cells. Isolated bacteria that had bound FITC-
insulin after 20 minutes exposure to insulin were then sorted out from at least 
10,000 cells according to stringent gating for strong FITC- fluorescence.  
After the initial exposure and sort, insulin-bound bright cells were re-
grown prior to re-sorting using FACS to assess the stability of the insulin-
binding phenotype. Insulin-bound cells were re-grown in either LB broth 
supplemented with CV (0.01 % (w/v)) and Burkholderia cepacia selective 
supplement, BCSM agar, or LB agar to monitor for growth and contamination. 
Re-growth between insulin exposure and re-sorting was for 48 hours.  
 
2.25 Persister assay for insulin binding  
To quantify insulin binding of Bcc persister cells, a persister cell assay 
using was used to reveal persister cells after treatment with 100x MIC of 
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ciprofloxacin or ceftazadime. Bacterial cultures were growth overnight in LB to 
stationary phase. Optical density was measured at OD590 to estimate the 
number of cells/ml. For stationary phase cultures, the absorbance OD590 of 0.2 
was approximately 2 x 108 CFU/ml. 500 μl of adjusted cultures were mixed with 
500 μl antibiotic solutions (with a final cell density of 108 CFU/ml per well of a 
48-well microtitre plate). Antibiotics used were ceftazidime or ciprofloxacin at 
100x MIC and incubated statically at 37° C for exactly 24 hours. 
Following incubation, the contents of each well of the 48-well microtitre 
plate were transferred to microcentrifuge tubes and centrifuged for 4 minutes at 
maximum speed. The spent LB supernatant was removed using a pipette, and 
1 ml fresh LB was used to re-suspend the pellet. At this point aliquots were 
removed to carry out post-treatment viable counts (t24h) to enable the calculation 
of persister cell frequency. CFU/ml was determined before, (t0) and after the 
antibiotic treatment (t24h). Persister frequency was calculated as (CFU/ml at t24) / 
(CFU at t0/2).The input, t0, is halved in the equation because the culture was 
initially standardised to 2 x 108 CFU/ml and then 500 µl of that standardised 
culture is mixed with 500 µl of antibiotic, thus halving the dilution to a final cell 
density of 108 CFU/ml. Antibiotic stocks were made up at double strength 
concentration to account for this dilution. 
To continue on and exposure persister cells to insulin, another 
centrifugation step was done with subsequent re-suspension in 1 ml MOPS. 
Microscopy of ceftazidime-derived persister cells entailed combining three 1 ml 
wells (technical replicates from the 48-well plate) prior to insulin exposure. After 
the insulin exposure and washing steps described in the previous paragraph, 20 
µl of washed insulin-exposed cells were pipetted onto a clean microscope slide, 
air dried, heat-fixed, and mounted with coverslips using Prolong-Gold anti-fade 
mounting solution (Promega). Cover-slipped slides were then dried in the dark 
overnight (and kept damp). Coverslips fixed in place with nail varnish the 
following day. Slides were then analysed on a Zeiss AXIOSTAR 
epifluorescence upright microscope under FITC and phase-contrast viewing at 
100x oil immersion magnification. Slide boxes were stored long-term at -20° C 
with desiccant.  
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For FCM analysis of ciprofloxacin-derived persister cells, eight (technical) 
replicates of 1 ml wells were pooled together for each strain from a 48-well 
plate. After pooling, the insulin-binding assay and subsequent wash steps were 
scaled up relative to the increase in volume. Samples were re-suspended in a 
final volume of 7 ml PBS prior to FCM analysis.  
 
2.26 Statistical analyses 
All experiments were performed at least in triplicate, with subsequent 
statistical analysis by one-way ANOVA and Tukey post-tests (Graphpad Prism 
5.0) or followed by other relevant comparisons such as a Dunnetts‟ test or 
orthogonal contrasts (IBM SPSS Statistics, v. 20) to determine p-values. 
Standard error of the mean is represented by error bars. P < 0.05 was deemed 
to be statistically significant. The type of statistical test used, sample size, p-
values, and error bars are outlined in each figure legend.  
Transcriptomic data was processed using two differing statistical 
methods. Microarray data were compared and calculated with the 1-way 
ANOVA test using GeneSpring GX version 7.3.1. (Agilent), whilst the RNA-seq 
analysis was analysed using CLC Genomics Workbench with a Kals‟ test and 
Bonferroni post-test. FDR-corrected p- values were deemed significantly when 
P < 0.05.  
 
2.27 DNA sequencing of B. multivorans C1576 and identification of loci 
encoding putative adhesins.  
Genomic DNA from B. multivorans C1576 was extracted using the 
PureLink Genomic DNA kit (Invitrogen) and sequenced on an Illumina platform 
following library preparation using the TruSeq DNA protocol (Illumina). Reads 
were initially mapped to the B. multivorans ATCC 17616 reference genome, 
enabling identification of unmapped reads (sequences present in C1576 but 
absent from ATCC 17616). These unmapped reads were subjected to both de 
novo assembly and re-mapping to alternative Bcc reference genomes. Mapping 
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and de novo assembly was performed using CLC Genomics Workbench (CLC 
bio). Loci encoding putative adhesins were located within the 
mapped/assembled sequence reads by BLASTN analysis, and the identity of 
the putative adhesins to known sequences was assessed by BLASTN and 
BLASTP analysis at NCBI and www.burkholderia.com (225).  
 
2.28 Dot-blot hybridisations  
Genomic DNA was extracted using the Pure Link Genomic DNA 
Purification kit (Invitrogen) and was normalised to 85 ng/μl in 0.1 M NaOH. 
Three microliter aliquots of the resulting DNA were replica-spotted onto 
Hybond-N+ membranes (GE Healthcare) and air-dried. Membranes were rinsed 
(4 x SSC, 5 minutes; 0.5 x SSC, 5 minutes) prior to baking (80° C, 2 hours). The 
PCR DIG probe Synthesis kit (Roche) was used to generate probes specific for 
the genes encoding the fimbrial usher protein and HecB-like protein, with the 
probe sequences corresponding to nucleotides 2515-2940 of JX191919 and 
nucleotides 12641-13084 of JX191920 respectively (see Appendix Table 9.1 for 
primer sequences). Subsequent pre-hybridisation, hybridisation, washing and 
detection were performed using the DIG-Easy Hyb, DIG Wash and Block Buffer 
Set, and CDP-Star (Roche) according to manufacturer‟s instructio
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Chapter 3: Characterisation of exopolysaccharide-dependent and -
independent phenotypes in the cystic fibrosis pathogen B. multivorans 
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3.1 Introduction  
Organisms of the Burkholderia cepacia complex (Bcc) are important 
pathogens of cystic fibrosis (CF) patients. B. multivorans is responsible for the 
majority of Bcc infections of CF patients in the U.K. Growth of members of the 
Bcc on numerous sugars and sugar alcohols can induce a dramatic 
overproduction of exopolysaccharide (EPS), a putative virulence factor. 
Amongst the most potent inducers of EPS production are mannitol (recently 
approved in CF patients as an inhaled osmolyte) and fructose (which is reported 
to be elevated in the blood and urine of diabetic patients (Kawasaki et al. 
2002)). Although levels of fructose in the lung have not been reported, it has 
been shown that glucose is elevated in the airways of diabetics (29). 
Consequently, if airway concentrations are similarly elevated, the onset of CF-
related diabetes (CFRD) or the therapeutic administration of mannitol could 
potentially promote EPS production within the lungs of Bcc-infected patients.   
Whilst an aim of this study was to assess the role of EPS in virulence, 
the present study also examined the extent to which differences were due to the 
EPS itself, or the culture conditions used to promote its production. 
Consequently, the adopted strategy was to create non-mucoid isogenic 
mutants; specifically, by inactivation of the bceB gene (which encodes a 
glycosyltransferase (216)) in the B. multivorans CF outbreak isolate C1576 and 
the environmental isolate ATCC 17616. C1576 is the index case of a 
transmissible outbreak of B. multivorans from a paediatric CF clinic in the U.K. 
(222). ATCC 17616 is the annotated genome reference strain for B. 
multivorans, and was originally isolated from the maize rhizosphere. The most 
commonly produced type of EPS by the Bcc is cepacian. The structure and role 
of BceB in the cepacian pathway has been previously characterised and 
described previously (216). The bce cluster is highly conserved amongst 
members of the Bcc, and is found in whole, or part, in nearly all members of the 
genus Burkholderia. As described by Ferreira et al., the proposed pathway 
leading to the sugar nucleotide precursors for cepacian (the most commonly 
produced EPS detected to be produced by members of the Bcc involves the 
BceB priming glycosyltransferase (Priming GT) which plays a role in transfer of 
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assembled sugar nucleotides onto the repeat unit of polysaccharide prior to 
transfer across the bacterial outer membrane. The Bce proteins within the 
cepacian biosynthesis pathway include those involved in nucleotide sugar 
biosynthesis (BceA, BceC, BceM, BceN, BceT), glycosyltransferase activity 
(BceB, BceG, BceH, BceJ, BceK, BceR), polymerisation/export functions 
(BceD, BceE, BceF, BceI, BceQ) and acyltransferase activity (BceO, BceS, 
BceU). BceP is of unknown function (68). Inactivation of the bceB gene in B. 
ambifaria resulted in total loss of mucoidy, and the present study predicted the 
same would be true in B. multivorans (17).  
The impact of EPS production on virulence relevant traits in B. 
multivorans was assessed by creating EPS-deficient bceB mutants. The use of 
bceB mutants alongside the respective ATCC 17616 and C1576 wild-type 
strains allowed for detection of EPS-independent and EPS-dependent 
phenotypes. An EPS-independent phenotype was attributed to the sugar or 
sugar alcohol used as a carbon source for growth rather than EPS. This 
differentiation between an EPS-dependent phenotype versus independent is a 
novel approach in contrast to previous literature reporting effects of mucoidy 
and the impact of EPS on virulence in wild-type strains only grown with mannitol 
to induce EPS, without an isogenic non-mucoid isolate to compare back to. The 
sugar response of B. multivorans to mannitol has not previously been 
characterised in this manner. The representative non-mucoid control used in 
phenotypic characterisation studies was mannose, which is another sugar 
elevated in diabetes (relevant to CFRD) (153). The phenotypic studies focused 
on mannitol (as a model for mucoidy inducing sugars) and mannose (non-
mucoid inducing) to assess EPS-independent and EPS-dependent phenotypes. 
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3.2 Aims  
To fully characterise the response of B. multivorans to mannitol and mannose 
by using phenotypic assays with an EPS-deficient mutant to assess phenotypes 
as EPS-dependent or EPS-independent in the following assays: 
 Biofilm formation and antibiotic exposed biofilm survival 
 Swimming motility 
 Virulence in Galleria mellonella  
 Macrophage uptake and survival 
 Resistance to oxidative stress induced by H2O2 
 Adhesion to mucin and extracellular matrix proteins 
 Invasion of A549 alveolar epithelial cells  
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
3.3 Results 
3.3.1 Inactivation of bceB in B. multivorans 
B. multivorans possesses several putative EPS biosynthetic gene 
clusters. The present study focused on the most highly conserved EPS cluster 
within the Bcc, the bce cluster. The present study demonstrates that inactivation 
of bceB (which encodes a glycosyltransferase) eliminated EPS biosynthesis in 
B. multivorans C1576 and ATCC 17616, irrespective of the sugar or sugar 
alcohol present in the growth media (shown in Figure 3.1, and summarised in 
Table 3.1). This indicated common pathways for EPS production are utilised in 
the response of different carbon sources. 
 
Figure 3.1 B. multivorans C1576 wild-type and EPS-deficient mutant grown on mannitol and 
mannose. Following 48 hours of growth B. multivorans C1576 wild-type and bceB crude (CR) EPS-
deficient mutant were assessed for the ability to produce EPS on mannitol and mannose sugar agar 
plates. The wild-type grown on mannose is non-mucoid (a) whilst the wild-type produces EPS on 
mannitol (b). The C1576 bceB CR EPS deficient mutant is non-mucoid on both mannose (c) and 
mannitol (d). Inactivation of bceB renders the strain EPS-deficient.  
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Figure 3.1 highlights the phenotypic differences between mannose and 
mannitol in the wild-type C1576. The wild-type is non-mucoid on mannose, but 
produces EPS on mannitol and induces a mucoid phenotype in an observable 
glossy sheen to the growth on the plate (Figure 3.1(b)). The C1576 bceB 
mutant is non-mucoid on all sugars. These same observations of mucoid/ non-
mucoid phenotypes were observed in the B. multivorans ATCC 17616 wild-type 
and bceB EPS-deficient mutant. These findings are summarized in Table 3.1. 
The purpose of Table 3.1 is aimed to specifically indicate the EPS status 
of the wild-type and bceB CR C1576 and ATCC 17616 on various carbon 
sources, and this was done alongside relevant controls. B. cenocepacia K56-2 
was used as a negative control. It carries an 11 bp deletion within the bceB 
gene and is non-mucoid on all sugars and sugar alcohols.  B. ambifaria was 
used as a basis for comparison from the literature (17). All sugars, with the 
exception of fructose, that induced EPS biosynthesis were sugar alcohols. All 
sugars and sugar alcohols tested failed to induce EPS production in the C1576 
and ATCC 17616 bceB CR mutants, indicating commonality of pathways for 
EPS biosynthesis regardless of carbon source or strain. This indicates bceB 
plays a broader role in other pathways of EPS biosynthesis rather than solely in 
the bce EPS cluster.  
 75 
 
Table 3.1. EPS biosynthesis of Bcc species when grown on sugar media agar supplemented with 
a variety of sugars and sugar alcohols. The purpose of Table 3.1 is to indicate the EPS status of B. 
multivorans wild-type C1576 and ATCC 17616 and bceB CR mutants on various carbon sources. All 
strains tested were ranked according to a scale previously described in Bartholdson et al. (17). EPS 
production was scored on a scale from – (no EPS) to +++ (very mucoid). An example of +++ mucoid 
growth can be seen in Figure 3.1 (b). B. ambifaria AMMD and B. cenocepacia K56-2 were included as 
controls. All the sugars used were in the D-enantiomer form.  
 
 
3.3.2 Assessing growth and mucoidy of B. multivorans on sugars and sugar 
alcohols  
Having created and confirmed the ATCC 17616 and C1576 bceB EPS-
deficient mutants, the wild-types and bceB mutants were used in growth assays 
to ensure that the inactivation of bceB did not alter the overnight growth optical 
density compared to the wild-type. This ensured difference in growth did not 
impact on phenotypes observed in future experiments. The B. multivorans wild-
type and mutants exhibited comparable growth in all sugars and sugar alcohols 
tested. 24 hour average OD590 was ~1.8 for mannitol and mannose, and lower 
overnight OD590 0.4-0.6 in glucose and galactose. Neither glucose nor galactose 
induced EPS synthesis. These sugars were not used of phenotypic studies. 
Growth in glucose is revisited in Chapter 4 with modified media used for the 
purposes of transcriptomic studies. For purposes of simplification, the 
remainder of the studies for virulence relevant phenotypes included mannitol as 
the model for EPS inducing growth condition, and mannose for non-mucoid 
growth condition, although fructose and glucose are included in transcriptomic 
studies reported in Chapter 4. These sugars were chosen not only due to 
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clinical importance but also because the wild-type and bceB CR mutants growth 
was comparable in D- mannitol or D-mannose. 
3.3.3 Mannitol promotes biofilm formation in an EPS-independent manner.  
Having carried out studies that confirmed the B. multivorans EPS-
deficient knockouts, phenotypes were characterised between the wild-type and 
bceB mutant for assessing the sugar response in phenotypic studies relevant to 
virulence. The impact of carbon source on biofilm formation in B. multivorans 
was first assessed.  
Pellicle formation, or biofilm formed in static conditions, was tested in B. 
multivorans ATCC 17616 and C1576 grown and incubated statically for up to 72 
hours at 37° C. Yeast extract media with or without sugars, LBB, or SCFM 
media with or without sugars, were inoculated and pellicle formation was 
assessed visually. B. multivorans ATCC 17616 formed thicker pellicles 
spanning the entire air/liquid interface as well as on the sides of the 50 ml 
Falcon tubes, whilst C1576 formed easily disrupted, thinner pellicles floating 
across surface of media. This is consistent with ATCC 17616 being a robust 
biofilm former. This method did not reveal any obvious sugar impacts on pellicle 
formation. To enable a more robust study of the impact different sugars have on 
biofilm formation, a quantitative assay was adopted, using the MBEC biofilm 
device. 
The environmental strain B. multivorans ATCC 17616 was used for 96-
well pegged lid biofilm assays as it is a robust overnight biofilm former. ATCC 
17616 wild-type and bceB mutant biofilm formation was assessed after 24 
hours of growth in mannitol (EPS-inducing) or mannose (non-EPS inducing). B. 
multivorans was grown on sugar yeast extract agar prior to inoculation into 96-
well plate biofilm device.  
The impact of sugars on biofilm formation was assessed by first 
preconditioning strains during overnight growth on sugar agar prior to 
inoculation into sugar broths for 24 hour biofilm formation (Figure 3.2). In these 
experiments, the wild-type ATCC 17616 formed significantly more biofilm in 
mannitol than in mannose. The bceB mutant also formed significantly more 
 77 
 
biofilm in mannitol than in mannose. These results indicate an EPS-
independent sugar effect on biofilm formation, with mannitol promoting biofilm 
formation.  Additionally, the bceB mutant in mannitol formed more biofilm than 
the wild-type in mannitol. This indicates more biofilm is formed in the absence of 
EPS. These findings highlight the wider impact of sugars and EPS production 
on biofilm formation. 
 
Figure 3.2 B. multivorans ATCC 17616 and bceB CR mutant biofilm formation. Assessment of 
biofilm formation indicates mannitol enhanced biofilm formation in an EPS-independent manner. 
The bceB CR mutant in mannitol also formed significantly more biofilm than the wild-type in 
mannitol. Graph is representative of at least three biological replicates, bars are representative of 
mean values from 16 wells per growth conditions/strain, and error bars are SEM. *** P< 0.0001. 
Statistical test used was 1-way ANOVA with post-test. 
 
3.3.4 Mannitol grown biofilms are resistant to tobramycin independent of EPS 
The impact of sugar grown biofilms and their resistance to antimicrobial 
killing was assessed.  CF patients are regularly administered antibiotic 
treatment with inhaled tobramycin for either Pseudomonas aeruginosa and/or 
Bcc infection. Due to the enhanced biofilm formation in mannitol, the potential 
clinical impact of EPS and biofilm resistance to antibiotic treatment, growth of B. 
multivorans ATCC 17616 in mannitol could alter the efficacy of tobramycin in an 
EPS-dependent or -independent manner.  ATCC 17616 biofilms grown in 
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mannitol or mannose were exposed to tobramycin at 4x the MIC (8 μg/ml) for 24 
hours. This concentration is clinically relevant as it is reported that following 
inhalation, tobramycin concentrations in the alveolar fluid have been recorded 
as high as 9.2 μg/ml (16).  
The biofilm-covered pegs were harvested and biomass was plated for 
viable counts. In previous biofilm assays, sugars played an EPS-independent 
role in ATCC 17616 biofilm formation. Mannitol promoted biofilm formation in an 
EPS independent manner (Figure 3.2). Mannitol enhanced biofilm survival in 
the presense of tobramycin in an EPS-independent manner (Figure 3.3). Both 
wild-type and bceB CR mutant mannose-grown biofilms had a 0.012-0.015 % 
average survival relative to untreated biofilms, in contrast to the mannitol-grown 
wild-type (11.4 % average survival) and bceB CR mutant (6.7 % average 
survival) biofilms.   
 
Figure 3.3 B. multivorans ATCC 17616 wild-type biofilms survived tobramycin exposure 
significantly better than mannose grown. Though there was no significant difference between the 
bceB CR mutants in mannitol compared to mannose, the similar trend as the wild-type was 
observed. The graph is representative of three biological replicates, and bars are the median values 
from three wells (N=3). Error bars are SEM and.  * P<0.05. Statistical significance was assessed 
using a 1-way ANOVA and post-test. 
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The ATCC 17616 wild-type and bceB mutant biofilms survived better 
after formation in mannitol compared to mannose. There was a significant 
difference between the wild-type in mannitol compared to mannose.  Survival of 
tobramycin treatment is likely EPS-independent, although the mannitol vs. 
mannose comparisons for the bceB CR mutant was not significant (P = 0.078). 
These studies highlight the impact of biofilm and sugars on ATCC 17616 
antimicrobial killing by the aminoglycoside tobramycin.   
3.3.5 Swimming motility is enhanced by mannitol in an EPS-independent 
manner 
The impact of mannose and mannitol on swimming motility was carried 
out by making swimming media with the same 2 % sugar and 0.2 % yeast 
extract agar used previously, with 0.3 % (w/v) agarose content. The impact of 
mannose and mannitol on swimming motility in B. multivorans ATCC 17616 and 
C1576 was assessed. Results show (Figure 3.4) mannitol enhanced motility in 
both wild-type B. multivorans ATCC 17616 and C1576 and for both bceB 
mutants. Differences in motility are an effect of the sugar, rather than EPS.  
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Figure 3.4. The impact of sugars on B. multivorans swimming motility. 0.3 % (w/v) agar 
supplemented with yeast extract and the sugar was inoculated with a standardised bacterial 
suspension. Figure shows median diameter measured on swimming agar plates totalling five plates 
per growth condition and strain (n=5). *** P < 0.0001. Asterisks indicate significant increase in 
motility in mannitol relative to non-mucoid mannose control. 1-way ANOVA and post-test were 
used to assess statistical significance.  
 
3.3.6 Growth in mannitol attenuated virulence in the Galleria mellonella model 
of infection  
G. mellonella (greater wax moth larvae) model of infection has been well 
established as a screening system for attenuated virulence studies for a number 
of bacteria, including the Burkholderia (175). B. multivorans was grown on 
sugar agar, standardised in PBS and used to infect larvae at an input of 
approximately 104  CFU. Controls were inoculated with PBS, and of this control 
group, 100 % survived. Results show C1576 wild-type and bceB mutant grown 
in mucoid grown conditions is attenuated in this model (Figure 3.5). Initially it 
was hypothesised that since the process of EPS production is metabolically 
expensive, the wild-type C1576 would be less virulent in the larvae. This was 
not the case, as both the wild-type and bceB mutant both were attenuated in 
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virulence following growth on mannitol. This indicated B. multivorans virulence 
was EPS-independent and attenuated virulence was not due to reduced fitness 
of the wild-type.  
 
Figure 3.5. Larval survival during B. multivorans infection. Survival of G. Mellonella was 
monitored and recorded at 24 and 48 hours (h) post-infection (PI). Larvae were inoculated with B. 
multivorans C1576 wild-type and bceB mutant grown on mannose or mannitol. Following growth in 
mannitol, C1576 bceB mutant was attenuated in virulence at 24 hours. 100 % of controls survived 
(inoculated with PBS). Asterisks denote significant attenuation relative to mannose. Bars represent 
average percentage survival from five separate experiments with 10 larvae each condition. Error 
bars are SEM.  ** P < 0.005, *** P<0.0001. Statistical significance was assessed by two-way ANOVA 
analysis followed a post-test.  
3.3.7 Impact of sugars on B. multivorans macrophage survival  
For this assay, J774.1 murine macrophages were infected (MOI 40) with 
mannitol or mannose-grown B. multivorans C1576. After two hours initial 
uptake, extracellular bacteria were killed with a two hour ceftazadime and 
kanamycin treatment. The four hour time point was taken two hours after 
antibiotic treatment. The 24 hour time point was taken after a separate two hour 
of antibiotic treatment. Infected monolayers were lysed, serially diluted, and 
plated for viable counts onto LB agar.  
Time points taken were input or 0 hours, 2, 4, and 24 hours. Figure 3.6 
shows the percentage of survival relative to input bacteria of the macrophage 
infection time series representative of several repeats of this macrophage 
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infection experiment. This study first examined whether any differences in 
uptake existed between mannitol or mannose growth C1576 wild-type and 
mutant. There were no significant differences between any of the strains at the 
2 hour time-point (Figure 3.6). There was some technical replicate-variation at 
this 2 hour time point for the wild-type – with one low value being an outlier 
(0.28 % survival) compared to the other two average percentage survival at 2 
hours post-infection (1.25 and 3.78 %). This lower value outlier further suggests 
more exploration (possibly with fluorescent microscopy) into earlier uptake time 
points is needed to definitively pinpoint the potential role for EPS in uptake by 
macrophages. In a separate experiment where only input and 2 post-infection 
time points were taken with mannitol-grown bacteria, the wild-type in mannitol 
compared to the bceB CR in mannitol, resulted in a 0.11 % and 0.85 % uptake, 
respectively, suggesting that EPS did indeed impact on uptake in this instance 
relative to the mutant in mannitol. Overall, difficulties with reproducibility of this 
experiment would be greatly improved by using engineered aminoglycoside-
sensitive strains, as outlined by Hamad et al. (86).  
At 4 and 24 hours post infection, (post infection periods considered 
relevant to intracellular survival and growth), the C1576 wild-type grown in 
mannitol (EPS-inducing) was significantly different (P < 0.05) from all three 
other samples. Figure 3.6 indicates that all 4 strains grew intracellularly. The 
C1576 wild-type and bceB CR mutant grown in mannitol appear different in 
growth rate from 4 to 24 hours compared to the mannose grown strains. There 
was a 1.2-log increase in growth in both the mannitol-grown wild-type and bceB 
mutant, indicating an EPS-independent ability to replicate and survive within 
macrophages during these periods. In the mannose-grown wild-type and bceB 
CR mutant, only a 0.9-1-log increase in growth occurred between 4 and 24 
hours post-infection. This suggests that mannitol promoted intracellular growth 
and survival relative to mannose. This leads to the conclusion that both wild-
type and bceB CR strains growth equally well in mannose as in mannitol, hence 
the inclusion of mannose throughout phenotypic studies presented in this 
chapter.  
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 Figure 3.6 Macrophage uptake and survival assay with B. multivorans C1576 wild-type and 
bceB mutant. C1576 was grown in mannitol or mannose-yeast extract broths, then standardised 
and used to infect J774.1 murine macrophages. Chart shows representative average percentage 
survival from three wells per condition. 2, 4 and 24-hour time points were taken. Error bars 
represent standard error (SEM). Statistical significance (calculated by orthogonal contrasts using 
SPSS) exists at 4 and-24 hours post infection between the wild-type C1576 grown in mannitol and 
the three other conditions.   
 
To improve upon the macrophage infection assay, the preference would 
have been to avoid high concentrations of ceftazadime and kanamycin which 
are routinely used in the literature for this type of assay. Hamad et al. reported a 
mutagenesis system for B. cenocepacia to create gentamicin sensitive mutants 
by deleting/inactivating a gentamicin efflux pump (86). The same approach was 
adapted for mutagenesis of oprA (gene involved in resistance to 
aminoglycosides e.g. gentamicin) in B. multivorans ATCC 17616 and C1576; 
however the process was unsuccessful after repeated attempts to obtain 
gentamicin sensitive mutants. Thus, this experiment was difficult to reproduce. 
In previous repeats of the macrophage infection assay, mannitol-grown wild-
type and bceB CR mutant were relatively equal in uptake at two hours post 
infection, though on one other previous experiment, the mutant was increased 
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in uptake 3-fold relative to the wild-type grown in mannose. This initial uptake 
time point required optimisation. From previous repeats of the macrophage 
survival assay, at 24 hours post infection the C1576 bceB CR mutant grown in 
mannitol and mannose had  a 9-10 % survival (relative to input), whilst the wild-
type C1576 grown in mannitol and mannose had a 1.3-3 % survival (relative to 
input), respectively. These results contradicted the data presented in Figure 3.6 
and again highlight the need for a reproducible system for modelling 
macrophage infection processes.  
During optimisation of MOI for the macrophage survival assay, it was 
observed that an MOI of 40 resulted in ~ 5 % survival (relative to input) of both 
wild-type and bceB CR at 24 hours post infection (the only time point taken 
during optimisation). When the MOI was increased to 100 (an excessive load of 
bacteria per macrophage), 45 % survival of the mannitol-grown wild-type was 
observed. However, the mannitol-grown C1576 bceB CR mutant lysates 
replicated to 300 % relative to the input of bacteria. It is likely in this case that 
bacteria had been taken up, replicated, and then spread to surrounding cells 
within the monolayer. The monolayer was not entirely intact at this time point as 
viewed under bright field microscopy, indicative of bacterial lysis of the 
macrophages.  
 
3.3.8 Growth in mannitol leads to protection from H2O2 induced oxidative stress  
A hydrogen peroxide in vitro protection assay was used to determine the 
impact of sugars on protection from H2O2 induced stress. As described in the 
methods chapter, B. multivorans C1576 mannitol- or mannose-grown culture 
were standardised to an OD590 of 1 in PBS prior to exposure to 5 mM H2O2.  
Figure 3.7 depicts average percentage survival of B. multivorans wild-type and 
bceB mutant following exposure to 5 mM H2O2. Mannitol grown C1576 wild-type 
and bceB mutant survived treatment with H2O2 better than mannose grown. The 
C1576 bceB mutant grown in mannitol survived significantly less than the wild-
type grown in mannitol. This indicates the mechanism for mannitol stress 
protection acts independent of EPS, although the presence of EPS may still 
play a role to some extent.   
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Figure 3.7. B. multivorans C1576 wild-type and bceB mutant grown in mannitol or mannose 
treated with 5 mM H2O2. Mannitol-grown C1576 wild-type and C1576 bceB CR mutant survived 
oxidative stress significantly better than mannose grown, whilst there still was a significant 
difference between the wild-type and bceB CR mutant in mannitol, indicating mannitol promotes 
survival by an EPS-dependent and –independent mechanism. The figure represents the mean of 
three wells per treatment (n=3). Error bars represent SEM and statistical significance was assessed 
using a 1-way ANOVA and post-tests. **P <0.005, ***P <0.0001 
 
3.3.9 Invasion of A549 epithelial cells is EPS-independent  
It has been shown previously that members of the Bcc are invasive to 
this cell line (32). Bacteria were grown in mannitol or mannose cultures and 
used to infect A549 epithelial cell monolayers (MOI 50). After 2 hours, 
extracellular bacteria were killed with antibiotic treatment. After an additional 2 
hours monolayers were lysed using Triton-X 100. Lysates, containing bacteria 
that had successfully invaded A549 cells and survived antibiotic treatment, were 
plated for viable counts. Results in Figure 3.8 shows the mannitol-grown C1576 
wild-type and bceB mutant invade A549 cells significantly better than when 
grown in mannose. Mannitol promoted invasion of A549 epithelial cells in an 
EPS- independent manner. Overall, it should be noted that invasion levels are 
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extremely low, however these results and significant differences were 
reproducible and thus deemed biologically relevant.  
 
Figure 3.8. The impact of sugars on invasion of A549 lung epithelial cells. A549 lung epithelial 
cells were infected with mannitol- and mannose-grown B. multivorans C1576 (MOI 50). C1576 
wild-type and bceB mutant was significantly more invasive when grown in mannitol compared to 
bacteria grown in mannose, indicating mannitol enhanced invasion was independent of EPS. 
Representative data from experiment repeated three times, bars are median of three wells (n=3) 
per strain and growth condition. * P < 0.05, ** P < 0.005, error bars represent SEM. Statistical 
significance was assessed using a 1-way ANOVA with post-tests.  
 
3.3.10 Impact of mucoidy and sugars on abiotic adhesion is strain variable  
3.3.10.1 The impact of EPS and sugars on adhesion to extracellular matrix 
proteins 
The impact of mucoidy and sugars on the ability of B. multivorans to 
adhere to three different types of extracellular matrix (ECM) proteins was 
assessed, by coating the wells of polystyrene plate with fibronectin, laminin, or 
collagen (type II). After allowing bacteria to adhere to coated wells for two 
hours, no differences were detected in the crystal violet reading (as assessed 
by reading absorbance at 570 nm) between mannitol or mannose grown C1576 
wild-type or bceB mutant (data not shown). These adhesion experiments were 
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optimised and repeated at least four times; no significant differences were 
observed.  
 
3.3.10.2 The impact of EPS and sugars on adhesion to mucin 
Next, the impact of mucoidy on adhesion to the glycoprotein mucin was 
assessed. Mucins are abundant in the mucus and CF respiratory tract and 
presence of mucin proteins are elevated in the lung during periods of pulmonary 
exacerbation. B. multivorans ATCC 17616 and C1576 bceB mutants were 
grown in mannitol or mannose. Cultures were standardised prior to application 
for three hours to mucin coated wells in a polystyrene plate. Wells were then 
washed 10x in PBS and protein/bacteria released from wells with Triton-X 100. 
Serial dilution of lysates onto LB agar allowed for calculation of viable CFU. The 
input and three hours post adhesion were used to calculate percentage 
adhesion. 
In the mucin adhesion assay, B. multivorans ATCC 17616 adhesion was 
EPS-dependent. The wild-type in mannitol adhered significantly more than the 
wild-type in mannose and the mannitol grown bceB mutant (Figure 3.9(a)). 
Mannitol grown C1576 wild-type and bceB mutant (Figure 3.9 (b)) adhered 
significantly better than wild-type grown in mannose. This indicates C1576 
adhesion to mucin is EPS-independent and that there is strain variation in 
mannitol promoted mucin adhesion, with mannitol having a broader positive 
effect on adhesion. 
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Figure 3.9. The role of EPS in promoting the adherence of B. multivorans to mucin is strain-
dependent. Bacteria were grown overnight in mannitol or mannose-containing media, prior to 
adhesion to mucin-coated wells for 3 h. Following washing, adhered bacteria were enumerated by 
viable counts. Data correspond to mean of three independent experiments, each in triplicate. Error 
bars indicate SEM. *** P < 0.0001. (a) Adhesion of wild-type B. multivorans ATCC 17616 and the 
corresponding EPS-deficient bceB mutant. The enhanced adhesion of wild-type observed in the 
presence of mannitol is abolished in the bceB mutant, indicating it to be EPS-dependent. (b) 
Adhesion of B. multivorans C1576 and the corresponding EPS-deficient bceB mutant. The enhanced 
adhesion of wild-type in presence of mannitol is retained in the bceB mutant, indicating it to be 
EPS-independent. 
These mucin adhesion results, and additional experiments where the 
characterisation of novel adhesins identified in B. multivorans C1576, will be 
described further in Chapter 5. Data shown in Figure 3.9 here, is re-presented 
in Chapter 5 as a means to re-iterate rationale for the sequencing and 
characterisation study.  
3.4 Discussion  
  B. multivorans is now the most frequently isolated member of the 
Bcc in CF patients, however relatively little is known about the virulence and the 
role of EPS in this species. Results from the present study suggest EPS-
dependent and EPS-independent phenotypes are apparent following growth on 
mannitol. This study focused on mannitol and mannose as models for other 
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mucoid (EPS-inducing) and non-mucoid (non EPS-inducing) sugars. To 
determine the actual impact of EPS production and growth mannitol had on the 
phenotypic behaviour of B. multivorans, an EPS-deficient mutant was made by 
insertional inactivation of the bceB gene, which encodes a glycosyltransferase 
within the bce EPS cluster. Virulence-related phenotypes assessed within this 
chapter were altered following growth in the presence of mannitol compared to 
mannose, and these phenotypes were largely EPS-independent. Throughout 
these experiments, the differentiation between EPS-dependent and -
independent phenotypes was distinguished by using the bceB mutant.  
 Cumulatively, the phenotypic assays used to study B. multivorans in the 
present study showed the influence clinically relevant sugars have on virulence-
related strategies and phenotypic behaviour of this opportunistic pathogen. The 
assessment of phenotypes, which were the focus of this study, would not have 
been attributable to EPS (EPS-dependent) or broader sugar effect (EPS-
independent) without the inclusion of the bceB non-mucoid mutants. An EPS-
deficient mutant has not previously been used to assess Bcc phenotypes and 
the association with mucoidy and EPS production, and therefore it is possible 
that previous studies outlining the impact of mucoidy on behaviour of the 
organisms have not taken into full account the broader impact the sugar plays 
on phenotypes such as motility and stress survival.  
 The present study demonstrated that inactivation of bceB eliminated EPS 
biosynthesis irrespective of the sugar or sugar alcohol present. This indicated 
that EPS pathways must be common in their response to different sugars, thus 
confirming the crucial role of the bceB gene and its protein product in 
biosynthesis of EPS in B. multivorans. In phenotypic studies, growth on 
mannitol enhanced motility, increased biofilm formation and invasion of A549 
epithelial cells, and attenuated virulence in the G. mellonella insect model of 
infection. Crucially, these same observations were made in the wild-type and in 
the non-mucoid bceB mutant, indicating that these phenotypes are EPS-
independent.  
 90 
 
 The present study found growth on mannitol (and to some degree EPS) 
promoted invasiveness to A549 epithelial cells. It was previously reported that 
B. multivorans and B. cenocepacia are invasive to A549 epithelial cells, and that 
lipase activity is linked to the ability to invade (140). In other cell lines, literatures 
suggested the production of EPS by the Bcc could functionally mask uptake and 
recognition by immune cells; however the present study observed no 
differences were observed between the C1576 mannitol-grown wild-type 
(mucoid) or bceB non-mucoid mutant at 2 hours post infection.  At 4 and 24 
hours post infection, it was observed that both strains in mannose and mannitol 
were able to survive and replicate in macrophages. At both 4 and 24 hours, the 
wild-type C1576 grown in mannitol was significantly different than the other 
samples.  
Admittedly, due to difficulties in reproducibility and the intrinsically 
resistant nature of Burkholderia requiring high concentrations of antibiotics (to 
kill extracellular bacteria), it would be best for future experiments to utilise 
aminoglycoside-sensitive strains, created by a clean deletion of gentamicin-
specific efflux pump genes (as described by Hamad et al. for B. cenocepacia 
(86)). The use of gentamicin-sensitive strains in conjunction with fluorescent 
confocal microscopy would be an ideal combination to further elucidate the role 
EPS in macrophage uptake and survival in B. multivorans. In the present study, 
attempts were made to generate gentamicin-sensitive B. multivorans strains, 
but this proved unsuccessful. It is possible that B. multivorans compensated for 
the deletion of one gentamicin efflux pump by activating others. Using confocal 
microscopy, it has been observed that members of the Bcc can survive and 
multiply in vesicles within macrophages for extended periods of time. These 
specialised vesicles have been termed Burkholderia cepacia containing vesicles 
(BcCV‟s) and were quantifiable using fluorescent confocal microscopy (109). 
Recent studies have reported B. multivorans co-localisation with lysozymes in 
BcCV‟s during 2-6 hours post-macrophage infection, though there was strain 
variation observed (172). A study including both microscopy and 
aminoglycoside-sensitive mutants could elucidate the mechanism of mannose-
or mannitol-grown B. multivorans survival within macrophages at varying time 
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points, and confirm the significant difference at 4 and 24 hours between wild-
type mannitol-grown (EPS-inducing growth condition) from other samples.  
Since it is possible there are other gentamicin efflux pumps able to 
compensate for the loss in B. multivorans, it may require more than one 
gentamicin efflux pump clean deletion to create a gentamicin sensitive strain. 
Additionally, full assembly of the C1576 genome would also be of benefit for 
creating a gentamicin-sensitive CF isolate.  
Abiotic adhesion to mucin was EPS-independent in the CF clinical isolate 
C1576. This EPS-independent adhesion could allow for a competitive 
advantage during pulmonary exacerbations in the CF lung, during which time 
mucin levels are elevated. The adhesion of the environmental strain ATCC 
17616 was EPS-dependent, perhaps owing to its environmental lifestyle, where 
EPS is reported to play a role in adhesion and initial colonisation for many plant 
symbionts and pathogens (68). The EPS-independent adhesion of C1576 
indicated variance between these two isolates from different sources. This 
variance was further explored by sequencing the CF isolate C1576. Subsequent 
analysis of the de novo assembled sequence and results on the study of novel 
adhesins identified and characterised are presented and discussed in Chapter 
5. Furthermore, studies used to assess whether growth on different sugars and 
sugar alcohols influenced the transcriptional profiles of B. multivorans, and 
analysis of the EPS composition and biological activity following growth on 
mannitol and fructose are described and discussed in Chapters 4, 6 and 7, 
respectively.   
Mannitol is a sugar alcohol formed by the reduction of mannose or 
fructose. It is involved in the bacterial catabolism pathway, where it serves as a 
source of fermentable sugar (191). The inhaled administration of the 
recommended 800 mg a day of mannitol as an osmolyte for CF patients or the 
use of mannitol-coated antibiotics (2,3) could impact the phenotypic behaviour 
of the organism. The clinical trials reported during development of inhaled 
mannitol have shown two weeks of treatment does not alter bacterial diversity 
or bacterial load. It is possible that administration of mannitol could put selective 
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pressure within the lung to select for loss of EPS production, potentially leading 
to a mucoid to non-mucoid transition and more aggressive infection. However, 
many of the phenotypes observed in B. multivorans wild-type and mutant were 
not dependent on the production of EPS but rather an effect of mannitol itself. 
The present study examined the impact of growth in mannitol and mannose on 
B. multivorans biofilms, and the impact of sugars on biofilm eradication by 
tobramycin, an aminoglycoside antibiotic. Findings showed mannitol promoted 
biofilm formation and survival against antimicrobial killing in an EPS-
independent manner. Tobramycin is prescribed for the treatment of Bcc and P. 
aeruginosa CF respiratory infections, therefore the potential for EPS or mannitol 
to protect biofilms from eradication by antibiotic treatment is clinically relevant. 
Biofilms are implicated in chronic recurrent infections and are made of dormant 
cells and highly antibiotic resistant persister cells. It has been reported that 
mannitol enabled the eradication of bacterial persisters by aminoglycosides (6). 
Mannitol was used to activate E. coli persister cells prior to treatment with 
gentamicin, streptomycin, and kanamycin. This combination resulted in reduced 
persister cell survival and halted the spread of E. coli in the murine model of 
infection. The quinolones and β-lactam classes of antibiotics were not enhanced 
in bactericidal killing against isolated E.coli persister cells by mannitol, 
suggested mannitol specifically potentiated persister cell killing for 
aminoglycosides only. Allison et al. suggest the addition of mannitol or other 
metabolites could increase bactericidal effects of antibiotics against biofilms and 
persister cells, thereby improving eradication of chronic and recurrent infections 
(6). Based on these findings, it might be expected that growth in mannitol might 
enhance biofilm eradication by tobramycin through its actions on persister cells; 
however the present study found the opposite effect of enhanced biofilm 
survival following tobramycin exposure. The present study used mature biofilms 
grown on polystyrene pegs, which likely contained a more realistic mix of cell 
types, and therefore is more clinically relevant than an isolated population of 
persister cells.  
Elevated sugars due to administration of inhaled mannitol, or glucose, 
(which is known to be elevated in diabetic airways (29)) could influence 
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phenotypic behaviour by increasing available carbon source in the airways, or 
by inducing EPS production. It seems prudent to monitor the impact of mannitol 
administration or the onset of CFRD on the microbiology and behaviour of the 
organism within the context of CF lung disease and CFRD management. This 
could be done by using YEM growth media to monitor for loss of mucoidy and 
link EPS with disease progression. An indication of whether the organisms had 
switched between a mucoid or non-mucoid phenotype over a period of 
colonisation could guide treatment options and predictability of infection 
outcome, although both host and bacterial factors would play roles. The 
administration of mannitol could promote the mucoid to non-mucoid transition 
by placing selective pressure on the metabolically expensive EPS biosynthesis 
process. Silva et al. showed that a non-mucoid B. multivorans isolate survived 
long-term nutrient deprivation better than a mucoid isolate, thus suggesting 
mucoidy could be a disadvantage to chronic infection where nutrient deprivation 
and stresses are encountered. The study also suggested that in the mucoid and 
non-mucoid CF isolate pair, taken 13 years apart, bacterial fitness had changed 
to survive in the CF lung by supressing EPS production ability and varying other 
phenotypic traits (178). This brings into question whether monitoring clinical 
isolates on YEM alone is enough for monitoring the broader potential for clinical 
impact of mannitol administration on the CF lung. It may be conducive to use 
the 96-well biofilm assay to assess if mannitol administration enhanced 
antibiotic resistance during or after the course of treatment.  
The data from the present study suggest a role for mannitol in stress 
protection of B. multivorans. The evidence related to biofilm formation and 
antibiotic resistance, oxidative stress survival, as well as a role for motility are in 
agreement that mannitol benefits the organism, triggering phenotypic changes 
relevant to stress survival and virulence. The importance and role of EPS in the 
clinical lifestyle of B. multivorans and other members of the Bcc has been a 
topic of discussion in the literature. Zlosnik and colleagues suggested that a 
mucoid strain could be associated with a strain that favours a chronic 
attenuated infection (234). EPS-dependent and independent traits outlined in 
the present study could be linked to survival in the CF lung, where interactions 
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with phagocytes, community lifestyle within biofilms, and exposure to antibiotics 
and other stresses, are common.  
Taken together, these data indicated inhaled mannitol could have potentially 
deleterious effects on the CF lung harbouring a B. multivorans infection. Sugars 
and sugar alcohols altered the behaviour of the organism and induced putative 
stress resistance and virulence-related phenotypic changes linked to 
persistence and chronic infection. Careful consideration when prescribing 
mannitol and watchfulness for any changes in bacterial phenotypes during and 
after mannitol treatment would aide guidance of treatment options and 
prediction of infection outcome. 
 95 
 
3.5 Conclusions 
1. The bce gene cluster plays a pivotal role in EPS biosynthesis in B. 
multivorans. Inactivation of bceB resulted in total loss of mucoidy on all 
sugars and sugar alcohols tested, which suggests commonality of EPS 
biosynthesis pathways. 
2. There exists a wider role for mannitol in the behaviour and response of B. 
multivorans based on results from virulence related in vitro and in vivo 
phenotypic studies. The bceB isogenic mutant used in assays alongside 
wild-type EPS-producing strains allowed assignment of phenotypes as EPS-
dependent or EPS-independent.   
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Chapter 4: Transcriptomic profiling of the B. multivorans sugar response 
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4.1 Introduction 
To date, few gene expression studies have examined B. multivorans, and 
transcriptional profiling of the response to clinically relevant sugars and the 
determination of the molecular basis for EPS biosynthesis has not been 
performed. The present study used transcriptional profiling by two different 
methods, microarray and RNA-seq, to determine the B. multivorans whole 
genome sugar response to clinically relevant sugars fructose, mannitol (both 
EPS-inducing), mannose and glucose (non-EPS inducing). The present study 
describes the impact of clinically relevant sugars on mucoidy and gene 
expression of both an environmental B. multivorans isolate (ATCC 17616) and a 
CF isolate (C1576) in EPS and non-EPS inducing sugars.  
Literature suggests a role for mucoidy in stress protection pertinent to 
chronic infection. A study by Silva et al. indicated motility, chemotaxis, biofilm 
formation, nitrogen metabolism; antibiotic resistance, membrane proteins, and 
secretion genes were altered in the transcriptome profile comparison of a B. 
multivorans clonal non-mucoid and mucoid isolates (178). Determining an 
organism‟s transcriptional response to growth on different clinically relevant 
sugars would reveal the underlying process of EPS biosynthesis and allow for 
interpretation of B. multivorans behaviour relevant to potential ramifications in 
the CF lung. The current study adopted a well-rounded approach to assess the 
nutritional cues for EPS and B. multivorans gene expression changes in 
response to clinically relevant sugars fructose, mannitol, mannose and glucose. 
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4.2 Aims 
1. Use transcriptomic profiling methods (microarrays and RNA-seq), to 
examine the whole genome regulation of B. multivorans following growth on 
fructose, mannose, glucose, and mannitol. Identify commonalities with 
previously published transcriptome studies of Bcc and mucoidy and relate 
findings to Chapter 3 phenotypic studies. 
2. Study EPS induced by differeing sugars/nutritional cues and the 
transcriptional response that results in EPS production in order to define the 
genetic basis for EPS production. 
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4.3 Results 
4.3.1 Growth media used to investigate nutritional cues of EPS induction 
Prior to selecting growth conditions for use in transcriptomic studies, the 
mucoidy of B. multivorans in a variety of nutritional conditions was assessed. It 
is well established that YEM induces mucoidy in the Bcc, but the molecular 
basis and genetic controls of EPS induction by mannitol or YEM or any specific 
nutritional cue is not known. Therefore the present study examined EPS 
induction in defined media with and without mannitol, as well as by modifying 
standard YEM by altering mannitol or yeast extract concentrations.  
N-minimal media with 2 % (w/v) mannitol failed to support EPS 
production in B. multivorans even after 48 hours of growth. Synthetic Cystic 
Fibrosis sputum Media (SCFM) + 2 % (w/v) mannitol did induce EPS production 
of both B. multivorans ATCC 17616 and C1676 (Table 4.1).The impact of 
concentration of YE in the media whilst maintaining the sugar present at 2 % 
(w/v) was next assessed based on previous observations with N-minimal media 
that something in addition to mannitol was required for EPS-induction. 
Increasing the YE content of YEM from 0.2 % to 2 % (w/v) rendered B. 
multivorans non-mucoid. Thus this suggested there must be a nutritional 
deprivation or concentration gradient requirement to induce EPS biosynthesis. 
The impact of changing concentration of the EPS-induction sugar mannitol was 
assessed. The sugar agar YE concentration was held constant (0.2 % (w/v)), 
and mannitol concentration varied from 0.25 %-2 % (w/v). At 0.25 % (w/v) 
mannitol, B. multivorans still produced EPS produced, therefore, for ATCC 
17616 microarrays the lower reduced 0.25 % (w/v) mannitol (reduced YEM) 
was used and compared to the standard YEM media. This comparison was 
used to identify any dose-dependent whole genome responses to mannitol.  
As previously highlighted in Chapter 3, D-glucose and D-galactose did not 
support robust growth in B. multivorans when used to supplement 0.2 (w/v) YE. 
When the YE was increased in the media to 2 % (w/v) with 2 % (w/v) D-glucose 
growth was robust. The comparison between this D-glucose containing media 
(YEG) and non-mucoid YEM is the only comparison made with D-glucose where 
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the only difference in the media is the sugar. Genes differentially expressed 
were in response to glucose or mannitol rather than EPS production.  
Table 4.1. B. multivorans growth on different media alters mucoidy. B. multivorans ATCC 17616 
and C1576 mucoidy was scored as ‘+’ if EPS was visibly produced, and ‘-’ if non-mucoid. YE, yeast 
extract. SCFM, synthetic cystic fibrosis media (made as described by Palmer et al.). *No observed 
growth defect in glucose (YEG). 
Media  YE conc. (% w/v) Sugar conc. (% w/v) Mucoidy 
YE/SUGAR MEDIA    
Non-mucoid YEM 2 2 - 
Reduced YEM 0.2 0.25 + 
YEG* 2 2 - 
YEM 0.2 2 + 
YEF 0.2 2 + 
YEO 0.2 2 - 
OTHER MEDIA    
N-minimal + Mannitol n/a 2 - 
SCFM* + Mannitol n/a 2 + 
*Palmer et al.. (149) 
Thus, growth media chosen for transcriptional profiling based on these 
studies of the nutritional cues for EPS production included, for microarray 
growth conditions, EPS-inducing D-fructose (YEF) and two concentrations of 
mannitol (0.25 % (w/v) „reduced YEM‟) and standard YEM. The non-mucoid 
control used in the microarray studies was mannose (YEO). Cardiff University 
collaborators had designed an Agilent custom ATCC 17616 4 x 44K microarray 
platform, which restricted use to the environmental ATCC 17616 isolate. 
The use of the clinical isolate without a fully annotated reference genome 
was possible using RNA-seq. Growth conditions for B. multivorans C1576 RNA-
seq analysis included two mannitol-containing growth media: standard YEM and 
non-mucoid YEM. YEO, and YEG, were also included.  
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These different growth conditions enabled comparisons and whole 
genome expression analysis of the B. multivorans sugar response. 
Comparisons were made between growth conditions that were altered in only 
sugar content. Though it would seem more clinically relevant to utilised SCFM 
media with or without the clinically relevant sugars in this study, the aim was to 
fundamentally assess the underlying transcriptional controls of EPS production 
to assess the whole genome response to clinically relevant sugars. Thus, the 
growth media commonly used to induce EPS (YEM) and variation of this media 
was adopted for transcriptional profiling (Table 4.1).  
4.3.2 Transcriptional profiling sample quality control  
Quality control of data obtained from the microarray study was assessed 
using GeneSpring GX software version 7.3.1, by Dr. Andrea Sass (formerly of 
Cardiff University, presently of University of Ghent). B. multivorans ATCC 17616 
microarray replicate samples were clustered for similarity (Figure 4.1). The 
mucoid fructose and mannitol samples clustered together, and mannose and 
the lower percentage of mannitol are separate in the tree hierarchy. This 
analysis, and raw data processing, expression analysis and statistical tests 
were generated by GeneSpring software. Lists of significantly differentially 
expressed genes were analysed using Microsoft Excel.  
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Figure 4.1. B. multivorans ATCC 17616 microarray biological replicates. The samples clustered 
together by growth conditions, with mucoid conditions D-fructose (YEF) and the higher concentration of 
D-mannitol (YEM) more closely related on the tree than reduced YEM and D-mannose (YEO). Clustering 
was based on sample and default settings on GeneSpring GX software version 7.3.1 expression analysis 
software.  
All microarray data, fold changes and p-values of gene lists can be found 
in the Appendix CD. Microarray differentially expressed genes with a less than 1.5-
fold-change were excluded from statistical analysis. Data significance was achieved 
by 1-way ANOVA analysis. Intergenic (IG) regions were excluded in the microarray 
gene expression analysis.  
In Figure 4.2, hierarchical clustering of RNA-seq samples is shown. During 
quality control of RNA-seq data, it become clear through principal component 
analysis using a projection scatter plots, as well as RPKM values, that only 2/3 
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biological replicates per condition should be carried forward for further analysis. 
Reasons for these dissimilarities between the remaining biological replicates have 
not been identified, but outliers were excluded to prevent skewing of data. Thus, two 
biological replicates per growth condition were used for statistical analysis and data 
presented in following discussion are based on four pair-wise sample comparisons. 
The YEM, YEG and non-mucoid YEM growth conditions clustered on a branch 
separate from the YEO samples, but pairs of samples from different growth 
conditions were still distinct. RNA-seq data was analysed with CLC Genomics 
Workbench expression analysis software (CLC bio). Each pairwise comparison was 
followed by statistical testing using Kals‟ test and post-tests with FDR-adjusted p-
values. The ATCC 17616 reference genome was used to map C1576 RNA-seq 
reads. Future research will also include mapping RNA-seq reads to the B. 
multivorans CGD1 reference genome, and further assessing the C1576 
transcriptional response with a larger sample size.  
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Figure 4.2. B. multivorans C1576 RNA-seq biological replicates. Hierarchical cluster generated by CLC 
Genomics workbench (CLC bio) for sample quality control prior to expression analysis. Non-mucoid 
growth conditions: YEO, non-mucoid YEM and YEG. Mucoid condition: YEM. Two biological replicates 
(Rep) per sample and pair-wise comparisons were carried forward for statistical analysis.  
 
Genes in the RNA-seq data not significantly differentially regulated were 
not included in any further analysis. Significantly regulated genes common to all 
pairwise comparison from biological replicates were identified and used for data 
analysis. Complete gene lists of significant differentially expressed genes and 
raw data from the RNA-seq study are included in the Appendix CD.  
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4.3.3 Transcriptome distribution of global differential gene expression  
The number of genes differentially transcribed in B. multivorans ATCC 
17616 and C1576 from the transcriptome studies are listed in Table 4.2. 
 
Table 4.2 B. multivorans global gene expression in response to growth on different sugars. B. 
multivorans ATCC 17616 and C1576 differentially expressed genes but there were overall fewer 
genes differentially expressed in C1576 likely due to the variability between samples. Two 
biological replicates per growth condition were used for RNA-seq analysis. ‘vs.’ indicates genes 
differentially regulated in the first growth condition relative to the second.  
  
Number of genes significantly altered in gene 
expression 
B. multivorans growth 
condition 
  Upregulated Downregulated Total 
ATCC 17616 Microarray 
   YEM vs. YEO  825 647 1472 
Reduced YEM vs. YEO  886 738 1624 
YEF vs. YEO  804 792 1596 
Common genes mucoid vs. YEO  386 420 806 
C1576 RNA-seq  
   YEM vs. YEO  86 36 122 
YEG vs. non-mucoid YEM 8 266 274 
YEM vs. non-mucoid YEM 68 436 504 
 
In order to define the impacts of clinically relevant sugars on gene 
expression in mucoid (EPS-inducing) and non-mucoid growth conditions, 
transcriptional profiling was performed in growth conditions outlined in Table 
4.2. Overall, the three mucoid growth conditions used for ATCC 17616 
microarray, there were 386 commonly upregulated genes and 420 commonly 
down regulated genes. There were a much greater number of differentially 
expressed genes in the microarray dataset than in the RNA-seq data set. This 
is likely due to the variance between RNA-seq samples forcing the use of only 
two biological replicates per growth condition and thus fewer genes were 
deemed statistically significant. In the RNA-seq analysis, there were 86 
upregulated genes in YEM vs. YEO, and 36 downregulated. Appendix Table 9.6 
lists common genes to C1576 YEM vs. YEO, and all three ATCC 17616 mucoid 
 106 
 
conditions vs. YEO. The conditions resulted in 39 differentially expressed 
genes. Of these 39 genes, only three showed differential regulation between 
strains (being upregulated in C1576 and downregulated in ATCC 17616), 
indicating minimal strain variation during growth in mucoid-growth conditions.  
4.3.4 B. multivorans global gene expression of EPS biosynthetic genes 
Due to the mucoid B. multivorans phenotype during growth on mannitol 
and fructose, it was predicted that EPS genes such as the bce cluster, would be 
upregulated in B. multivorans strains following growth on EPS-inducing sugars. 
As expected, in the YEM vs. YEO C1576 RNA-seq data set, 6 bce EPS cluster 
genes were highly upregulated in YEM relative to YEO. Several bce genes in 
YEM relative to non-mucoid YEM comparison were upregulated as expected 
(Table 9.7). C1576 RNA-seq data from the YEM relative to YEO growth 
condition was validated by quantitative real-time PCR (qRT-PCR) and showed a 
193-fold upregulation in bceB. It is clear from this data that the bce cluster is 
involved in C1576 mannitol-induced EPS production. In contrast, microarray 
results indicated key EPS cluster genes in ATCC 17616 YEM and YEF relative 
to non-mucoid YEO were not upregulated (although many genes in the bce 
cluster were expressed) (Appendix Table 9.8). ATCC 17616, like C1576, was 
visibly mucoid during growth on reduced YEM, standard YEM, and YEF agar 
plates. Results from, Chapter 3 indicated ATCC 17616 and C1576 require bceB 
for the production of EPS on all sugars tested, indicating a common pathway 
connecting Bcc EPS biosynthesis. Results from this study showed no 
upregulation of known EPS genes was observed in ATCC 17616, including the 
bce cluster. Thus, EPS production in ATCC 17616 is not via upregulation of the 
bce or wcb EPS clusters. The downregulation of bceB ATCC 17616 microarray 
results was validated using qRT-PCR. Results showed ATCC 17616 in YEM 
(relative to YEO) downregulated bceB 14-fold.  
There were several genes of EPS clusters first identified in B. 
cenocepacia, which have orthologs in B. multivorans ATCC 17616 that could be 
responsible at least in part for EPS production. Nine different genes related to 
these alternative EPS clusters were upregulated in ATCC 1716 YEM vs. YEO 
growth conditions, and eight were upregulated in YEF vs. YEO comparison. Of 
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those upregulated genes from the two growth conditions, seven were commonly 
upregulated in mannitol and fructose. Their putative roles included 
peptidoglycan glycosyltransferase activity, transcriptional regulators, and ABC 
transporters. In ATCC 17616 mucoid YEF and YEM relative to YEO both 
Bmul_4113 (a putative polyphosphate kinase) and Bmul_4390 (a Crp/FNA 
family transcriptional regulator)  were downregulated. In contrast, both genes 
were upregulated in C1576 (Table 9.7), thus showing the same trend as the bce 
cluster in which ATCC 17616 varies from C1576 in genes used for EPS 
production. Of note is the general expression, but not differential expression, of 
the bce cluster in ATCC 17616. Therefore the cluster could still play a role in 
EPS production, as evidenced by the ATCC 17616 bceB mutant being non-
mucoid on all sugars (refer to Chapter 3 Results).  
In the ATCC 17616 15 different bce cluster genes were upregulated in 
YEF relative to YEM comparison. This was interesting, because neither the YEF 
nor YEM vs. YEO comparisons individually upregulated bce genes (as 
discussed above). This suggested these EPS-inducing sugars are not equal in 
their impact on EPS gene expression. Due to differences between different 
EPS-inducing carbon sources, and the fact that Bcc studies exclusively use 
mannitol to induce EPS biosynthesis, the potential for differences between B. 
multivorans ATCC 17616 and C1576 fructose-or mannitol-derived EPS 
composition and biological activity are assessed as part of this dissertation. 
Results from those studies are presented and discussed in Chapters 6 and 7, 
respectively.  
4.3.5 Genes involved in cell wall integrity and permeability 
Cell wall integrity and permeability are important for maintaining bacterial 
survival and success in the host environment, as well as the allowance for 
secretion systems for the export of virulence proteins and adhesive structures. 
The reduction in outer membrane proteins is an important adaption to maintain 
the impermeability of the outer membrane and improve antibiotic resistance in 
Gram-negative bacteria (10).  
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Differential expression of outer-membrane protein coding genes in the B. 
multivorans ATCC 17616 and C1576 are listed in the Appendix Table 9.9 and 
9.10, respectively. Porin genes differentially expressed in ATCC 17616 mannitol 
and fructose vs. YEO were generally downregulated. This overall decreased 
expression in ATCC 17616 outer-membrane protein-encoding genes is 
suggestive of a less permeable outer membrane structure in EPS-inducing 
growth conditions, which could indicate an antibiotic resistant adaption. If grown 
in YEM, which results in downregulation of eight different porin- encoding genes 
in ATCC 17616, this could explain the enhanced resistance to tobramycin 
observed for mannitol-grown ATCC 17616 biofilms previously discussed in 
Chapter 3.  In contrast to the B. multivorans ATCC 17616 microarray study, 
whilst three porin-encoding genes showed differential expression in C1576 
under YEG relative to non-mucoid YEM, none were differentially expressed in 
YEM relative to YEO, suggesting strain-to-strain variation.  
 
4.3.6 Differential regulation of transcription and signal transduction genes 
Aside from the potential for EPS-producing strains differing in their 
membrane integrity, altering the carbon source for growth also altered the 
expression of large numbers of transcriptional regulators in the ATCC 17616 
microarray and RNA-seq data sets, suggesting a major rewiring of B. 
multivorans transcriptional networks as part of the whole-genome response to 
different sugars contained in the growth media. Of keen interest to this study 
was to identify regulators highly enhanced in expression in all mucoid growth 
conditions relative to non-mucoid.  
The ATCC 17616 transcriptional regulators enhanced in expression are 
listed in Appendix Tables 9.11 and those differentially expressed in growth 
conditions of interest for C1576 in Table 9.12. These tables are not all-inclusive- 
they list the most upregulated or common transcriptional regulators genes from 
growth conditions of interest. Two LysR family of transcriptional regulators, 
(Bmul_2557 and Bmul_5074), an AraC transcriptional regulator (Bmul_3782), 
and the TetR transcriptional regulator (Bmul_4689) were commonly regulated in 
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all the mucoid vs. YEO ATCC 17616 microarray data sets. In the C1576 RNA-
seq data, although not significant in all pairwise comparisons (and thus not 
included in Table 9.11), it was noted that Bmul_2557 was enhanced in 
expression in 2/4 YEM vs. Non-mucoid YEM pair-wise comparisons, suggesting 
this regulator could be linked to mannitol-based induction of EPS, although 
further validation is required. Had time allowed, these regulators enhanced in 
expression common to both strains‟ transcriptome profiling data would have 
been pursued using molecular mutagenesis techniques. Currently, without 
knowing the targets of these regulators, it is difficult speculate what impact their 
differential regulation has on the behaviour of the organism.  
Of note, concerning motility is the upregulation in ATCC 17616 YEM vs. 
YEO of the flagella transcriptional activators flhC, flhD, and flgM. This is detailed 
as part of the flagella assembly pathway in Figure 4.5. 
 
4.3.7 B. multivorans differential expression of motility genes 
Transcriptomic profiling revealed altered gene expression related to 
motility and chemotaxis in EPS-inducing conditions in the two B. multivorans 
isolates. Phenotypic studies showed mannitol-enhanced motility in wild-type 
ATCC 17616 and C1576 and the corresponding non-mucoid bceB mutants 
(Chapter 3, Figure 3.6). This mannitol-enhanced motility was EPS-independent 
thus the impact on motility was due to effects of mannitol. The ATCC 17616 
microarray data, motility genes were upregulated in mucoid growth conditions 
relative to YEO (Figure 4.3 (a), and Appendix Table 9.13). This observation 
correlated with phenotypic studies from Chapter three which showed mannitol 
enhanced motility relative to mannose. Figure 4.3 (b) shows that fructose 
enhanced motility, but not to the same extent as mannitol. In accordance with 
the phenotypic study, the microarray data showed YEF vs. YEO upregulated 
fewer motility related genes compared to the YEM vs. YEO (Appendix, Table 
9.12). In the reduced YEM vs. YEO fewer motility-related genes were 
upregulated compared to YEM, suggesting that mannitol-enhanced motility is 
dependent on the concentration of mannitol. Bmul_0162 (motA) and its 
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enhanced expression in the ATCC 17616 microarrays was validated by qRT-
PCR - motA was upregulated 8-fold in YEM vs. YEO and 4-fold in YEF relative 
to non-mucoid YEO.  
 
(a) 
 
Figure 4.3 (a). Differences between carbon sources in enhancement of motility. GeneSpring 
display shows on the x-axis, sample/growth conditions, relative to (log) intensity normalised 
expression of B. multivorans ATCC 17616 flagella-related genes significantly differentially 
expressed in the microarray data set (36 selected genes in total). Most upregulated flagella genes 
were in YEM, corroborated by phenotypic studies and qRT-PCR. Values above one are upregulated, 
below one are downregulated.  
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(b) 
  
Figure 4.3 (b). Phenotypic study corroborates significant mannitol enhanced motility more 
than motility enhanced in fructose. This same data set presented in Chapter 3 (without the 
fructose motility data), which showed significant differences between mannitol and mannose in 
both the wild-type and bceB CR mutant. Asterisks with bars indicate mannitol enhanced motility 
relative to fructose, and asterisks alone are significant upregulation of motility in fructose relative 
to mannose.  
 
Chemotaxis genes were altered in the B. multivorans ATCC 17616 data 
set that are involved in the pathway leading on to flagella biosynthesis. Figure 
4.4 shows in green chemotaxis genes upregulated in ATCC 17616 YEF vs. 
YEO, but cheW, cheZ and MotA/B were also upregulated in YEM relative to 
YEO.  MotA/B were downregulated in the C1576 YEG relative to non-mucoid 
YEM comparison.  
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Figure 4.4 B. multivorans genes involved in bacterial chemotaxis. This pathway leads on to 
flagella biosynthesis which is summarised in Figure 4.5. In the B. multivorans ATCC 17616 YEF vs. 
YEO data set, red boxes show genes downregulated; dark green boxes indicate upregulation, light 
green boxes indicate organism specific pathways but lack of differential expression, and white 
boxes show genes with no orthologue in B. multivorans but are involved in the pathway in other 
organisms. This figure was made using KEGG Mapper Search&Color pathway. Reference organism 
selected was B. multivorans ATCC 17616 (JGI). 
 
Figure 4.5 summarises the flagella assembly pathway and the 
differentially expressed genes in YEF relative to YEO growth conditions from 
the transcriptome profiling of ATCC 17616. Although YEF vs. YEO differentially 
regulate genes are shown, there were many similarities between the two 
mucoid growth conditions and their upregulation of motility genes.  
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Figure 4.5. B. multivorans ATCC 17616 flagella assembly pathway. Dark green boxes indicate a 
gene is upregulated in ATCC 17616 YEM vs. YEO data sets, whilst light green boxes indicate no 
significant differential expression. The majority of these genes were also upregulated in YEF vs. 
YEO. This figure was made using KEGG Mapper Search&Color pathway. Reference organism 
selected was B. multivorans ATCC 17616 (JGI). See Appendix Table 9.13 and 9.14 for further details 
of ATCC 17616 and C1576 differentially regulated flagella-related genes and fold changes.  
 
Mannitol- and fructose-enhanced motility in ATCC 17616 and C1576 wild-type 
and bceB CR mutants was shown in phenotypic studies. This data indicated 
C1576 was more motile in mannitol than ATCC 17616, indicating strain 
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variation. However, flagella synthesis and regulator genes were not observed in 
the C1576 YEM vs. YEO RNA-seq significantly expressed genes, though there 
were some genes relating to flagella biosynthesis and chemotaxis differentially 
regulated in YEM vs. non-mucoid YEM (Table 9.14). This highlights the need for 
further transcriptional analysis of C1576, which was hampered by variation 
between replicates and resulted in only two replicates per growth condition. 
Cases where variation between the two strains is observed over an entire 
pathway and contradicts phenotypic data, highlights it would be worth 
reassessing the C1576 transcriptional response to validate these observations.  
 
4.3.8 Differential expression of genes related nitrogen metabolism 
Differential expression of nitrogen metabolism during growth on EPS-
inducing and non-inducing sugars could indicate alternative energy pathways or 
anaerobic metabolism is being utilised (178). Appendix Tables 9.15 and 9.16 
present genes pertinent to nitrogen metabolism and assimilation from the ATCC 
17616 microarray and C1576 RNA-seq data, respectively. In the ATCC 17616 
YEF vs. YEO microarray data, nitrate reductase-encoding genes narG and narH 
were upregulated, along with decreased expression of several nitrate ABC 
transporters. Genes connected to nitrogen metabolism are likely connected to 
anaerobic metabolism by reduction of nitrate and upregulation of genes such as 
these have been linked to B. pseudomallei survival within macrophages and B. 
multivorans adaption to the CF lung (43,178). Two genes related to nitrogen 
metabolism were also identified in the C1576 RNA-seq data; these genes were 
linked to metabolism and secondary metabolite biosynthesis. 
 
4.3.9 B. multivorans secretion genes differentially expressed following growth 
on different sugars  
The C1576 RNA-seq YEG vs. non-mucoid YEM comparison resulted in a 
group of secretion genes decreased in expression, suggesting protein export 
and secretion via the Sec pathway was altered during growth on different 
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carbon sources. Figure 4.6 summarises the roles of these genes in protein 
secretion and export (details in Appendix Table 9.17). 
 
 
Figure 4.6 B. multivorans C1576 secretion genes. YEG vs. non-mucoid YEM growth conditions 
from the C1576 RNA-seq data resulted in decreased expression of genes related to the Sec protein 
export pathway. Light green boxes were not differentially expressed in the C1576 data set, while 
red boxes indicate gene was decreased in expression, and white boxes are genes in pathway 
without orthologues in B. multivorans. This figure was made using KEGG Mapper Search&Color 
pathway. Reference organism selected was B. multivorans ATCC 17616 (JGI). See Appendix Table 
9.17 and 9.18 for further details of C1576 and ATCC 17616 differentially regulated secretion-
related genes and accompanying fold changes.  
 
Whilst there were secretion-related genes altered in expression in the 
ATCC 17616 microarray data set, (Appendix Table 9.18), including the 
upregulation of two different Vrg family Type VI secretion genes in the YEM and 
YEF relative to YEO comparisons, no distinct single secretion pathway was 
altered as was observed in C1576. It has been shown in B. pseudomallei that 
type six secretion genes are upregulated during macrophage infection (43). This 
indicates growth on different EPS-inducing sugars does not significantly alter 
protein secretion and export in ATCC 17616 for the conditions profiled in the 
present study.  
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4.3.10 Expression of antibiotic resistance-related genes  
In the RNA-seq C1576 data, no differentially expressed antibiotic-
resistance-related genes were observed in growth conditions of interest. In the 
ATCC 17616 microarray study, YEF and YEM relative to YEO comparisons 
resulted in five antibiotic resistance-related genes commonly regulated these 
EPS-inducing conditions (Appendix Table 9.19). The ATCC 17616 YEF vs. 
YEO resulted in three β-lactamase domain-containing proteins enhanced in 
expression. The reduced YEM growth condition (not listed in table) did not differ 
significantly in the regulation of antibiotic resistance-related genes relative to 
standard YEM, indicating no strong correlation between antibiotic resistance-
related genes and mannitol dosage. General trends appear to be focused on 
the downregulation of RND efflux systems and several ABC transporters linked 
to antibiotic transport mechanisms in these mucoid conditions. In all, YEM 
conditions resulted in the downregulated of 15 different antibiotic-resistance 
genes, while the YEF growth condition 13 different resistance genes (all relative 
to non-mucoid control YEO). Of the seven RND efflux pump proteins 
downregulated, six were downregulated. The importance of RND efflux 
transporters has been discussed in a transcriptome analysis of B. cenocepacia, 
which showed a role for these pumps was much wider than just drug resistance, 
but also influenced biofilms formation and other traits relevant to pathogenesis 
(19).  
 
4.3.11 B. multivorans differential expression of metabolism-related genes  
It would be expected that different carbon sources used for growth and 
stimulation of EPS-production could elicit central carbohydrate metabolism 
pathways, as possibly differential impacts on metabolism and other secondary 
metabolism processes.  In the ATCC 17616 mucoid growth conditions relative 
to YEO data sets, genes encoding products involved in fructose and mannose 
metabolism and the pentose phosphate pathway were found to be differentially 
expressed (Table 9.20). However, there were differences between mucoid 
growth conditions. ATCC 17616 upregulated fructose/mannose/pentose 
phosphate metabolism and synthesis pathways in YEF relative to YEO but not 
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in the YEM relative to YEO. In the ATCC 17616 reduced YEM relative to YEO 
data set are a plethora of glutathione metabolism-related genes (linked to 
nitrogen assimilation and metabolism) which could indicate reduction of the 
main carbon source mannitol results in altered metabolic pathways seeking 
alternative energy sources due to decreased carbon availability.  
In the ATCC 17616 YEF relative to YEO comparison is a cluster of 
upregulated succinate dehydrogenase/fumarate reductase activity. These 
genes, sdhC, sdhD and sdhB are involved in oxidative phosphorylation and 
metabolic processes related to the TCA cycle (based on KEGG pathway 
predictions) and these genes encode proteins closely associated in a complex 
with flavo proteins and iron containing proteins involved in electron transport 
and oxidative phosphorylation. This indicates fructose metabolism impacted the 
organism differently than mannitol, as these genes were differentially regulated 
in the YEF relative to YEO comparison, but absent in the YEM relative to YEO 
comparison.  
Another upregulated gene of note in the YEF relative to YEO data (but 
absent in the YEM vs. YEO comparison) is the gene encoding cstA, a peptide 
transporter shown to be induced by carbon starvation and the global regulator 
csrA in E. coli (65,174). Again, it is interesting this gene was enhanced in 
expression in the YEF conditions relative to YEO but not in YEM relative to 
YEO.  
In the C1576 RNA-seq data set genes involved in monosaccharide 
transport were downregulated – including several ABC transporters involved in 
polyol and monosaccharide transport, most notably in the YEG vs. non-mucoid 
YEM where genes differentially expressed then will represent the organisms‟ 
specific response to glucose or mannitol rather than EPS or nutrient deprivation 
(Appendix Table 9.21). Of note are the group of genes rbsA, rbsB, and rbsC all 
decreased in expression in YEG relative to non-mucoid YEM; in Haemophilus 
influenzae these genes have been linked to quorum signal uptake, mature 
biofilms formation, and are linked to chemotaxis (9). Another group of genes 
downregulated in the YEG vs. non-mucoid YEM data encoding binding-protein 
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dependent inner membrane transport system are Bmul_2428, Bmul_2429 and 
Bmul_2430. These three genes appear to be part of an operon involved in 
transport and orthologues in B. mallei are annotated as encoding maltose-
binding and transporting proteins. 
 
4.3.12 Mucoid growth conditions and differential expression of genes related to 
adhesion 
Transcriptomic data was assessed for any adhesin-related gene 
expression to add to the Chapter 3 observations of mucin adhesion variation 
between the two B. multivorans strains in this study. Phenotypic studies had 
previously shown EPS-dependent adhesion in the environmental isolate ATCC 
17616. In the ATCC 17616 microarray data, downregulation of a fimbrial 
biogenesis usher protein was observed in YEM vs. YEO (Table 9.22). In all 
mucoid vs. non-mucoid B. multivorans ATCC 17616 and C1576 data is the 
gene Bmul_3709, encoding a haemolysin-type calcium-binding region protein 
that has been well-characterised in other members of the Bcc as a 22kDa 
adhesin (adhA) associated with a cable pilus required for B. cenocepacia 
binding and transmigration across epithelial cells and linked to persistence 
(77,201). The calcium-binding region contained in adhA has been linked to 
other secreted proteins involved in protein re-folding after transport across the 
cell membrane and has been reported to facilitate protease activity in P. 
aeruginosa and to binding of erythrocytes by E.coli (18,123). Bmul_3709 has 
orthologues in 13 other Burkholderia species, according to genomes available 
on burkholderia.com, and 82 % homologous at the amino acid level to B. 
cenocepacia J2315 BCAM2143 (or bapA, synonym for adhA). Although the role 
of this bapA/adhA adhesin is well-characterised in B. cenocepacia, confirmation 
is needed to determine and describe what role this highly upregulated gene in 
mannitol may play in B. multivorans and virulence. As adhA is the most highly 
upregulated gene common to the mucoid vs. non-mucoid data sets, and is most 
upregulated in C1576 YEM vs. YEO (Table 9.23) it would be of interest to study 
through mutagenesis the role of this adhesin in B. multivorans virulence. 
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In the RNA-seq data set, adhesins were enhanced in expression in the 
CF isolate C1576, which correlated with the phenotypic study which showed 
mucin adhesion was enhanced by mannitol in this isolate independent of EPS 
production. This mannitol enhanced EPS-independent adhesion in C1576 
spurred the whole genome sequencing of C1576 and the RNA-seq analysis to 
define the transcriptional response of this isolate in relation to virulence 
associated genes. Due to the fact that the adhesins identified in C1576 were not 
present in ATCC 17616, the reference genomes of B. multivorans CGD1 (a 
clinical chronic granulomatous disease isolate) and B. ambifaria MC0-4 were 
used to identify these adhesins from the RNA-seq data where. Specifically 
genes encoding fimbrial and filamentous haemagglutinin-related genes were 
assessed, and more detail on these adhesins and their mannitol enhanced 
expression in C1576 is presented and discussed in Chapter 5. Briefly, the gene 
expression profiles from YEM vs. YEO growth conditions indicate mannitol 
upregulated entire adhesin-related loci (Appendix Table 9.23).  
4.3.1 Mucoid growth conditions and differential expression of genes related to 
oxidative stress survival 
Superoxide dismutase (SOD) proteins are involved in protection against 
reactive oxygen species and oxidative stress. Genes coding for SOD proteins 
were differentially expressed in the B. multivorans ATCC 17616 transcriptome 
profiling (Table 9.22). Specifically, genes encoding two different SOD encoding 
genes were equally upregulated in all three mucoid conditions of the ATCC 
17616 data relative to YEO. Production of peroxidases, SOD, and catalases are 
bacterial tools for dealing with reactive oxygen species/oxidative stress. Use of 
these tools has been confirmed for all species of the Bcc (112). In the 
phenotypic studies presented in Chapter 3, EPS-independent mannitol-
enhanced survival to hydrogen peroxide exposure was observed in C1576 and 
bceB CR mutant following their growth in mannitol (or mannose) containing 
broths. However, the wild-type EPS producing C1576 also still survived 
hydrogen peroxide treatment better than the bceB CR mutant in mannitol, 
indicating some protection may be due to EPS. Though no differentially 
expressed SOD-encoding genes were detected in C1576 RNA-seq growth 
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conditions, in the ATCC 17616 microarray data the two upregulated SOD-
encoding genes indicate mucoid-inducing sugars could contribute to enhanced 
oxidative stress survival in ATCC 17616. Future studies would be advantageous 
to confirm this using an in vitro oxidative stress assay with B. multivorans in 
order to validate this observation for ATCC 17616.  
 
4.4 Discussion 
The growth of Bcc on numerous sugars and sugar alcohols is known to 
induce dramatic overproduction of EPS, a putative virulence factor linked to 
immune response evasion and chronic or persistent disease. The therapeutic 
administration of mannitol, or the onset of CFRD and associated elevated 
sugars, may promote EPS production within the lungs of Bcc-infected patients 
or have wider unknown consequences on the bacterial cell (and thus course of 
infection). Growth on minimal media where mannitol is the only carbon source 
does not result in EPS production, indicating some additional component(s) in 
the media, besides mannitol, trigger EPS biosynthesis. Studies presented in 
Chapter 3 showed mannitol dramatically altered motility, biofilm formation, 
survival of H2O2 oxidative stress, and other virulence-related phenotypes. 
Crucially, these same observations were made in both the wild-type B. 
multivorans C1576 and in an isogenic non-mucoid mutant. These studies 
highlighted a wider transcriptional response to mannitol that impacts directly on 
virulence traits.  
Using B. multivorans ATCC 17616 (an environmental isolate) and C1576, a 
CF outbreak isolate, the aim of this project was to employ microarray and RNA-
seq to define (at a transcriptional level) how sugars like mannitol and fructose 
promote EPS production, and how clinically relevant sugars influence the global 
gene expression of B. multivorans. Results from transcriptional profiling of 
ATCC 17616 showed the environmental isolate did not upregulate bce or wcb 
EPS biosynthetic gene clusters in mucoid growth conditions, but did upregulate 
parts of other less-studied EPS clusters. Of interest was the comparison 
between the two mucoid conditions, YEF vs. YEM, which resulted in 
upregulation of numerous genes in the bce cluster relative to YEM, indicating 
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differences exist between these sugars. It has been reported that ATCC 17616 
produces the most common type of Bcc EPS, cepacian (68), whilst C1576 is 
reported to produces a mix of polysaccharides besides cepacian (88). Thus, 
although bce is linked to cepacian biosynthesis, cepacian could be made via 
other uncharacterised polysaccharide biosynthesis pathways, or pathways for 
other types of polysaccharide biosynthesis could be redundant and contribute 
towards EPS biosynthesis regulation. In ATCC 17616, the bce cluster was 
expressed, but not upregulated in YEM or YEF relative to YEO. From previous 
studies in Chapter 3 it is known that bceB disruption abolished EPS production 
in ATCC 17616 and C1576, thus the bce cluster is involved in ATCC 17616 
EPS biosynthesis, but it must not be the only gene cluster involved. This 
suggests a master regulator involved in EPS biosynthesis and other stress 
responses that could be linked or activated by mannitol and EPS-inducing 
sugars. In contrast, C1576 did upregulate the bce cluster in YEM relative to 
YEO. This indicates a potential strain difference in how B. multivorans responds 
to mannitol at a transcriptomic level. There were other observed strain 
variations in phenotypic studies such as adhesion to mucin and swimming 
motility. Additionally, three novel adhesins identified in the genome of C1576 
but absent from the ATCC 17616 genome were found to be specifically 
upregulated by mannitol (these adhesins are the subject of the following 
Chapter 5 and paper published in the journal Microbiology (61)). These strain 
variations clearly indicated that transcriptome analysis of the C1576 response to 
mannitol is essential to understand the basis for EPS synthesis in this organism, 
and the wider impact of mannitol on virulence. 
The present study used the comparison of transcriptome profiles from ATCC 
17616 microarrays with RNA-seq data from C1576 to reveal some 
commonalities that may lead to identification of the EPS regulators (and genes) 
involved. Many transcriptional regulators were differentially expressed in the 
transcriptional profiles of ATCC 17616 and C1576, indicating the influence 
different sugars and EPS induction have on the major rewiring of cellular 
processes. The upregulated transcriptional regulators in mucoid growth 
conditions are potential candidates for future study and could be linked to 
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transcriptional control of whole organisms stress responses and/or EPS 
biosynthesis.  
B. multivorans ATCC 17616 and C1576 were altered in global gene 
expression related to motility, EPS-related genes, secretion and outer 
membrane proteins, nitrogen metabolism and other genes involved in stress 
resistance, and antibiotic resistance. Some differences between strains both 
grown in YEM relative to YEO were observed as well as some mannitol dose-
dependent differences in ATCC 17616 (specifically related to motility). Fructose 
and mannitol-grown ATCC 17616 in most instances resulted in commonly 
regulated genes increased or decreased in fold-change to the same extent. 
Antibiotic resistance genes abundantly differentially expressed in ATCC 17616 
YEF vs. YEO and the YEM vs. YEO, indicate the carbon source and mucoidy 
impacts on the antibiotic resistance systems in this organism; similar antibiotic 
resistance genes were absent from differentially expressed genes in C1576 
RNA-seq data. Efflux transporters such as the RND (resistance nodulation 
resistance division) super family of efflux pumps have been shown to influence 
not only antibiotic resistance profiles of B. cenocepacia but wider virulence 
relevant attributes such as biofilm formation (19).  
The instances of strain variability between the C1576 and ATCC 17616 
could be down to the variability in the RNA-seq data, and the resulting small 
number of genes identified as being differentially expressed in various growth 
conditions of interest and thus fewer genes reached statistical significance for 
further analysis. Of the pathways identified as altered in different ATCC 17616 
following growth on different sugars, many were not altered in corresponding 
C1576 data sets. In light of the variability between replicates this does not 
necessarily mean that those genes were not altered in C1576, but rather 
significance of those genes was lost. Additional transcriptomic studies of C1576 
in response to mannitol is required to elucidate to what extent differences 
between these B. multivorans strains is accurate.  
A publication by Silva et al. compared the transcriptomes of B. multivorans 
clonal CF isolates (one mucoid, one non-mucoid). They observed many similar 
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alterations in gene expression as in the present study of B. multivorans 
transcriptome comparisons of mucoid vs. non-mucoid growth conditions. A 
summary of some of the striking similarities between the Silva et al. data set 
and data from the ATCC 17616 and C1576 transcriptome profiles can be found 
in Appendix Table 9.24, with the Silva et al. data presented with mucoid vs. 
non-mucoid isolate. Genes that overlapped between the two studies reveal the 
potential significance between mannitol induction of genes related to nitrogen 
metabolism, secretion, and motility. Silva and colleagues observed an overall 
increase in transcripts of genes encoding for nitrogen metabolism indicating 
reduced metabolic needs in the non-mucoid isolate as an adaption to chronic 
infection relative to the mucoid, initial isolate (178). Silva and co-authors 
suggested due to the lack of EPS biosynthesis of their non-mucoid clonal 
isolate, metabolic pathways were altered, and loss of the ability to produce 
EPS, and reduced in motility-related gene expression were additional means of 
adapting to the CF lung environment. From personal communications with the 
authors of the Silva et al. study (138), they found no mutations within known 
EPS biosynthetic genes to explain the appearance of the non-mucoid isolate. 
Although there could be a mutation in a yet unidentified EPS gene that could 
explain EPS-deficiency of this isolate, it is also suggestive of a mutation in a 
global regulator controlling EPS or stress response in general (of which EPS is 
included). The overlap of differentially expressed gene networks and pathways 
identified in the present study and the Silva et al. study suggests the regulator 
controlling EPS is also involved with regulation of several other pathways 
relevant to stress response, survival or adaption. The transcriptional regulator 
Bmul_2557 was upregulated in the Silva et al. data mucoid vs. non-mucoid 
isolate, and in both ATCC 17616 YEF and YEM growth conditions relative to 
YEO. Additionally, though not significant in all pairwise comparisons, 
Bmul_2557 was also upregulated in YEM vs. non-mucoid YEM C1576 RNA-seq 
data – indicating it is EPS specific not an upregulation in response to just 
mannitol. This transcriptional regulator and several other potential candidates 
could be missing links to elucidating EPS regulation in the Bcc. 
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What effect alterations in gene expression induced by mannitol and EPS 
biosynthesis have on B. multivorans in the CF lung are unknown. The 
recommended dose of inhaled mannitol is 800 mg per day. In a normal human 
lung, with an average volume of 4.3 litres, this dosage would be equivalent to 
~1.02 mM of mannitol per day directly into the airways. This concentration is 
likely an underestimate for mannitol distribution in a CF lung which is obstructed 
with inflammation, mucous and bacterial biofilm. Localised concentration of 
mannitol thus could be significantly higher than the estimated amount for a 
healthy lung. Media used to study mucoidy in the Bcc YEM in the present study 
(109.9 mM mannitol) and reduced YEM (13.7 mM mannitol), appear to be high 
relative to the estimated 1.02 mM within 4.3 litre lung. However, in the ATCC 
17616 microarray studies where two different concentrations of mannitol were 
used to induce EPS, the comparison of the standard YEM and reduced YEM 
relative to YEO suggested some differences but mainly similarities between the 
two mannitol doses. The reduced YEM condition resulted in upregulated genes 
linked to nitrogen metabolism, likely due to reduced carbon source availability, 
however the lower dosage of mannitol still upregulated flagella related genes 
and the transcriptional regulator Bmul_2557. Though motility related genes 
were not as highly upregulated in the reduced YEM compared to standard YEM, 
a large number of genes encoding proteins involved in flagella assembly and 
chemotaxis were observed, as well as several genes involved in antibiotic 
resistance (namely common β-lactamase containing proteins), type six 
secretion genes, SOD production, and iron uptake and transport.    
Beyond EPS and transcriptional regulators, growth on mannitol and fructose 
altered expression of secretion-related genes, antibiotic resistance genes, and 
outer membrane proteins. The Silva et al. data showed nine type VI secretion 
genes with increased expression in their mucoid vs. non-mucoid data set (178), 
of which bcsJ was upregulated in mucoid conditions in ATCC 17616. Altered 
gene expression in virulence-related genes could have potential links with 
phenotypic assays, such as the attenuated virulence of mannitol-grown B. 
multivorans C1576 in the insect model G. mellonella, or the mannitol enhanced 
invasion of A549 human lung epithelial cells. B. multivorans can flourish in 
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different niche environments, from the soil to the CF lung. In order to 
accomplish this diverse life-style, it must evolve, acquire and be successful 
against the onslaught of immune response, oxygen variability, oxidative stress, 
physical clearance, and frequent long-term high antibiotic exposure at high 
concentrations. Currently the effects of EPS production in vivo and the role for 
mucoidy and its impact (positive or negative) on virulence in the CF lung are 
unknown. The present dissertation highlights the potential effects of mannitol 
treatment and elevation of clinically relevant sugars on the whole-organismal 
behaviour of B. multivorans. Findings of the numerous impacts of mannitol on 
phenotypes and gene expression relevant to virulence suggest further 
exploration of alternative osmolyte would be advisable. Researchers are 
however looking into another sugar alcohol, xylitol, as an osmolyte (229). 
However, based on the present study observations that B. multivorans gene 
expression is altered beyond EPS biosynthesis induced by different sugars, the 
same could be true for other sugar alcohols and carbon sources not included in 
the present study. The sugars chosen for the present study were used due to 
their present clinical relevance to CF treatment and due to elevation in CFRD. 
The present study contributes to sparse knowledge about mucoidy and 
virulence in B. multivorans. For the first time, sugars besides mannitol have 
been used to induce EPS for gene expression studies. Defining the role of 
mucoidy and virulence in B. multivorans is crucial for understanding the basis 
for EPS biosynthesis. Overall, improved understanding of the impact of carbon 
source on mucoidy and virulence could highlight reasons for the unpredictability 
of infection attributed to Bcc CF lung infection, as the majority of B. multivorans 
clinical isolates often maintain the ability to produce EPS. By investigating two 
isolates under mucoid and non-mucoid growth conditions, the identification of 
the whole organism response to EPS-inducing clinically relevant sugars was 
possible. Overall, for both isolates, different sugars had a much broader 
influence on whole genome gene regulation rather than solely influencing EPS 
biosynthesis-related transcription. 
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4.5 Conclusions  
1. Growth on minimal media where mannitol is the only carbon source does 
not result in EPS production, indicating some additional component(s) in 
the media, besides mannitol, trigger EPS biosynthesis. 
2. ATCC 17616 did not differentially regulate known EPS genes of the bce 
cluster in mucoid growth conditions. In contrast, C1576 did differentially 
express EPS genes involved in the bce cluster in mucoid versus non-
mucoid growth conditions. 
3. Growth on different sugars resulted in differential expression of genes 
involved in antibiotic resistance, motility, chemotaxis, and metabolism.  
4. Transcriptional regulators highly upregulated in mucoid growth conditions 
are potential candidates for future study and could be linked to 
transcriptional control of EPS production.  
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Chapter 5: Identification and characterisation of novel adhesins in a B. 
multivorans CF outbreak isolate 
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5.1 Introduction 
When grown on certain carbon sources (most notably mannitol), Bcc 
species produce exopolysaccharide (EPS), resulting in a mucoid phenotype 
(17). EPS production by the Bcc has been associated with bacterial persistence 
within the lung (51), biofilm formation (56) and inhibition of neutrophil activity 
(33), whilst it has recently been proposed that an inverse correlation exists 
between the quantity of EPS production by Bcc organisms and the rate of 
decline in CF lung function (233). Bcc EPS production induced by mannitol has 
gained clinical relevance following the approval of a dried-powder preparation of 
mannitol for use as an inhaled osmolyte in CF patients. Whilst mannitol therapy 
clearly improves CF lung function (23,59,93,193), the potential impact on 
Burkholderia organisms within the lung is unknown. 
In the present study, the role played by mannitol and the associated 
mucoid phenotype in bacterial adherence was investigated. As reported 
previously in Chapter 3, mannitol promoted B. multivorans adherence in a 
strain-dependent manner which differed in the way EPS contributed to adhesion 
to mucin. The present study reports the genome sequencing of a CF outbreak 
strain B. multivorans C1576. Sequencing enabled the identification of two B. 
multivorans-specific adhesin loci. Specific adhesins have not previously been 
described in B. multivorans. These fimbrial and afimbrial loci, which contribute 
to biofilm formation and mucin adherence, appear specific to B. multivorans and 
show enhanced expression in the presence of mannitol. These observations 
provide new insight into B. multivorans biology and highlight the potential 
microbiological impact of inhaled mannitol therapy in CF patients. 
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5.2 Aims 
Examine the EPS-independent adhesion phenotype in CF outbreak-isolate 
C1576 using the following approaches: 
a. Whole genome sequencing to identify putative adhesins 
b. Insertional mutagenesis of identified adhesins 
c. Characterise adhesins in phenotypic assays 
d. Assess distribution of adhesins amongst a panel of clinical and 
environmental Bcc isolates.  
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5.3 Results 
5.3.1 The contribution of EPS to adhesion is strain-dependent in B. multivorans 
In the Bcc, disruption of the gene encoding the BceB glycosyltransferase 
eliminates EPS biosynthesis when bacteria were grown on mannitol (17). 
Consequently, to enable EPS-dependent and EPS-independent effects of 
mannitol to be determined, as outlined in Chapter 3, two representative strains 
of B. multivorans were inactivated for bceB - the environmental isolate B. 
multivorans ATCC 17616 and the CF isolate B. multivorans C1576. The C1576 
CF isolate is the index case of an outbreak within a paediatric CF unit in 
Glasgow (UK) (222), and has previously been designated as sequence type 
(ST)-27 by multi-locus sequence typing (MLST). The phenotypes of the 
resulting non-mucoid mutants were characterised extensively and described 
within Chapter 3. Disruption of bceB in the two B. multivorans strains resulted in 
a complete loss of EPS production, as judged by visual scoring of mucoidy and 
quantitative analyses (dry weight and sugar content) of EPS extractions from 
wild-type and bceB mutants following growth on YEM media (data not shown). 
Disruption of bceB did not impact on the growth of strains under any culture 
conditions tested.  
Wild-type and bceB mutants of each strain were cultured in the presence 
of either mannitol (EPS-inducing) or mannose (non-inducing) prior to quantifying 
adherence to mucin. As shown in Figure 5.1 (same data presented in previous 
Chapter 3) mannitol promoted adherence of both wild-type isolates relative to 
the mannose, non-mucoid control. As shown in Fig. 5.1, within the context of 
the mucin adhesion in vitro assay, the environmental ATCC 17616 strain 
adhered considerably better to mucin than the clinical isolate C1576. However, 
irrespective of their basal level of adherence, mannitol promoted adherence of 
both strains to mucin (orthogonal contrast, ATCC 17616: P < 0.0005; C1576: P 
< 0.0005). 
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Figure 5.1 B. multivorans strains ATCC 17616 and C1576 (wild-type and bceB mutant of each) 
adhesin to mucin. Strains were grown overnight in either mannitol-containing media (YEM) or 
mannose-containing media, prior to assessing adherence to mucin-coated wells. The ATCC 17616 
adhered significantly better to mucin than the C1576 (note the differing scales on the y-axes). 
However, irrespective of this difference, growth in mannitol promoted the adherence of both 
strains (relative to growth in mannose). Disruption of the bceB gene in ATCC 17616 abolished the 
enhanced adherence observed following growth in mannitol, indicating it to be EPS-dependent (a). 
In contrast, inactivation of bceB in C1576 did not affect the enhanced adherence, indicating it to be 
EPS-independent (b).  Data correspond to mean of three independent experiments, each in 
triplicate. Error bars indicate SEM. *** P < 0.0005. 
 
Mannose was chosen as a non-EPS-inducing control as the growth 
dynamics of the mannitol- and mannose-grown bacteria were comparable. 
Mannose has been suggested to act as an anti-adhesive for certain bacterial 
species, reducing adherence to epithelial cells (1). However, it has previously 
been reported that mannose does not block mucin-binding by Pseudomonas 
(Burkholderia) cepacia (168). Consistent with this, mucin adherence of B. 
multivorans C1576 was not reduced by pre-treatment with mannose (Figure 
5.2), suggesting that the differential adherence observed between the mannitol- 
and mannose-grown cultures is due to mannitol promoting adherence, rather 
than mannose reducing adherence. 
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Figure 5.2. Mucin adhesion assay carried out following pre-treatment of mannitol-grown 
bacteria with mannose. B. multivorans C1576 was grown overnight in mannitol and yeast extract 
(YEM) broth, then cells were washed and harvested, and re-suspended in PBS. Then, mannose (PBS 
+ Mannose) or mannitol (PBS + Mannitol) was added to a final concentration of 2 % (w/v), the 
same concentration in YEM or mannose-containing sugar media. The control was PBS alone (PBS) 
added to a standardised culture. Bars represent percentage adhesion relative to the PBS control, 
average of three wells (n=3) per treatment. Error bars represent SEM.  
 
Whilst mannitol promoted adherence of both isolates to mucin, 
comparison of the wild-type and EPS-deficient bceB mutants revealed differing 
roles for EPS. Inactivation of bceB in ATCC 17616 blocked this enhanced 
adherence (Figure 5.1(a)), indicating that it was EPS-dependent. In contrast, 
the enhanced adherence of C1576 was still evident following inactivation of 
bceB (Figure 5.1(b)), indicating that it was independent of EPS status. These 
observations led us to investigate the genome of C1576 in an attempt to identify 
strain-specific adhesins that may account for this strain-to-strain variation in 
adherence phenotype. 
 
5.3.2 Identification of loci encoding putative fimbrial and afimbrial adhesins in B. 
multivorans C1576.  
 Illumina genome sequencing of isolate C1576 with subsequent mapping 
to the ATCC 17616 reference genome allowed us to identify sequences present 
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within C1576 that were absent from ATCC 17616. Analysis of these unmapped 
reads resulted in the identification of two distinct loci encoding putative fimbrial 
and afimbrial adhesins (Fig. 5.3). The sequences of these loci have been 
deposited in GenBank under the accession numbers JX191919 (fimbrial) and 
JX191920 (afimbrial).   
The putative fimbriae-encoding locus is predicted to encode three 
putative fimbrial proteins, a FimC chaperone protein and a fimbrial usher 
protein. The nucleotide sequence of the locus is >99 % identical to an 
equivalent fimbriae-encoding locus present in B. multivorans CGD1, a recently-
sequenced isolate from a chronic granulomatous disease (CGD) patient (211). 
In CGD1, the locus is formed by genes BURMUCGD1_3349 to 
BURMUCGD1_3353. The organisation of the locus is identical in the two 
isolates, and amino acid identity between the corresponding encoded proteins 
is 99-100 %. A similar locus with the same gene organisation is observed in two 
other sequenced CGD B. multivorans isolates (CGD2 and CGD2M), although 
the percentage amino acid identity of the encoded proteins compared to those 
of C1576 is lower (average 83 %). Outside of B. multivorans, the predicted 
fimbrial proteins of B. multivorans C1576 typically exhibit 35-55 % amino acid 
identity with proteins encoded by comparable loci in other sequenced 
Burkholderia or non-Burkholderia species.  
The locus encoding the putative afimbrial adhesin of B. multivorans 
C1576 is depicted in Fig. 5.3 (b). Based on sequence similarity to 
representative proteins (Appendix Figures 9.1 & 9.2), the locus is predicted to 
encode components of a two-partner secretion (TPS) pathway responsible for 
the secretion of an adhesin of the filamentous haemagglutinin (FHA) family. The 
locus encodes two putative TpsA proteins (264 kDa and 68 kDa respectively) 
that belong to the FHA-family of outer membrane proteins, although only the 
larger of these two proteins has a mass consistent with the large exoproteins of 
the TpsA (hecA-like) family. The locus is also predicted to encode a single 
protein of the TpsB family that likely facilitates secretion of the FHA family 
adhesin(s). Phylogenetic analysis confirms relatedness of this protein to known 
TpsB transporter proteins, particularly the HecB protein of Erwinia chrysanthemi 
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(102,162) (Figure. 9.3). Consequently, the present study proposes that the 
TpsB family protein of B. multivorans C1576 is a HecB-like protein. Consistent 
with this, comparable phylogenetic analysis of the 264 kDa TpsA family protein 
of B. multivorans C1576 shows relatedness to the HecA protein of Erwinia 
chrysanthemi (Fig. 9.4 in the Appendix), although the phylogenetic distances 
are greater than that observed between the corresponding TpsB proteins. 
Immediately downstream of the hecB-like gene is a gene encoding a putative 
PpiC-type peptidyl-prolyl cis-trans isomerase (PPIase) protein, predicted to 
localise to the cytoplasmic membrane.  It is conceivable that this PPIase plays a 
role in the secretion of the FHA family protein, as has been described for a 
periplasmic PPIase of Bordetella pertussis (89).  
Analyses of available Burkholderia genomes reveals that the closest 
FHA-related adhesins to that of B. multivorans C1576 are found in the 
environmental isolate B. ambifaria MC40-6 (approximately 83 % amino acid 
identity between corresponding proteins) and B. phymatum STM815 
(approximately 65 % amino acid identity between corresponding proteins). 
Amino acid identity to related proteins of non-Burkholderia species (including 
the prototypic FHA/FhaC of Bordetella pertussis and the HecA/HecB of Erwinia 
chrysanthemi) is approximately 28-30 %.  
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Figure 5.3. The fimbrial and putative FHA loci identified within B. multivorans C1576. Dashed 
outline denotes genes targeted by insertional inactivation. FHA OMP, Filamentous haemagglutinin 
outer membrane protein; PPIase, PpiC-type peptidyl-prolyl cis-trans isomerase. (a) The C1576 
fimbrial locus encodes five fimbrial proteins relating to fimbrial chaperone and assembly. (b)The 
C1576 putative FHA-like locus encodes a putative HecA/HecB two-partner secretion (TPS) system, 
predicted to facilitate the secretion of the HecA-like encoded filamentous haemagglutinin.  
 
5.3.3 The loci encoding putative adhesins of B. multivorans C1576 differ in 
strain distribution. 
The analysis of available genome sequences referred to above 
suggested that the two loci were not widely distributed within the Bcc and wider 
Burkholderia genus. Using dot-blot hybridization, the distribution of each locus 
was assessed (based on the presence or absence of a representative gene for 
each) within a wider panel of Burkholderia isolates, with a particular focus on 
clinical B. multivorans isolates (Table 5.1).  
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Table 5.1. Distribution of the the putative HecA-like, HecB-like and fim adhesins amongst 
clinical and environmental B. multivorans isolates. Isolates are sub-divided into ST-27 and non-
ST-27 (‘other’). None of the adhesins were detected in non-B. multivorans isolates. Southern 
hybridisation dot-blot analysis was carried out using DIG-labelled PCR probes for each adhesin.  
Clinical Environ. 
 
hecA 
hecB 
fim 
ST-27 
26/26 
26/26 
26/26 
Other 
4/57 
5/57 
47/57 
 
0/6 
0/6 
3/6 
 
A representative image of the dot-blot analysis for a panel of B. multivorans 
isolates is shown in Figure 5.4. 
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Figure 5.4. Dot-blot hybridisation of genomic DNA from B. multivorans clinical and 
environmental strain panel.  Adhesins were detected with DIG-labelled probes in a panel of 
clinical and environmental B. multivorans isolates. DIG-labelled adhesin-specific probes and 
genomic DNA from B. multivorans and Bcc isolates were hybridised and blocked using ROCHE 
Southern Hybridisation buffers, and visualised using CDP-Star chemiluminescence substrate. As can 
be seen based on this representative image, more strains contained the fimbrial usher adhesin than 
the two afimbrial hecA-like and hecB-like adhesins.  
Genomic DNA was isolated from a total of 97 Bcc isolates, comprising 83 
clinical B. multivorans isolates (including 26 representatives of strain ST-27), six 
environmental B. multivorans isolates, and representatives of other Bcc species 
(for strain details, see Appendix, Table 9.5).  
Genomic DNA from the assembled strain panel was probed for the 
presence of genes encoding the putative fimbrial usher and the HecB-like 
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proteins. Based on the presence of these representative genes, results 
(summarised in Table 5.1, and detailed in Table 9.5) reveal that the locus 
encoding the putative fimbrial proteins is widely distributed amongst both clinical 
and environmental B. multivorans isolates, being observed in 76/89 isolates 
tested. In contrast, the locus encoding the FHA-family adhesin is more 
restricted in distribution, being limited to clinical isolates and particularly the ST-
27 outbreak strain (occurring in 100 % of ST-27 isolates, compared to < 9 % of 
non-ST-27 isolates). None of the non- B. multivorans isolates within the strain 
panel harboured either gene.  
5.3.4 The fimbrial and FHA-family adhesins of B. multivorans C1576 contribute 
to adherence and biofilm formation.  
Next, the present study sought to evaluate the role of these putative 
adhesins in adherence and biofilm formation. Individual mutants were 
generated by insertional inactivation of the genes encoding the putative HecA-
like, HecB-like and fimbrial usher proteins (resulting in strains and vector 
constructs hecA CR, hecB CR and fim CR respectively, Chapter 2 Table 2.1, 
Table 2.2). Both the hecB-like and fim crude mutants were complemented in 
trans using the pDA17 constitutive expression vector. The hecA CR mutant was 
not complemented due to the large size of the gene (> 8 kb).  However, RT-
PCR analysis of hecA CR mutant confirmed that the expression of downstream 
genes was maintained following hecA inactivation. Additionally, RT-PCR 
analysis confirmed that genes flanking all of the inactivated genes within each 
of the mutants were still expressed (data not shown, primers used for RT-PCR 
can be found in Appendix Table 9.3). 
To evaluate the role of the adhesins in abiotic adherence, the ability of 
the strains to adhere to mucin and to the extracellular matrix protein fibronectin 
was assessed. None of the mutants exhibited a significant reduction in 
fibronectin binding (P > 0.05, data not shown).  
In contrast, adhesin mutants were significantly reduced in their 
adherence to mucin relative to the wild-type strain (P < 0.0005; Fig. 5.5(a)). 
Appropriate complementation of two of the mutants (fim CO and hecB CO) 
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partially restored mucin adherence (P < 0.05 relative to the corresponding 
mutant strain), albeit not to wild-type levels (Figure. 5.5 (a)). This partial 
complementation has been observed previously with the pDA17 vector, 
including in a recent study of an adhesin-like gene of B. cenocepacia (134), and 
this could reflect sub-optimal gene dosage from the complementation vector.  
Next assessed was adherence to the A549 human lung epithelial cell 
line. As shown in Figure 5.5(b), the fim, hecA and hecB crude mutants showed 
significantly reduced adherence to A549 cells relative to wild-type. In contrast to 
the mucin and fibronectin adherence assays, complementation of the fim and 
hecB mutants failed to restore adherence to A549 cells. It is conceivable that 
overexpression of these adhesins from the complementation vector masked 
other cell-surface components that play an important role in the adhesion of B. 
multivorans to epithelial cells.  
Next, the ability of all strains to form biofilm was assessed using the 
MBEC biofilm assay device (Innovotech). As shown in Figure. 5.5 (c), all three 
mutant strains (fim CR, hecA CR and hecB CR) exhibited significantly impaired 
biofilm formation relative to wildtype C1576 (P < 0.0005), indicating that both 
adhesins are important for biofilm formation. Appropriate complementation of 
both mutants fully restored biofilm formation (Figure. 5.5(c)). 
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Figure 5.5. Adhesins of B. multivorans C1576 contribute to biotic and abiotic adherence and 
biofilm formation. Wild-type B. multivorans C1576, the fim, hecA and hecB CR insertional mutants 
and complemented strains were assessed for adherence and biofilm formation. Graphs show 
representative data from at least three independent experiments. Asterisks alone indicate 
statistical significance relative to wild-type C1576, whilst asterisks with bracket bar directly 
beneath compare the adhesin mutant (CR) to the corresponding complemented strain (CO). * P < 
0.05, ** P < 0.005, *** P < 0.0001 as assessed by orthogonal contrast and 1-way ANOVA with Tukey 
post-test. Error bars represent SEM. (a) Mucin adherence assay showed all adhesin mutants 
significantly impaired in adherence to mucin. Complementation of fim and hecB mutants only 
partially-restored adherence. Results are expressed as percentage adhesion relative to input. (b) 
Adherence to A549 epithelial cells. All mutants were significantly impaired in their adherence to 
A549 cells. Complementation failed to restore adhesion. Results are expressed as percentage 
adhesion relative to input. (c) All mutants show reduced biofilm formation relative to wild-type, 
with fim and hecB complementation fully restoring biofilm formation.  
 
Finally, to investigate the role of these adhesins during infection, all 
strains were assessed within the G. mellonella infection model, a model that 
has been used previously to investigate the role of Burkholderia adhesins (134). 
Neither mutant exhibited altered larval killing compared to wild-type C1576, with 
all strains killing 100 % of larvae within 72 hours at an inoculum of 
approximately 104 CFU (data not shown). Larvae injected with PBS exhibited 
100 % survival for the duration of the experiment. Therefore, individually, the 
putative fimbrial usher protein or the HecA- and HecB-like proteins are not 
required for full virulence in the G. mellonella model. 
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5.3.5 Mannitol promotes expression of both adhesin loci, enhancing adherence 
of C1576 
As had been previously shown, growth of C1576 in mannitol promoted 
adherence to mucin in an EPS-independent manner (Fig. 5.1). Having identified 
adhesins within C1576, their expression in the presence of mannitol was also 
assessed. As part of the wider on-going study of the genome-wide 
transcriptional response of B. multivorans to mannitol (discussed in depth in the 
previous chapter, Chapter 4), RNA-seq analysis on the Illumina platform was 
performed. Analysis of this transcriptome dataset reveals that growth in 
mannitol promotes expression of both loci encoding the putative fimbrial and 
afimbrial adhesins (Fig. 5.6). This is particularly the case for the putative 
fimbriae-encoding locus, every gene of which is significantly upregulated by 
growth in mannitol. All genes of the putative fimbriae-encoding locus were 
significantly upregulated following growth in YEM, with 2.5- to 13-fold increases 
in expression relative to that observed in mannose-grown cultures. Upregulation 
of the locus encoding the putative FHA-family adhesins was also observed, 
albeit to a lesser extent (1.5- to 2-fold). Of those, only the genes encoding the 
putative 68 kDa FHA-like protein (FHA OMP 2) and HecB-like protein were 
deemed to be significantly upregulated.  
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Figure 5.6 RNA-seq analysis reveals elevated expression of both putative adhesin-encoding loci 
following growth in mannitol. The relative expression of the genes of the putative adhesin-
encoding loci of B. multivorans C1576 was assessed by RNA-seq. The graph shows the fold change 
in gene expression observed following growth in the mannitol-containing YEM media, relative to 
the expression level observed in equivalent mannose-containing media. For each gene, data are 
depicted in two ways: (1) The horizontal bar indicates the fold change that was calculated from the 
combined analysis of the two biological replicates per condition; (2) the variance in the fold change 
for each gene is shown by the individual data points (filled circles) that each represent analysis of 
the biological replicates individually (i.e. a single pairwise mannitol-vs.-mannose comparison). The 
fold change of the fimC gene could not be calculated for two of the four pairwise comparisons as 
one of the mannose-grown samples had an RPKM value of 0. Asterisks denote FDR-adjusted P-
values (* P < 0.05, *** P < 0.0005), and relate to the combined analysis of the biological replicates. 
Having shown this upregulation of adhesins in response to mannitol, it 
was next determined to what extent the individual adhesins contributed to the 
mannitol-promoted adherence phenotype shown in Figure 5.1 (b). The wild-type 
and adhesin mutants were cultured in mannose or mannitol-supplemented broth 
prior to the mucin adherence assay. Relative to wild-type, both fim CR and 
hecB CR mutants showed impaired mucin adherence following growth in 
mannose-containing media (P < 0.05), consistent with the results presented in 
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Figure 5.5 (a), and consistent with a general defect in adherence following 
inactivation of either adhesin. Despite this lower basal level of adherence, the 
adherence of the fim CR strain was still elevated 5- to 6-fold following growth in 
mannitol (P < 0.0005). This is consistent with observations of the wild-type, and 
suggests that the putative fimbrial adhesin does not play a significant role in the 
enhanced mucin adherence that is induced by mannitol.  In contrast, the 
adherence of the hecA CR and hecB CR strain was not enhanced following 
growth in mannitol (P > 0.05), indicating that the putative FHA-family adhesin 
loci contributes to the mannitol-induced mucin adherence. Whilst it is the 
fimbrial locus that is most significantly elevated following growth in mannitol 
(Figure 5.6), it is the locus encoding the putative FHA-family adhesin that 
appears to be a key determinant of the enhanced adherence. Although perhaps 
unexpected, this may reflect the fact that the hecB gene is predicted to encode 
the transporter for the FHA adhesin rather than the adhesin itself, and thus 
hecB expression is not a reliable indicator for the amount of mature adhesin on 
the cell surface.  
 
5.4 Discussion 
In this study two distinct adhesin loci were described in B. multivorans 
that each played a role in adherence and biofilm formation. These loci varied in 
their strain distribution; the fimbrial locus was widely distributed in clinical and 
environmental B. multivorans isolates, whilst the FHA locus was restricted to 
clinical B. multivorans isolates, and was particularly associated with those of the 
ST-27 outbreak strain. Strikingly, mannitol, recently approved as an inhaled 
osmolyte therapy for CF patients, up-regulated both loci and promoted bacterial 
adherence.  
Whilst adhesins have been described in other Bcc and within the wider 
Burkholderia genus (13,134,201), the present study represents the first 
characterisation of fimbrial and FHA adhesins within Bcc, and the first 
characterisation of any adhesins within B. multivorans. FHA adhesins of B. 
pseudomallei play a role in adhesion to human epithelial cells (179), consistent 
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with our observations in B. multivorans. Whilst fimbrial and FHA adhesins are 
common within Burkholderia, there is considerable diversity between adhesins 
of different species, as evidenced by the present study in which amino acid 
identity to comparable adhesins in other Burkholderia species was typically 35-
55 %. Such sequence variation profoundly alters adhesin binding specificities 
and affinities, impacting on host tropism and capacity for virulence (90,185). 
Burkholderia species are an extremely versatile group of organisms that 
includes human, animal and plant pathogens. The role played by species-
specific adhesins in conferring such diverse host adaptations remains to be 
elucidated.  
In contrast to the widely-distributed fimbrial locus, it is striking that the 
FHA-like locus reported in the present study was found only in clinical isolates, 
although further environmental isolates need to be studied to test this 
association more rigorously. The low number of environmental B. multivorans 
included in the assembled strain panel reflect the infrequent isolation of this 
species from the natural environment (14).  Furthermore, all but two of the FHA-
positive clinical isolates (detailed in the Appendix, Table 9.5) belong to 
sequence types associated with patient-to-patient transmission, notably ST-27, 
ST-25 and ST-179 (14). Putative transmissibility factors have been identified in 
other Bcc species (46), and whilst their predictive value has been questioned 
(80), our observations justify further studies to investigate the strength of the 
association of the FHA-encoding locus with transmissible strains, and its 
potential as a marker for transmissibility amongst clinical B. multivorans. 
The rationale for this study of adhesins within the B. multivorans ST-27 
strain stemmed from our observations that whilst mannitol promoted bacterial 
adherence to mucin, the role played by EPS was strain-dependent. The present 
study emphasises the difficulty in establishing the role of EPS in virulence, as 
the growth conditions commonly used to induce and study EPS (the mannitol-
containing media, YEM) clearly illicit a response within the bacterium that is 
wider than the EPS biosynthetic pathway. Consequently, attempts to identify the 
role of EPS through phenotypic observations of whole organisms risk being 
skewed by the wider non-EPS response to mannitol, potentially resulting in 
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phenotypic traits being wrongly assigned to the mucoid phenotype. The present 
approach undertaken in this study (comparison of wild-type and isogenic EPS-
deficient mutant formulated in Chapter 3) is better-suited for defining 
phenotypes truly associated with EPS production. The strain-dependent role of 
EPS in promoting bacterial adherence highlights the multi-factorial aspect of 
Bcc virulence, and the fact that the contribution of individual virulence 
determinants within any given strain is influenced by the presence or absence 
of other complementary factors. One consequence of this is that the biological 
significance of the documented mucoid to non-mucoid transition frequently 
observed amongst Bcc CF isolates (234) will be heavily strain-dependent. 
Whilst the ability to utilise mannitol as a carbon and energy source is 
common amongst both Bcc and Pseudomonas aeruginosa (the dominant CF 
pathogen), it was considered unlikely that inhaled mannitol therapy would 
significantly affect bacterial burden in the lung (161), and this appears to have 
been borne out by subsequent clinical trials (93,193). However, the fact 
mannitol promotes EPS, together with our observations that mannitol promotes 
expression of adhesins that contribute to adherence and biofilm formation, 
indicate that administration of mannitol is likely to have profound phenotypic 
consequences on Bcc within the lung, even if bacterial burden is unaltered. 
Whilst inhaled mannitol therapy clearly improves lung function (3,23,59), it 
would appear prudent to monitor the microbiology status of CF patients 
receiving mannitol, particularly those infected with Bcc.  
In summary, this study has identified and characterised B. multivorans-
specific fimbrial and FHA-like adhesins, confirming their role in biotic and abiotic 
adherence, and biofilm formation. In so doing, this study has highlighted the 
strain-to-strain variation in EPS contribution to Bcc virulence, and the difficulty in 
assigning phenotypic traits to EPS due to the wider response of Bcc to 
mannitol. Previous studies (described in Chapter 4) aimed to define the 
genome-wide response to mannitol and identify global regulators that may be 
responsible. From those studies, candidate transcriptional regulators were 
identified and though not within the scope of this present study, would be 
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interesting candidates for mutagenesis and characterisation in order to define 
Bcc EPS regulation. 
Overall, the impact of mannitol on the Bcc is unequivocal, and close 
monitoring of Bcc-infected patients receiving inhaled mannitol therapy would 
appear prudent. The broader impacts of sugars relevant to diabetes and 
mannitol on the phenotypic and gene expression behaviour of the organism 
require careful consideration when considering the appropriate treatment and 
disease management options for CF patients.  
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5.5 Conclusion 
1.  Fimbrial and afimbrial adhesins in B. multivorans contribute to biotic and 
abiotic adherence and biofilm formation.  
2. The distribution of the FHA-like afimbrial adhesins was restricted to clinical B. 
multivorans isolates.  
3. C1576 growth on mannitol upregulates both adhesin loci and thus mannitol 
as an inhaled osmolyte has potential impacts directly on virulence of this 
organisms in the CF lung. 
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Chapter 6: Composition analysis of mannitol- and fructose-derived 
exopolysaccharide produced by B. multivorans 
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6.1 Introduction  
Bcc mucoid isolates are linked to chronic persistent infection and 
inhibited clearance in the mouse chronic lung infection model (51). Although 
EPS production is still debated to occur in vivo, the impact of mucoidy on the 
progression of Bcc infection has been interpreted across a panel of 100 clinical 
isolates paired with detailed clinical data, revealing a potential link in mucoid 
strains favouring persistent rather than acute infection (233). In previous 
chapters of the present dissertation, the varied impacts of EPS production and 
the EPS-inducing sugar mannitol on virulence relevant phenotypes (Chapter 3 
and 5) and gene expression (Chapter 4) were discussed. Findings from these 
previous studies indicated phenotypic or gene expression profiles were altered 
following growth on yeast extract sugar agars containing fructose, mannose, 
glucose, and mannitol. These sugars are of interest due to clinical relevance 
(mannitol is an approved inhaled osmolyte in CF patients; glucose, fructose and 
mannose are elevated in diabetics urine and blood). Mannitol and fructose 
induce a mucoid, EPS-producing phenotype in B. multivorans. Although levels 
of fructose in the lung have not been reported, it has been shown that glucose 
is elevated in the airways of diabetics (29). The structure and biological activity 
of Bcc EPS derived from mannitol has been studied and characterised to some 
extent; however no studies have included fructose, or any other sugars that 
induce EPS synthesis. One study suggested up to ~ 80 % of CF isolates 
produce EPS (139). Production of EPS by members of the Bcc has been shown 
to use the bce EPS biosynthetic gene cluster; this gene cluster was the focus of 
Chapter 3, assessing the impact of mucoid on virulence-relevant B. multivorans 
phenotypes. The present study characterised the EPS composition from 
mannitol- and fructose-induced B. multivorans EPS. In the following Chapter 7, 
the biological activity of fructose-and mannitol-derived EPS will be examined. 
Some studies have reported the dominant type of EPS made by the Bcc is 
cepacian, and other types of EPS. Interestingly, though the bce operon is 
required for EPS biosynthesis and is linked to cepacian production, a mixture of 
up to five polysaccharides have been identified from mannitol-induced EPS-
producing Bcc isolates (88). The inclusion of fructose as well as mannitol in the 
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following EPS composition studies aimed to further understanding of the 
biological role of carbon source and the impact of different EPS-inducing sugars 
may have on B. multivorans EPS composition. This knowledge would forward 
understanding of the role EPS production and carbon utilisation plays within the 
host. The main aim of the present study was to assess whether B. multivorans 
ATCC 17616 (environmental isolate) and C1576 (clinical isolate) EPS 
composition differed following growth on fructose and mannitol.  
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6.2 Aims 
1. Develop and refine EPS sample extraction and preparation to enable mass 
spectrometry analysis. 
2. Optimise sugar detection and analysis methods using QQQ-LCMS 
3. Assess the impact of carbon source used for growth on B. multivorans EPS 
composition, specifically EPS induced following B. multivorans ATCC 17616 
and C1576 growth on fructose and mannitol.  
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6.3 Results  
6.3.1 Standards for EPS mass spectrometry analysis  
The repeating unit structure of the exopolysaccharide cepacian has been 
the focus of previous studies in the literature. Analysis of Bcc EPS including 
methylation, sugar analysis, chromatography hydrolysis, mass spectrometry, 
and NMR studies aimed at identifying the structure, acetylation state, and 
repeating unit of cepacian induced following growth in mannitol (37,39,107).  
The repeating unit (RU) was determined first in structure and further 
characterised as the building block for cepacian (37-39,107,117). Cepacian 
consists mainly of a highly branded heptasaccharide-RU. The oligosaccharide 
structure of the biological RU of cepacian was previously elucidated using B. 
pyrrocinia BTS7 (39). The cepacian RU contains D-glucose, D-galactose, D-
mannose, and D-rhamnose in a ratio of 1:1:3:1 (38). These four sugars were 
chosen as standards to assess EPS composition of B. multivorans ATCC 17616 
and C1576 grown on fructose and mannitol.  
A mix of four sugars was prepared to form a standard sugar mix. Each 
sugar was combined at equal concentrations and then serially diluted to be 
used to create a standard curve. Concentrations used were: 10 mM, 0.1 mM, 
0.5 mM, 0.025 mM, 0.0125 mM. Individual standards of each sugar were run at 
10 mM and were included on each QQQ-LCMS run for EPS composition 
analysis, along with the sugar standard mix (at five concentrations) and EPS 
samples. Figure 6.1 shows the chromatogram of the standard mix of the sugars 
in the order at which they eluted. The mass spectrometer used was the 6410 
enhanced sensitivity triple quadrupole (QQQ) (Agilent Technologies). The QQQ 
was linked to an Agilent 1200 series HPLC stack for online LC-MS. Serial 
dilutions of the sugar mixes were included in every QQQ-LCMS run in order to 
obtain standard curves (for sample concentration calculation) and monitor 
sensitivity and calibration of the mass spectrometer. Figure 6.1 shows fructose 
and fucose in the standard mix, but these sugars were not included in further 
analysis as they were not detected in the B. multivorans EPS samples after 
preliminary analysis (data not shown). Of note is the overlap of glucose and 
galactose peaks (and to some extent mannose) at the same acquisition time 
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and mass. This issue was problematic during early data analysis and method 
optimisation and is discussed in following results sections.  
 
 
Figure 6.1. Chromatogram of the sugar standard mix. Sugars shown on axes indicate elute in ion 
counts (y-axis) vs. acquisition (or retention) time (x-axis). Retention time indicates length (in 
minutes) of time compound spent on the HILIC column prior to detection relative to the other 
sugars. Fructose and fucose were easily detectable, as was rhamnose. The mass-to-charge ratio 
(m/z) of each sugar is included in parentheses next to the sugar name. Mannose, glucose, galactose, 
13Mannose and 13Glucose were included to demonstrate the m/z difference of 1 in the 13C 
labelling of one carbon in each of those sugars.  
 
6.3.2 Verification of sugar content in B. multivorans EPS extracts 
Once the sugar standards were selected and identified at individual 
masses and acquisition times, EPS from B. multivorans could be extracted 
following 48 hours of ATCC 17616 and C1576 growth on mannitol or fructose 
sugar agar. To confirm sugars were present within EPS extracts, the Dubois 
test (phenol sulphuric acid) was performed. This method uses a colorimetric 
detection for the determination of sugars and is used to determine the 
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concentration of individual sugars making up polysaccharides (66). Results from 
the Dubois assay showed that sugars were present at low concentrations. Thus 
a highly concentrated sample amount was chosen for mass spectrometry 
analysis. Ten milligrams (± 0.5 mg) of crude EPS extract for each sample was 
found to be a reliable quantity for mass spectrometry analysis. The methods for 
further sample preparation were next optimised.  
 
6.3.3 Optimisation of internal sugar standards 
Due to the co-elution of sugars of the same mass (glucose, galactose, 
and mannose), heavy labelled 13C sugars were used for direct quantification via 
standard addition at a final concentration of 0.05 mM. Internal standards (re-
suspended in HPLC grade water) were added and 10 mg EPS was re-
suspended to a final volume of 50 µl. The 13C sugars were added into EPS 
samples and are detected at a different mass than the accompanying 
unlabelled sugar, so amounts can be quantified easier between these sugars of 
the same mass.  
6.3.4 Acid hydrolysis of EPS extracts 
Analysis of the constituent monosaccharides of the EPS was carried out 
by hydrolysis. Acid hydrolysis optimisation involved extensive trials using 
different reaction conditions. Temperature, length of hydrolysis, and type of acid 
were optimised to achieve a completely hydrolysed sample at a determinable 
concentration without extensive charring. EPS samples with and without the 
heavy labelled sugars were hydrolysed in 2 M trifluoroacetic (TFA) acid or 
glacial acetic acid (17 M) in screw cap glass universal tubes at 100, 120, or 165 
°C for 1, 2, 3, or 4 hours. These acid hydrolysis trials were carried out on 
mannitol-derived C1576 EPS. In the end, the decision was made to use the 
stronger, TFA acid at 2 M (as was previously reported in the literature (51)) as 
the acetic acid did not completely or as effectively hydrolyse the polysaccharide 
samples, observed as groupings of steep chromatogram peaks at high retention 
times that did not align with any standards used. Also, the length reported in 
literature for a 2 M TFA acid hydrolysis for 2 hours was shortened to 1 hour, as 
there was less apparent charring but still complete hydrolysis at the 1 hour time 
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point. Literature sources reported using the higher 165 °C temperature; based 
on previous Ph.D. research work in the lab of Professor N. Smirnoff (221), the 
temperature was decreased slightly to 110° C, which still proved effective with a 
1 hour hydrolysis of the polysaccharide constituents. Finally, during the 
hydrolysis step, an issue arose with evaporation of the sample which resulted in 
low concentration of sugars in early mass spectrometry results. A switch from 
glass universals during acid hydrolysis to air-tight Teflon capped-Reacti-vials 
was made to avoid the issue of sample loss during acid treatment. These steps 
to optimise the acid hydrolysis process of sample preparation greatly improved 
the amount of sugars detected by mass spectrometry making detection and 
analysis robust. Following acid hydrolysis, the sample was snap frozen, freeze 
dried, and re-suspended in 50 µl HPLC-grade H2O (original starting material 
was 10 mg ± 0.5 mg freeze-dried EPS).  
 
6.3.5 Glucose oxidase treatment of EPS extracts 
Finally, for each type of EPS sample, the separation of glucose and 
galactose for quantitation was difficult, even with standard addition of heavy 
labelled sugars in each sample. For each mannitol- and fructose-derived EPS 
sample from B. multivorans ATCC 17616 and C1576, there were three sample 
preparations: (i) acid hydrolysed, (ii) acid hydrolysed with 13C labelled sugar (for 
standard addition quantitation), and (iii) acid hydrolysed glucose oxidase-treated 
13C labelled (spiked for standard addition). The glucose oxidase treatment 
selectively destroyed glucose using glucose oxidase, catalase, followed by an 
acetonitrile precipitation to remove protein. By creating these three types of 
samples for each B. multivorans EPS extract the different sugars even of the 
same mass were detectable as separate entities. An attempt at also using the 
galactose oxidase enzyme was carried out; however reaction conditions were 
not optimised further once the glucose oxidase destruction was proven 
successful (Figure 6.2). EPS extracts with and without glucose-oxidase 
treatment and EPS samples with or without standard addition of 13C labelled 
sugars, allowed for quantified concentration by comparing the difference 
between the individual sugar peaks in chromatograms.  
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Figure 6.2. Destruction of a glucose by glucose oxidase. 10 mM glucose shown in blue line is a 
standard. B. multivorans C1576 mannitol-derived EPS was treated with glucose oxidase (black line), 
or was not treated by glucose oxidase (orange). Graph axes show counts vs. acquisition time. The 
mass-to-charge ratio (m/z) of each sugar is 179.06. The glucose-oxidase treated sample shows no 
peak where the glucose standard lies. 
 
6.3.6 QQQ-LCMS method 
The triple quadrupole (QQQ) MS was used for the task of performing 
targeted analysis for mannose, galactose, glucose and rhamnose. The HPLC 
and MS source parameters were previously optimised for hexoses and other 
sugars based on work carried out in sugar analysis by Dr. Hannah Florance and 
Dr. Mike Page (University of Exeter). Raw data was processed using 
MassHunter Qualitative and Quantitative software (Agilent). Data obtained from 
mass spectrometry runs were analysed in Microsoft Excel spread sheets for 
quantitative, standard peak addition and standard curve analysis. 1-way 
ANOVA statistical analyses and post-tests were then applied to identify if there 
were significant differences in EPS composition of samples from different 
carbon sources and different strains. The mobile phase buffers used for QQQ-
LCMS analyses were optimised to improve chromatography and resolution. 
Mobile phase A was 90 % LCMS grade acetonitrile and 10 % H2O, with 0.1 % 
ammonia. Mobile phase B contained 10 % LCMS-grade acetonitrile and 90 % 
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LCMS grade H2O with 0.1% ammonia and 5 mM ammonium formate. 
Ammonium formate improved chromatography but decreased sensitivity; 
ammonia balanced this out by improving the sensitivity of detection.  
 
6.3.7 Data processing  
Following QQQ-LCMS runs, raw data was analysed with MassHunter 
software (Agilent) and the software was used to calculate peak areas for the 
sugars of interest in EPS samples. This analysis was limited to detection of 
glucose, mannose, galactose and rhamnose by mass. Concentrations of sugars 
were estimated based on the standard curve for each individual sugar taken 
from the mixed sugar standard chromatograms. 13C –internal standard (spiked) 
samples were used to directly calculate sugar composition relative to the un-
spiked samples by: 
Signal Spike = Signal Spiked - Signal Sample 
Then the instrument response was calculated per unit of measure (mM) 
Instrument Response (nmol-1) = Signal Spike / Conc Spiked 
 
Followed by calculation of concentration by dividing the sample signal by the 
instrument response, or 
Conc Sample = Signal Sample / Response (nmol
-1) 
 
The dilution factor was accounted for in the sample by 
  
Final Conc Sample Ext = Conc Sample Extract * Dilution factor 
Where 
Conc Sample Extract = (Conc Sample / 5 µl) x 50 µl 
Then concentration of sample in dry weight material from extract was 
determined by 
nmol per g = (Final Conc Sample Ext * 1000/10 mg) 
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These equations were built into an Excel worksheet where retention times, 
injection volumes, peak areas (manually selected from data files using the 
Agilent workstation MassHunter software) and amount of starting material were 
input into the spread sheet and automatically calculated to minimise errors in 
calculations from one experiment to another.  
6.3.8 B. multivorans EPS composition analysis  
Detection of individual sugars was successful after extensive 
optimisation of sample preparation. Figures 6.3 and 6.4 represent at least three 
combined biological replicates from different EPS sample extractions of 
mannitol- and fructose-derived EPS. These EPS samples were subjected to the 
same processes of extraction, sample hydrolysis and/or standard addition. 
Figure 6.3 shows EPS composition profiles of B. multivorans ATCC 17616, the 
environmental isolate (Figure 6.3 (a, b)), and C1576, the CF outbreak-isolate 
(Figure 6.3 (c, d)). Based on the reports that state ATCC 17616 produces only 
cepacian, and C1576 a mixture of different EPS types, the ratios of sugar 
composition were compared to known cepacian sugar ratios. As previously 
stated, the cepacian RU (based on analysis of B. pyrrocinia EPS) contained 
rhamnose, mannose, glucose and galactose in a ratio of 1:3:1:1. ATCC 17616 
is reported to produce only cepacian; a comparison of ATCC 17616 mannitol-
derived EPS with cepacian reveals altered rhamnose, mannose, and galactose 
average (EPS molar ratio of 2:5:1:3 of rhamnose, mannose, glucose, and 
galactose). Differences between the ATCC 17616 EPS from YEM and cepacian 
could be due to the technical variation in the mass spectrometer. The ratios of 
individual replicates were pooled (n= 4 run on the same mass spectrometer but 
on different days) and error could have been introduced by sample variation 
from differing mass spectrometry runs. The content of ATCC 17616 YEM 
glucose and galactose was significantly different (1:3 ratio), whereas the 
cepacian glucose to galactose ratio is 1:1.  
The ATCC 17616 fructose-derived EPS had a rhamnose, mannose, 
glucose and galactose profile of 3:2:1:4. Clearly, these ratios are again different 
from cepacian, possibly due to technical variation but also potentially due to 
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fructose altering the EPS profile of ATCC 17616. Although the mannitol and 
fructose molar ratio comparison is not significantly different between strains or 
carbon-sources, this could be due to technical variability between mass 
spectrometry runs (see Table 6.1) rather than actual lack of significant 
differences. One EPS sample was run on different days (in order to assess the 
technical variability from day-to-day use of the mass spectrometer). This did 
result in different concentrations of sugar measured. The sample C1576 YEM 
EPS extract actual sugar concentrations are shown in Table 6.1, but similar 
observations were made for all other EPS samples. Table 6.1 shows clear 
technical variation and inconsistencies from one sample run (1st run, 2nd run) for 
some sugars on the QQQ-LCMS. The most obvious variability lies in 
quantification of glucose and galactose are the two sugars most clearly 
drastically different from one mass spectrometry analysis to another. Although 
the average molar ratio of C1576 YEM between rhamnose and galactose is 
significant, as is the glucose and galactose content comparison (Figure 6.3), 
these significant differences were not present in the C1576 fructose-derived 
EPS. Compared to cepacian, C1576 YEM contains more galactose but less 
mannose than cepacian, by the rhamnose, mannose, glucose, galactose ratio 
of 1:2:1:5 (C1576 fructose-derived EPS was also different from cepacian – with 
ratio for the same sugars estimated as 3:2:2:3). Though the differences 
between cepacian and C1576 samples would be interesting due to the fact that 
C1576 is known to produce multiples types of polysaccharide, results are not 
reproducible from one run on the mass spectrometer to another so differences 
cannot be confidently assigned to carbon source or strain variation.  
 
 
Table 6.1. Technical variability in sugar analysis method. A B. multivorans C1576 EPS 
composition profile is shown. The same EPS extract sample from mannitol grown C1576 was run 
under the same mass spectrometry conditions, on two different days. Rhamnose concentration did 
not vary, but mannose, galactose and glucose concentrations did. 1st, 1st run; 2nd, 2nd run.  
  Sugar concentration (mM) 
B. multivorans Rhamnose Mannose Galactose Glucose  
Strain/EPS 1
st
  2
nd
 1
st
 2
nd
 1
st
 2
nd
 1
st
 2
nd
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C1576 mannitol 0.041 0.042 0.001 0.006 0.007 0.018 1.050 0.110 
 
Although there could have been some minor biological variability, the methods 
used for Bcc growth and EPS extraction are well established in the literature for 
studying Bcc EPS. The present study only utilised one mass spectrometry 
technique to study EPS composition. Other research groups specialised to work 
in polymer and carbohydrate chemistry interrogate composition, acetylation 
status, and structure of EPS samples, and therefore a more comprehensive 
approach using a variety of techniques would be useful for future research, 
which should be focused on developing a more specific method for sugar 
composition and develop a way to differentiate sugars of the same mass 
(glucose, mannose, galactose) by more reliable means. In Figure 6.4, the EPS 
of both B. multivorans strains is compared from both carbon sources. There 
appear to be potential differences between ATCC 17616 and C1576, and 
between strains grown on the same sugars, but there were no significant 
differences of comparisons between individual sugars. The data presented in 
Figure 6.4 is the same molar ratios presented in Figure 6.3, only combined and 
compared in different ways. One key point to remember is the large error bars 
from the composition analysis of B. multivorans EPS was the technical issues 
with reproducibility. Therefore it is difficult to draw conclusions until further 
studies are undertaken as the impacts of different EPS-inducing sugars on B. 
multivorans EPS composition.  
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Figure 6.3. Composition of B. multivorans EPS profiles. Fructose- and mannitol-derived EPS 
profiles from B. multivorans ATCC17616 and C1576. ATCC17616 EPS derived from mannitol (a) 
contains significantly less glucose than galactose and in the fructose derived EPS from the same 
strain; this same difference exists (b) but is not statistically significant. C1576 EPS derived from 
mannitol contains significantly more galactose that glucose or rhamnose (c) whilst these 
differences are not observed in the fructose derived EPS from the same isolate (d).  * P < 0.05, 1-
way ANOVA analysis.  
ATCC 17616 
C1576 
Mannitol 
 
Fructose 
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Figure 6.4. Relative comparisons between mannitol-and fructose-derived B. multivorans EPS. 
EPS profiles compared between B. multivorans ATCC 17616 and C1576. Molar ratios were 
calculated, and no statistical differences between EPS derived were observed, likely due to large 
variation between replicates, as indicated by SEM error bars. Data shown are mean values of 3-4 
biological replicates.  
 
6.4 Discussion 
Previous chapters of the present dissertation have discussed the wide-
reaching impact of carbon source on the phenotypic and transcriptomic 
behaviour of B. multivorans. The present chapter aimed to assess the impact of 
carbon source on the actual composition of EPS. Chapter 7 will focus on the 
impact different carbon sources have on the biological activity of EPS. B. 
multivorans C1576 grown on mannitol produces a mixed polysaccharide based 
on previous reports. Knowledge of the composition of polysaccharides is useful 
for understanding EPS properties, tailoring polymers with desired 
characteristics, and providing insight into potential antigenic interactions or 
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properties (88). EPS production has been detected in numerous clinical and 
environmental Bcc isolates following growth with mannitol (68,88,142). Results 
from mass spectrometry-based analysis of C1576 EPS derived from fructose 
versus mannitol indicates that the sugar ratios do not differ significantly 
depending on carbon source used for growth or strain type.  
Concerning the impact different sugars and EPS induction have on 
phenotypic behaviour (see previous Chapters 3 and 5) and gene expression 
profiles (see previous Chapters 4 and 5) growth on mannitol, fructose, glucose 
and mannose altered phenotypic behaviour and gene-expression with regards 
to virulence-relevant traits. These results were largely EPS-independent, even 
though mannitol and fructose both induce EPS production in B. multivorans 
wild-type ATCC 17616 and C1576. Thus, though the present study could not 
conclude definitely whether different sugars impact EPS composition, the body 
of work presented in this dissertation still suggests altering the carbon source 
used to induce EPS production broadly influences the behaviour of the whole 
organism.  
Future study, beyond the scope of this dissertation, could assess 
incorporation of mannitol and fructose during growth and EPS production in B. 
multivorans through the use of radio-labelled 13C sugars as growth substrates. 
This would assess whether B. multivorans uses an EPS-inducing sugar in 
carbohydrate metabolism or solely as a means to induce EPS production. 
Future work is required to improve current EPS compositional analysis and 
define structural alterations different carbon sources may have on EPS. This 
could involve NMR analysis of EPS for structural analysis. Improved mass 
spectrometry analysis to enable sugar composition content would seem 
prudent, as the methods and equipment applied to the present study was not a 
reliable technology for assessing EPS composition. It was also not a good 
method for determining if different types of polysaccharides were present in the 
different EPS extracts. One direct way of assessing if ATCC 17616 takes and 
converts mannitol to mannose preferentially would be to grow ATCC 17616 on 
growth media with 13C mannitol.  By detection of different sugar fractions, the 
presence of 13C labelled break down products such as mannose, or other 
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labelled sugars, would indicate mannitol is broken down during metabolism, 
rather than acting solely as a signal of EPS production. Since Burkholderia 
breakdown mannitol into mannose, detection of 13C labelled mannose of 
fructose (products of B. multivorans mannitol and fructose sugar metabolism), it 
could be inferred that if C1576 and ATCC 17616 contain different ratios of these 
13C labelled breakdown products, the two strains metabolise or utilise mannitol 
differently and may therefore produce EPS differently. 
Fructose and mannitol both induce EPS production in the Bcc. Though 
cepacian is the most commonly isolated EPS, some strains produce more than 
one type of polysaccharide. It may be beneficial for an environmental organism 
or clinical isolate to produce different types or switching EPS to allow for 
adherence modification depending on environment, surface properties, or 
stress. Further study on EPS induction and biosynthesis, and importance of 
carbon source on the structure and function of EPS are required to better 
understand the biological significance and impacts of mannitol, fructose, and 
other EPS inducing sugars, on the Bcc.  
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 6.5 Conclusions  
1. B. multivorans ATCC 17616 and C1576 EPS derived from fructose or 
mannitol did not significantly differ in glucose, rhamnose, galactose, or 
mannose composition using the methods utilised in this study.  
2. Future research should utilise more reliable and technically reproducible 
means to quantify composition of EPS.  
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Chapter 7: Differences in biological activity between fructose- and 
mannitol-derived B. multivorans exopolysaccharide  
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7.1 Introduction 
The present study furthers work from previous chapters concerning EPS 
and the influences of different sugars on B. multivorans phenotypic behaviour, 
gene expression, and EPS composition. Mannitol and fructose are sugars that 
induce the biosynthesis of EPS members of the Bcc. Mannitol was recently 
approved as an inhaled osmolyte in CF patients, and fructose has been 
reported to be elevated in diabetics. Levels of fructose in the lung have not 
been reported, but glucose is elevated in the airways of diabetics (29). As a 
virulence factor, EPS may be a protective barrier against immune system 
detection, and aide in establishing mature, architecturally sound, biofilms that 
are difficult to eradicate in the CF lung (51,56). Environmental Bcc could utilise 
EPS as a means of attachment during initial colonisation and close association 
with plant roots for nitrogen fixation purposes (69).  
EPS can act as barrier against metal toxicity. Iron is elevated in CF 
sputum (84), lavage fluid, and lung tissues (74). Bcc EPS is protective against 
desiccation and iron toxicity (but not zinc) (69). Bcc EPS protection from drying 
could result in persistence in the home or hospital environment, thus providing a 
source for environmental acquisition. A significant part of the innate immune 
response is neutrophil influx to the CF lung are toxic reactive oxygen species 
(ROS), which are highly bactericidal. Bcc mannitol-derived EPS is protective 
against ROS (33). However, all knowledge of the Bcc EPS and the impact of 
mucoidy have stemmed from analysis of biological activity, composition and 
structure of EPS derived solely from growth on mannitol. Fructose or any other 
EPS-inducing sugars have not previously been included in these studies.  
This study provides evidence for carbon source specific biological activity, 
indicating for the first time that growth in either fructose or mannitol alters B. 
multivorans EPS biological activity. EPS protection could be related to stress 
resistance pertinent to the environmental and opportunistic lifestyle of B. 
multivorans.  
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7.2 Aims  
1. This study aimed to assess B. multivorans biological activity of fructose- and 
mannitol-derived EPS through iron toxicity and desiccation survival assays.  
 
2. The ability of mannitol- and fructose-derived EPS to scavenge ROS was also 
assessed.  
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7.3 Results 
7.3.1 EPS protection from iron toxicity stress is strain- and carbon source -
dependent.  
The protective effect of EPS against toxic levels of iron (Fe2+) was 
assessed. EPS was extracted from mannitol or fructose grown B. multivorans 
ATCC 17616 and C1576, using the methods described previously (Methods 
section 2.20). B. multivorans ATCC 17616 and C1576 were grown overnight in 
mannose broths. B. multivorans was then challenged with toxic levels of Fe 2+ at 
a concentration of 50 mM ferrous sulphate, in the presence or absence of EPS.  
Results showed that following iron ion stress with ferrous sulphate, 
neither fructose- nor mannitol derived EPS significantly protected ATCC 17616 
from Fe2+ toxicity (Figure 7.1(a), at 1 hour and 3 hour time points. In contrast, 
C1576 incubated with mannitol-derived EPS was protected from Fe2+ toxicity 
compared to the no- EPS control (C1576 mannose) at the 1 hour time point 
(Figure 7.1(b).  
Carbon source-dependent protection of C1576 fructose-derived EPS and 
mannitol-derived EPS was compared. The C1576 mannitol-derived EPS was 
significantly protective against iron toxicity. Fructose-derived EPS was not 
protective. C1576 fructose-derived EPS was not protective compared to the no-
EPS control C1576 Mannose, and significantly reduced in survival compared to 
the mannitol-derived (YEM) EPS. Therefore, B. multivorans EPS confers 
resistance to iron toxicity protection in a carbon source- and strain-dependent 
and manner.  
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Figure 7.1. EPS protection of B. multivorans to 50 mM of iron stress. YEM, mannitol-derived EPS; 
YEF, fructose-derived EPS. Graph shows (a) 1 hour and 3 hour time points representing percentage 
survival relative to input of B. multivorans ATCC 17616 (b) 1 and 3 hour time point representing 
percentage survival relative to input of B. multivorans C1576. N=3 wells per condition. Statistical 
significance was assessed with 1-way ANOVA analysis and Tukey- post-test (*** P < 0.0001).  
 
Although the C1576 three hour time points appears significant when 
comparing C1576 Mannose to the YEM (Figure 7.1 (b)) they are not. 
Additionally, there are statistical significances between strains, with the C1576 
no-EPS control survival the iron exposure significantly better after 1 hour than 
the ATCC 17616 no-EPS control (P< 0.001 ***) and the C1576 mannitol-derived 
EPS conferring resistance to iron toxicity significantly better than the ATCC 
17616 mannitol-derived EPS (which was not protective at all to the ATCC 
17616 no-EPS control).  
 
7.3.2 Effect of EPS on desiccation survival is strain - and - carbon source 
dependent  
The effect of EPS on protection from desiccation was assessed. B. 
multivorans ATCC 17616 and C1576 were grown overnight in mannose. Then, 
with or without the addition of fructose- or mannitol-derived EPS, samples 
aliquots were added to wells of a polystyrene 96-well plate, air dried, and then 
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kept at 30° C for several days of desiccation. Viable counts were taken by 
rehydrating wells with sterile PBS and plating serial dilutions onto LB agar.  
After three days of desiccation, fructose-derived EPS from the 
environmental isolate ATCC 17616 was significantly protective against 
desiccation compared to the mannitol-derived EPS and the no-EPS control 
(ATCC 17616 Mannose) shown in Figure 7.2 (a); an asterisk above the YEF 
EPS sample indicates significant relative to the no-EPS mannose control.  
ATCC 17616 mannitol-derived EPS was not protective at all relative to the no-
EPS control, and thus significantly reduced in survival relative to the fructose-
derived EPS (significant at days two and three, signified by the bar between the 
two samples). Desiccation survival drops between day one and day two for all 
groups in Figure 7.2 (a).  
Both fructose- and mannitol-derived EPS protected C1576 after one day 
of desiccation, although not significant statistically (Figure 7.2 (b)). Following an 
overall drop in viability on day two, the mannitol-derived EPS resulted in 
significantly better C1576 survival that with fructose-derived or no-EPS 
samples. At three days of desiccation, some growth of the surviving viable cells 
brought percentage survival level in all three conditions after three days 
desiccation. This suggests C1576 in all conditions was able to survive 
desiccation better than the ATCC 17616 no-EPS and YEM EPS samples.  
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Figure 7.2. Effect of EPS against desiccation. Graphs show EPS derived from mannitol and 
fructose grown B. multivorans ATCC 17616 (a) and C1576 (b) in desiccation assay. Bars represent 
the percentage survival relative to input after 1, 2 and 3 days. YEM = mannitol-derived EPS, YEF = 
fructose-derived EPS. N=3, Asterisks with bars below indicate comparison between two conditions. 
Asterisks without a bar represent significant difference relative to mannose no-EPs control. 
Statistical significance assessed using 1-way ANOVA and Tukey post-test (P <0.05 *, P< 0.001 ***).  
 
Contamination was monitored over the three day desiccation time points 
by re-hydrating un-inoculated and plating onto LB agar. Still, it is clear a higher 
number of cells were recovered after several days in desiccation exposure for 
both strains. It is possible that EPS shielded surviving cells and these survivors 
replicated, as the temperature of incubation during the desiccation assay (30° 
C) supports growth in most members of the Bcc. EPS could lock in moisture 
and protect cells from drying out, leaving them potentially still metabolically 
active during desiccation. Interestingly, after two days of desiccation, both 
mannitol- and fructose-derived EPS from the clinical isolate C1576 survived 
significantly better than ATCC 17616 with both types of EPS (P< 0.001 ***, *, 
respectively).  
 
7.3.3 B. multivorans ATCC 17616 EPS, but not C1576 EPS, scavenges ROS  
The xanthine/xanthine oxidase and peroxidase cell free system was used 
for the generation of ROS. Chemiluminescence (CL) detection with isoluminol 
was utilised to measure hydroxyl radical generation. CL was measured in a 
fluorescent plate reader, and EPS (added to reactions to intercept the hydroxyl 
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radical reaction with isoluminol) or SOD (catalyses superoxides to hydrogen 
peroxide and oxygen rather than hydroxyl radicals).  The reaction scheme is 
summarised in Figure 7.3.  
 
 
Figure 7.3. Chemical generation of ROS and hydroxyl radical generation with detection by 
isoluminol. Xanthine and xanthine oxidase react with molecular oxygen to give reactive oxygen 
species (ROS). The peroxidase was added (green box, horse radish peroxidase) to generate 
hydroxyl radicals; some of the ROS transitions to hydrogen peroxide. The enzyme SOD (red box) 
favours the ROS shift to generation of hydrogen peroxide and oxygen rather than hydroxyl radicals. 
Isoluminol detects the hydroxyl radicals generated in this system, and if EPS is added (red box), this 
detection is intercepted. Once the EPS and hydroxyl radicals have interacted, the polysaccharide is 
modified further (dashed black box, not assessed in this assay were what modification were 
incurred by the EPS). The chemiluminescence signal was collected using a fluorescent plate reader. 
Iron, copper, and other transition metals (not included in the assay for the present study – dashed 
black box) can scavenge ROS and prevent reactive oxygen from interacting with the peroxidant and 
becoming hydroxyl radicals.  
 
In the presence of molecular oxygen, xanthine/xanthine oxidase converts 
to oxygen radicals, which then are converted in the presence of a peroxidase to 
hydroxyl radicals, which can be scavenged by polysaccharides. Isoluminol 
detects hydroxyl radicals and generates CL, indicative of the presence of ROS 
(specifically hydroxyl radicals). Superoxide dismutases (SOD) catalyse the 
dismutation of superoxides into oxygen and hydrogen peroxide. This same in 
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vitro ROS system was previously reported in a study that showed mannitol-
derived EPS from B. cenocepacia quenched ROS production (33).  
This study assessed the ability of EPS from B. multivorans grown on 
mannitol and fructose, to quench ROS production in the xanthine/xanthine 
oxidase system. CL generation allowed for the quantification of the EPS 
intercepting the isoluminol CL reaction with hydroxyl radicals. This percentage 
interception of CL ROS detection was calculated with the following equation: % 
interception of CL response by EPS or SOD = ((normal activity – SOD/EPS CL 
response)/normal activity)*100, where „normal activity‟ was the no-EPS control, 
and intercepted CL response was by either the SOD or B. multivorans EPS 
intercepting the hydroxyl radicals from detection by isoluminol. Figure 7.4 shows 
the xanthine/xanthine oxidase CL reaction for three different conditions. Each 
graph shows the superoxide dismutase (SOD), which inhibits hydroxyl radical 
production, and the no-EPS control where ROS are generated and peroxidated 
to hydroxyl radicals and fully detected by isoluminol. C1576 fructose EPS 
(Figure 7.4(a)) and mannitol EPS (Figure 7.4(b)) intercepted or scavenged 
nearly 100 % of the hydroxyl radicals, judged by the CL signal response near 0. 
The EPS concentration used for reaction inhibition was 1 mg/ml. The same 
trend was observed for C1576 EPS at 0.5 mg/ml EPS concentration (data not 
shown). 
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Figure 7.4. In vitro production of ROS and EPS. Graph shows percentage inhibition of CL 
response. C1576 EPS intercepted the CL response from isoluminol detection of ROS by scavenging 
hydroxyl radicals. Fructose- and mannitol-derived EPS was used at 1 mg/ml EPS, reaction 
conditions (a-b). SOD used as control for prevention of hydroxyl radical generation. N=4 wells per 
reactions condition. 
Figure 7.5 depicts the same controls as used in Figure 7.4, with the 
negative control SOD and no-EPS control intercepting (or not) the % CL 
response. Figure 7.5 shows % CL response in the presence of ATCC 17616 
fructose- and mannitol-derived EPS (Figure 7.5 (a-b)). The same trend was 
observed for 0.5 mg/ml EPS (data not shown).  
Although there were no significant differences between the ability of 
mannitol-or fructose-derived EPS to scavenge ROS, there is observed strain 
variation in ability to scavenge ROS. C1576 EPS did not scavenge ROS but 
ATCC 17616 EPS did. ATCC 17616 fructose-derived EPS scavenged hydroxyl 
radicals and thus quenched the CL response relative to C1576 fructose-derived 
EPS in this system (P = 0.031). ATCC 17616 mannitol-derived EPS scavenged 
ROS significantly better in this system compared to C1576 mannitol EPS (P = 
0.0073). No carbon-source specific differences in biological activity were 
observed in this assay. 
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Figure 7.5. In vitro production of ROS and EPS. Graph shows percentage inhibition of CL 
response. 1 mg fructose- and mannitol-derived ATCC 17616 EPS intercepted the CL detection of 
hydroxyl radical production (a, b). SOD was used as control for reaction. N=4 wells per reactions 
condition.  
 
7.3.4 Summary of strain and carbon source variation in biological activity 
The carbon source and strain influence the biological activity of B. 
multivorans EPS, depending on the type of assay used to assess biological 
activity. Subtle alterations in EPS composition, due to growth on different 
carbon sources could change polysaccharide structure and environmental 
interactions. No studies to date have compared the biological of activity of Bcc 
EPS from any other carbon source besides mannitol. Table 7.1 summarises the 
protective effect of EPS in stress conditions, namely iron toxicity, desiccation, 
and exposure to ROS. 
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Table 7.1. Biological activity of EPS summarised for B. multivorans strains ATCC 1616 and 
C1576. In the table, ‘Yes’ or ‘No’ indicates EPS does or does not play a role in protection from iron 
stress, desiccation, or EPS does/does not scavenge ROS in the xanthine oxidase assay. 
B. multivorans EPS Iron ion stress Desiccation  Scavenges ROS 
ATCC 17616 Fructose No Yes Yes 
 
ATCC 17616 Mannitol No No Yes 
 
C1576 Fructose  No No No 
 
C1576 Mannitol Yes Yes No 
 
Overall, different strains produce EPSs with differing biological activities. 
This study compared the biological activity of EPS isolate from two different B. 
multivorans isolates from drastically different origins (soil, CF lung). Not only 
was there strain –to-strain differences in EPS iron toxicity, desiccation 
protection and ROS scavenging, but also variation in protection dependent on 
carbon-source from which the EPS was derived. Survival of desiccation was 
dependent on the carbon source used to induce EPS biosynthesis for both 
strains; however, C1576 survived desiccation better with the addition of 
mannitol-derived EPS, whilst ATCC 17616 survived desiccation following the 
addition of fructose-derived EPS. Previous studies had shown that mannitol-
induced Bcc EPS scavenged ROS, thus it is interesting that C1576 mannitol-
induced EPS did not scavenge ROS whilst both ATCC 17616 mannitol-and 
fructose-derived EPS did. 
 
7.4 Discussion 
EPS produced by members of the Bcc is a putative virulence factor and 
may play roles in host adhesion, signalling, and could act as a physical barrier 
from toxic substances or stresses (69). It is important to understand the roles 
EPS may play in the CF host, because studies have shown mucoidy could be 
indicative of chronic infection; thus EPS could influence bacterial stress 
resistance and infection outcome in CF patients (233).  
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Treatment of the CF lung with inhaled mannitol could potentially trigger 
EPS production in vivo. Although fructose induces EPS biosynthesis and is 
elevated in the blood and urine of diabetics, there is no existing evidence (to the 
authors‟ knowledge) that fructose is elevated in air way tissues (as glucose is 
reported to be (29)). However, fructose induced EPS was included as a means 
to compare the impact of carbon source on EPS biological activity, in addition to 
the fact that it is one of several sugars elevated in diabetics. 
The three in vitro experiments in the present study highlight the biological 
activity of EPS produced by a B. multivorans CF isolate and environmental 
isolate. Ferreira et al. showed B. cepacia EPS was not protective to drying or 
iron ion stress, whilst EPS from B. multivorans and B. xenovorans was 
protective from these stresses (69). Bylund et al. showed B. cenocepacia 
mannitol-derived EPS, as had been shown for alginate from P. aeruginosa, 
could scavenge ROS (33,180). This study used the same assay as reported in 
Bylund et al., but used B. multivorans fructose-and mannitol-derived EPS.  
The present study first assessed the effect of EPS in protection against 
iron toxicity. Metal concentrations are elevated during pulmonary exacerbations 
and following lung transplantation (84,155). Ghio et al. reported that 
bronchoalveolar lavage (BAL) fluid from CF patients contains elevated levels of 
iron, ferritin, transferrin, heme and haemoglobin, thus indicating iron 
haemostasis is disrupted in the CF lung (74). Iron concentrations used in the 
present study were higher than levels reported during exacerbation or after lung 
transplant in CF patients, but if EPS were protective against high concentrations 
of iron toxicity, it is likely that EPS would protect B. multivorans from lower 
concentrations of iron comparable to elevated levels in the CF lung. Evidence 
for elevated iron and iron containing proteins is linked to hemosiderin-laden 
macrophages, reported to be elevated in patients following lung transplantation, 
and alveolar macrophages are highly practiced at iron uptake (133). It is 
assumed that macrophages containing iron intracellularly transport metals that 
can accumulate in the lower respiratory tract following lung transplant or 
exacerbation. Overall, regardless of the presence of respiratory disease there is 
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a cycle, and burden, of iron in the lower respiratory tract (200). Although normal 
levels of iron are required for bacterial survival, a surplus could lead to toxicity. 
B. multivorans environmental survival and resistance to disinfectants 
could be a reservoir for infection, especially if EPS were protective against 
elements found in disinfectants. Research has been done into the inclusion of 
various metals and nanoparticles in hospital surfaces, fabrics, cleaning 
solutions, and antimicrobial treatments to prevent bacterial infection in plants 
(73,129,146,169).  Copper surfaces, for instance, have been shown to kill 
Staphyloccocus haemolyticus via membrane damage (169); if B. multivorans 
were protected by EPS against iron, perhaps if exposed to a copper 
antimicrobial surface it may also survive.  More research is required to assess 
the protective effect of EPS against other metal stresses. ATCC 17616 the 
environmental isolate was not protected by killing due to iron toxicity, regardless 
of whether the EPS was mannitol- or fructose-derived. However, the CF isolate 
was able to survive iron toxicity better than the no-EPS control when mannitol-
derived EPS was added prior to iron toxicity exposure. The C1576 isolate is the 
index case of a transmissible outbreak of B. multivorans in a paediatric CF 
clinical outbreak (222).  
It may be interesting to note that in the transcriptomic analysis of B. 
multivorans sugar response (discussed in Chapter 4), B. multivorans C1576 
grown in mucoid-inducing YEM relative to non-mucoid growth conditions 
showed 16 significantly upregulated gene related to iron and other metal 
containing proteins involved in post-translational modification, and iron-uptake 
regulators involved in inorganic ion transport. This could indicate that mannitol 
present in the lung induces iron uptake but could at the same time offer 
protection from metal toxicity. In the present study, mannitol-derived EPS 
protected C1576 from iron stress significantly better than YEF-derived EPS and 
significantly better than mannose-grown (no-EPS) C1576 alone.  
In addition to stress survival from environmental metal toxicity, the ability 
to survive periods of desiccation would be advantageous to an environmental 
and opportunistic pathogen such as B. multivorans. There is the possibility that 
patients could acquire B. multivorans through the same environmental reservoir. 
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For example, C1576 enhanced environmental survival due to resistance to 
metal toxicity or desiccation survival could have contributed to the acquisition 
from the clinical environment. Several reports have been published that identify 
multiple patients in a specific area that acquired the same strain of B. 
multivorans at the same time (22,125,135,176,222). If bacteria could survive 
outside the host for several days, the hospital environment could be a mode of 
transmission, if surfaces and equipment were not thoroughly disinfected or 
sterilised. Overall however, the mode of transmission for B. multivorans is still 
unknown, and environmental and clinical isolates are often indistinguishable, 
thus it is largely assumed source of acquisition is from the natural environment 
(14). EPS protection from desiccation could contribute to environmental survival 
in the hospital or a manufacturing environment. The process of desiccation 
occurs in three phases (as outlined by Vriezen et al. (220)). The first phase of 
desiccation (i) involves drying of cells and slowing of the metabolic processes. 
Secondly, (ii) the storage phase marked by decline of cell viability, and thirdly, 
(iii) the rehydration phase or the return to viability. On scale with the time line 
used for the desiccation assay used in the present study, phase one (i) drying of 
cells would occur during Day 1 where cells were harvested, and dried, then 
incubated for multiple days. Phase two (ii) the storage phase, would be 
comparable to the Day 2 and 3 time points of the present study. Ferreira et al. 
suggested that due to the hygroscopic properties of cepacian, it retains 
moisture, thus retarding the loss of cell viability during the second phase (ii). 
This would account for the results of the present study, and correlates with 
findings from Ferreira et al. where mannitol-derived EPS protected Bcc strains 
from desiccation. Interestingly, their study showed no viable counts survived in 
any of the three species included in their study when no EPS added following 
three days of desiccation. However, the present study recovered viable cells 
after three days of desiccation (though only a small percentage, even in the 
presence of EPS, relative to input). The rate of desiccation is greatly dependent 
on the presence of salts, moisture and humidity, temperature, and other factors 
from the surrounding environment (220).   
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The transmissibility and environmental reservoirs of B. multivorans may 
be influenced by the ability to survive desiccation. Drabick et al. demonstrated 
strain-to-strain variation between survival on different types of surfaces; the 
greatest survival on PVC plastic being members of the Bcc (64). It has been 
suggested that subtle differences in environmental survival may be difficult to 
detect in vitro assays because usually only one stress at a time is applied (154), 
however survival to desiccation is an obvious attribute which would favour 
environmental persistence and potential reservoir for infection for B. 
multivorans, and based on results from the present study, B. multivorans EPS 
derived from growth on fructose significantly protected from desiccation the 
environmental isolate ATCC 17616, but not the CF isolate C1576. Mannitol-
derived EPS was not protective for ATCC 17616 but protected C1576 from 
desiccation.  
Differences between the results of iron and desiccation assays in the 
present study and Ferreira et al., both of which used B. multivorans ATCC 
17616, could be due to a number of factors. Firstly, the fact that different growth 
medias were used prior to EPS extractions; the present study and previous 
chapters of this thesis have described the impact of different growth media on 
EPS biological activity, transcriptomic, and phenotypic response of B. 
multivorans. In the Rhizobia, Gram-negative nitrogen fixing bacteria produce 
EPS in culture that is influenced by carbon source. Different carbon sources 
resulted in different Rhizobia EPS composition (92). Additionally, the present 
study always incubated the B. multivorans with the strain specific EPS for the 
iron and desiccation assays (e.g. ATCC 17616-derived EPS was added to 
ATCC 17616 and C1576-derived EPS was incubated with C1576). The Ferreira 
et al. study incubated B. multivorans ATCC 17616 with cepacian isolated from 
clinical isolate B. cepacia IST408. Therefore Ferreira et al. could not analyse 
strain-dependent EPS effects on stress survival, or the potential for a mixture of 
polysaccharides, as reportedly produced by C1576 (88), to be included.  
In addition to protection from metal toxicity and desiccation, additional 
environmental stressors such as oxidative stress and reactive oxygen species 
could be modulated by the biological activity of EPS. Bylund et al. studied B. 
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cenocepacia mannitol-derived EPS and found the EPS inhibited neutrophil 
chemotaxis and scavenged ROS in the xanthine/xanthine oxidase system (33). 
The present study utilised the same in vitro system for generating ROS in order 
to determine the ability of fructose- or mannitol-derived B. multivorans EPS to 
neutralise or scavenge ROS. The ability to do so could enable pathogens to 
evade the host immune response to infection, such as avoiding phagocytosis 
and antimicrobial killing. During chronic inflammation in the CF lung, B. 
multivorans would be exposed to toxic ROS compounds. Elevated iron in the 
respiratory tissues and other elevated metal concentrations could potentially 
support the increased generation of ROS, leading to not only an environment 
with elevated metal concentrations, but also oxidative stressors. These two 
components have been suggested as a mechanism for inflammatory response 
in respiratory diseases such as CF and chronic lung disease (155). The primary 
immune response in the CF lung is an influx of neutrophils. These cells are 
potent effector cells of the innate immune response that inundate the CF lung. 
The neutrophil influx in the lung, with end products of H2O2 and ROS, could 
favour the mucoid phenotype if EPS is protective against these components in 
vivo. Mannitol itself is described as a classical example of a hydroxyl radical 
scavenger (180). Mannitol was used at 100 mM to inhibit the CL response (96 
% inhibition) in a cell free system of generating free radicals (180). Inhibition of 
the CL response with mannitol was dose dependent, and at 0.1 mM did not 
inhibit the free radical generation/CL response at all. Interestingly, as shown in 
the schematic depicting the xanthine/xanthine oxidase reaction, transition 
metals copper and iron both can prevent superoxides from being peroxidated 
into hydroxyl radicals (180), suggesting that if EPS contained any such trace 
metals, EPS scavenging could be influenced by the metals contained in the 
EPS extracts rather than the polysaccharide scavenging hydroxyl radicals itself. 
In the present study EPS was checked for protein and DNA content, but not 
metal content, although Bcc-produced cepacian has not been reported, to the 
authors‟ knowledge, to contain metals.  
The inhaled administration of 800 mg of mannitol for rehydration od the CF 
lung could have several affects in protecting bacteria in the CF lung .This 
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concentration of mannitol could not only act as a scavenger of ROS in its own 
right, but also, by inducing EPS production in B. multivorans and other 
members of the Bcc, mannitol could trigger other mechanisms for ROS 
scavenging. Based on the xanthine oxidase system, the present study showed 
B. multivorans EPS could scavenge ROS when grown on mannitol and 
fructose, but this observation was strain-dependent. Based on previous reports 
that mannitol-derived Bcc EPS could scavenge ROS, it is interesting that clinical 
isolate C1576 mannitol- and fructose-derived EPS did not scavenge ROS, 
whilst both EPSs scavenged ROS from ATCC 17616. In its natural 
environment, rhizosphere isolate ATCC 17616 could require resistance to metal 
toxicity, desiccation and oxidative stress to enable continued close association 
with the plant host. If, as mentioned previously, either of the B. multivorans 
metals had EPS that contained metal, the presence of the metal in the 
polysaccharide could scavenge ROS more efficiently than an EPS that did not, 
thus a potential explanation of strain-variation.  
Fructose- and mannitol-induced EPS is of interest to the present study not 
only due to the sugars‟ ability to induce EPS biosynthesis in B. multivorans, but 
also due to B. multivorans transcriptomic response to sugars. In Chapter 4 of 
this dissertation, differences in the gene expression response following growth 
on fructose and mannitol were compared in the environmental isolate ATCC 
17616. Those findings suggested that in fructose, relative to mannitol (YEF vs. 
YEM), ATCC 17616 upregulated 194 genes including genes related to motility 
and chemotaxis, EPS biosynthesis, and several different phospholipases and 
transcriptional regulators. Among the 86 significantly down-regulated genes in 
fructose relative to mannitol were genes related to amino acid metabolism, 
succinate dehydrogenases, β-lactamases, ferric iron uptake mechanisms, 
hopanoid biosynthesis, pilli, type III secretion. The present study of EPS 
biological activity and these differences in transcriptomic response to the 
different sugars indicates that although both sugars induce a similar mucoid 
phenotype, phenotypic behaviour, gene expression, and biological activity of the 
EPS is dependent on the carbon source.   
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Evidence for EPS and stress resistance from this study indicate growth on 
mannitol and fructose could influence B. multivorans survival in the CF lung and 
the environment by altering the EPS biological activity. These studies indicate 
that the biological activity of EPS can vary depending on the culture conditions 
used to induce its production. It is not known what factors induce EPS 
production in vivo or in the natural environment, but the present study highlights 
EPS biological function in stress survival-related assays can be strain- and 
carbon source-dependent.
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7.5 Conclusions  
1. B. multivorans ATCC 17616 was not protected from iron stress by fructose- 
or mannitol-derived EPS. B. multivorans C1576 was protected from iron toxicity 
exposure by mannitol-derived EPS. This indicates strain-variation and carbon 
source variation in EPS protection.  
2. EPS derived from fructose was protective of ATCC 17616 during desiccation; 
however mannitol-derived EPS protected C1576 from desiccation. This 
indicates protection from desiccation is strain dependent.  
3. EPS derived from mannitol and fructose grown ATCC 17616 scavenged 
ROS, whilst neither C1576 mannitol- nor fructose- derived EPS scavenged 
ROS, indicating strain variation in ROS scavenging, but not carbon source 
derived variation.    
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Chapter 8: Insulin binding by members of the Burkholderia cepacia 
complex 
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8.1 Introduction 
Insulin is an anabolic signalling molecule with the primary function to 
regulate glucose uptake from the circulatory system in mammals. Insulin 
deficiency, glucose intolerance, or impaired sensitivity to insulin can lead to the 
development of diabetes, a serious cause of decline in health of CF patients 
(28). Cystic Fibrosis Related Diabetes (CFRD) (137) is now the most common 
comorbidity in patients with CF, occurring in 15-30 % of CF patients over 30 
years of age (7). CFRD is designated as a separate entity representing both 
type 1 and type 2 diabetes traits (232). Diabetes results in increased glucose, 
mannose and fructose levels in the urine and blood stream (98,153) and 
glucose elevated in airway tissues (29). It is well established that patients with 
diabetes mellitus alone are immune-compromised and therefore more prone to 
infection (4,7). The response of B. multivorans to certain sugars of clinical 
relevance was addressed in previous chapters of this dissertation. The focus of 
the present study was to assess the relevance of the onset of diabetes (which 
further immune compromises patients) and potential impacts of interactions 
between members of the Bcc and insulin. It is known that some members of 
Burkholderia bind insulin. B. pseudomallei possesses specific high affinity 
binding for human insulin (227) and this affinity appears to be influenced by 
insulin levels (96). B. cepacia was reported as able to bind insulin, potentially 
due to acid phosphatase activity (96).  A consistent pattern of patients 
presenting melioidosis (of which the causative agent is B. pseudomallei) were 
diabetics (40,156,227). Ultimately, although known to bind insulin, the impact of 
that binding on the progression of infection in B. pseudomallei and members of 
the Bcc is unknown. Observations of insulin binding by B. pseudomallei and 
members of the Bcc prompted further study of additional members of the Bcc 
(96,141,227).  
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8.2 Aims 
1. Determine the ability of members of the Bcc to bind insulin.  
2. If Bcc members do bind insulin, is insulin binding consistent across the whole 
population, and can insulin binding be enriched for? 
3. Assess whether Bcc insulin binding correlates with a ceftazidime- or 
ciprofloxacin-derived persister cell phenotype.  
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8.3 Results 
8.3.1 Screening for insulin binding in the Bcc  
Firstly, the ability of members of the Bcc to bind insulin was assessed 
based on the methods described by Kanai et al. and Nisr et al. (96,141). Both 
methods involved the use of FITC-labelled insulin (197).The Kanai et al. 
protocol reported an insulin binding method that had used an ATCC strain of 
Pseudomonas aeruginosa as a negative control which allowed a basis of 
comparison to insulin binding strains. Unfortunately, the B. (Pseudomonas) 
cepacia insulin binding strains used in the Kanai et al. study were not 
obtainable, although efforts were made to obtain the original strains from the 
authors or strain collections in order to have a positive control. The Kanai et al. 
method fixed agar-grown bacterial cells, „stained‟ them with insulin, incubated 
for 45 minutes at 37° C, and visualised insulin binding by fluorescent 
microscopy.  
During the course of the present study, Nisr et al. published a method 
that provided an improved, more descriptive and quantitative protocol for insulin 
binding. The method included a more detailed microscopy method and 
quantitation of insulin binding using fluorescent plate reader technology. Nisr et 
al. reported just three of the 45 microorganisms screened in their study bound 
insulin: CF isolates of B. multivorans, B. cenocepacia, and Aeromonas 
salmonicida (a fish pathogen). The method involved using MOPS buffer during 
insulin exposure, followed by centrifugation and washing steps with PBS. Insulin 
exposure was at room temperature, and cells were not fixed to slides with 
acetone prior to insulin exposure as in the Kanai et al. protocol. Rather than 
using acetone for fixing insulin-exposed cells, the Nisr et al. method used air 
drying and brief heat fixation. The Nisr et al. method was adopted for insulin 
binding plate reader assays and adapted for use in flow cytometry and persister 
cell assays. Using fluorescent microscopy (Figure 8.1), the FITC-insulin levels 
indicative of insulin-bound bacteria were significantly higher compared to levels 
of auto fluorescence or background fluorescence for positive insulin binding 
strains. Representative images for B. cenocepacia and B. multivorans are 
depicted in Figure 8.1 (cells bound to insulin were visualised under GFP 
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fluorescence). Bright field images of B. cenocepacia and B. multivorans and 
GFP show binding to FITC- labelled insulin is localised to bacterial cells (Figure 
8.1). Crucially, images show that not all cells in the field of view have bound to 
insulin. This observation was consistent and reproducible; a minority of cells out 
of the whole population bind insulin. Variation in the intensity of staining of 
individual cells may be attributable to (i) the method of fixation, (ii) different 
planes of focus, (iii) different levels of insulin binding saturation, or (iv), the 
possibility that some of the labelled insulin may have entered cells.
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Figure 8.1. Insulin binding 
visualised by fluorescent 
microscopy. Insulin binding was 
visualised at 100 x oil magnification 
on a Zeiss AXIOSTAR epifluorescence 
upright microscope. (a-b) B. 
multivorans C1576 FITC (a) and 
brightfield (b); (c-d) B. pyrrocinia 
ATCC 15958 FITC (c) and phase 
contrast (d); (e-f) B. ambifaria AMMD 
FITC  (e) and phase contrast (f); (g-h) 
B. cenocepacia J2315 FITC (g) and 
bright field (h); (i-j) B. cenocepacia 
K56-2 FITC (i) and bright field (j); (k-
l) P. aeruginosa ATCC 27853  FITC (k) 
and bright field (l). P. aeruginosa ATCC 27853 was a negative control (fluorescence in the FITC channel not above auto fluorescence). Cells were exposed to 1 µg/ml 
insulin.
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8.3.2 Screening for insulin binding quantitatively 
Initially, a fluorescent plate-reader assay was developed based on the 
Kanai et al. protocol; however, results showed low levels of insulin binding in a 
number of organisms screened (data not shown) contrary to previously obtained 
microscopy results, suggesting the Kanai et al. protocol was not optimal for 
quantitative insulin binding studies.  A fluorescent plate reader assay based on 
the Nisr et al. protocol was adopted. The 96-well plate assay allowed for 
quantitation of FITC-insulin binding based on fluorescence of numerous 
samples at once. Time trials to assess optimal incubation time for insulin 
exposure using the plate reader indicated no significant difference between 5, 
10, and 15 minute incubations for either B. multivorans ATCC 17616, C1576, or 
B. cenocepacia K56-2 (data not shown). Nisr et al. noted positive insulin binding 
in B. multivorans and B. cenocepacia after 5 minutes of incubation with insulin.  
After exposure to insulin, all strains had significantly enhanced fluorescence 
relative to the negative P. aeruginosa control (Figure 8.2). There were no 
significant differences between the insulin-binding strains.    
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Figure 8.2. Quantitation of insulin binding after insulin exposure. Graph shows B. multivorans 
C1576, B. vietnamiensis LMG 16232, B. cepacia ATCC 15958, B. cenocepacia K56-2, B. ambifaria 
AMMD, B. thailandensis E264, following exposure to 1 µg/ml FITC-insulin. Asterisks represent 
significance relative to negative insulin binding strain P. aeruginosa ATCC 27853. ** P < 0.005, *** P 
< 0.0001. Statistical significance was determined using a 1-way ANOVA and post-tests. Bars 
represent the mean from three individual wells.  
 
In this study, a panel of bacterial strains were assessed for insulin 
binding. Table 8.1 lists the bacterial strains screened for insulin binding, 
including four isolates of P. aeruginosa, one B. thailandensis strain, and 16 Bcc 
strains. Table 8.1 also indicates whether strains were assessed using the Kanai 
et al. or Nisr et al. insulin binding methods, or both, and whether the strain was 
positive (+), ambiguous (?), or negative (-) for insulin binding ability. These 
observations were made using both fluorescent microscopy and plate reader 
quantitative assays. The majority of ambiguous (?) binding strains were positive 
by microscopy but negative by the plate reader assay. Although the plate reader 
was quantitative, these strains which differed between the two methods were 
marked as ambiguous should be reassessed with flow cytometry. None of the 
four P. aeruginosa isolates bound insulin, and 10 of the 16 Burkholderia strains 
assessed bound insulin. The strains listed in bold were assessed for insulin 
binding using the more recently developed Nisr et al. insulin binding protocol. 
Strains not in bold were only assessed with the Kanai et al. method and this 
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should be taken into account – if time had permitted these strains would have 
been included in quantitative insulin binding protocols. Although background 
fluorescence was higher in the Kanai et al. microscope slides, individually bright 
insulin bound cells were still clearly visible. B. multivorans C1576 and ATCC 
17616, B. cenocepacia K56-2, B. ambifaria AMMD, and the P. aeruginosa 
negative control from Kanai et al. were studied using both methods. Although 
background fluorescence was higher with the Kanai et al. method and cells 
could also be assessed on the microscope, individual bright cells amidst the 
general population of insulin-binding strains were still visible. Given more time, 
these strains classed as ambiguous would be re-assessed for insulin binding 
using plate reader assays. Strains that were very clearly not insulin binding (-) 
or very clearly insulin-binding (+) were exclusively assigned these phenotypes.  
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Table 8.1. Insulin binding in a panel of bacterial strains. Insulin binding was assessed in a panel 
of 20 bacterial strains. ‘+’ indicates positive insulin binding phenotype; ‘–‘indicates lack of insulin 
binding, ‘?’ indicates ambiguous insulin binding due to results between microscopy and plate 
reader. Bold script indicates Nisr et al. protocol used rather than Kanai et al. method. *Asterisks 
denote strain was assessed with both insulin binding protocols. ** Asterisks indicate this sample 
was negative by plate reader but positive via microscopy.  
Species Strain ID Insulin binding 
B. ambifaria AMMD + 
B. anthina W92 - 
B. cenocepacia J2315 + 
B. cenocepacia MC0-3 + 
B. cenocepacia** ATCC 17765 ? 
B. cenocepacia*  K56-2 + 
B. cepacia** ATCC 17759 ? 
B. cepacia ATCC 25416 - 
B. dolosa** E12 ? 
B. multivorans* C1576 +  
B. multivorans* ATCC 17616 + 
B. pyrrocinia ATCC 15958 + 
B. stabilis  C7322 + 
B. stabilis  LMG 14294 - 
B. thailandensis* E264 + 
B. vietnamiensis PC 259 + 
B. vietnamiensis  LMG 16232 + 
P. aeruginosa PA01 - 
P. aeruginosa** H129 ? 
P. aeruginosa C3425 - 
P. aeruginosa*  ATCC 27853 - 
 
8.3.3 Insulin binding quantified by flow cytometry  
Leading on from confirmed observations of insulin binding in the Bcc, 
further assessment of the insulin binding was carried out using flow cytometry 
(FCM). A small population amongst the general population of B. cenocepacia 
J2315 cells bind insulin (Figure 8.1(g)).  J2315 insulin-bound cells were clearly 
distinguishable by fluorescent microscopy. FCM and Fluorescence Activated 
Cell Sorting (FACS) were used to quantify and isolate J2315 insulin-bound 
populations from the total population. FACS-sorted J2315 cells were confirmed 
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as FITC-insulin-bound by microscopy, indicating the sorting process 
successfully isolated FITC insulin-bound cells (Figure 8.3). 
 
 
Figure 8.3. FACS sorted B. cenocepacia J21315 after insulin exposure. Confirmation by 100x oil 
immersion fluorescence microscopy of (a) FITC-bound insulin B. cenocepacia J2315 cells and (b) 
phase contrast image after insulin-bound cells were isolated by FACS.  
 
Following the successful isolation of insulin-bound B. cenocepacia J2315 
by FACS (Figure 8.3), the same sorted insulin-bound cells were re-cultured for 
48 hours using either selective agar or selective broth (as described in Chapter 
2 Methods section 2.24). B. cenocepacia J2315 is a slow growing strain. Due to 
the potential stress on cells during the sorting process, J2315 was not readily 
culturable, hence the 48 hour growth period between sorting rounds. J2315 
cells were harvested and re-exposed to insulin, followed by additional rounds of 
FACS analysis to quantify insulin binding to determine if the insulin binding 
subpopulation could be enriched. In total, three rounds of sorting were carried 
out for this assay. Between re-growth and subsequent FACS analyses, potential 
contamination was prevented by aseptically cleaning the FACS system. 
Contamination was monitored for every 24 hours by sampling and plating each 
J2315 culture onto LB agar.  
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Figure 8.4. FACS analysis results following isolation of FITC-insulin bound J2315. FACS analysis 
of FITC-bound-insulin B. cenocepacia J2315, with subsequent culturing and FACS analysis three 
separate times (1x, 2x, 3x). J2315 negative control was not exposed to insulin and was made from a 
fresh overnight culture. N=3. (a) LB broth or (b) BCSM selective agar with selective supplements 
was used for culturing. *P<0.05, ***P<0.0001. Statistical significance was assessed by using a 1-way 
ANOVA and post-tests. Bars are representative median values from three biological replicates.  
 
Figure 8.4 depicts results of insulin bound cells re-cultured from broths (a) or 
plates (b). Controls used were J2315 not exposed to insulin (J2315 Negative 
control) from a fresh overnight broth for each sort. J2315 Insulin NEW (fresh 
overnight broth, exposed to insulin) was an insulin exposed control to compare 
back to for insulin binding enrichment. Overall, differences are apparent, but 
they are not consistent between the FACS analyses. The observation that is 
consistent is J2315 is not enriched for insulin binding after repeated isolation 
and culturing, and overall the percentage of insulin-bound cells remained very 
low, consistently less than 1 %.   
Following repeated attempts of this experiment, the conclusion still held 
that a small percentage of the total population of cells bound insulin. Despite 
apparent increases in binding after a second round of sorting Figure 8.4(b), (on 
previous page), shows significant difference in the twice-sorted plate and broth 
grown cultures, relative to the NEW J2315. In these conditions, insulin-binding 
cells were not enriched for following FACS isolation. Therefore, insulin binding 
was not a stable phenotype that could be enriched for by repeated sorting and 
 198 
 
culture, and this suggested insulin binding cells were phenotypically distinct 
from the general cell population. 
 
8.3.4 Persister cells and insulin binding 
Insulin binding potentially could encompass phenotypically distinct 
variants, reminiscent of persister cells. Persister cells are genetically identical 
but phenotypically different dormant non-dividing cells within a given population 
that can be revealed after exposure to high concentrations of antibiotics. B. 
cenocepacia and B. multivorans were used in persister cell assays in this study, 
using clinically relevant antibiotics ceftazidime and ciprofloxacin.  
 
8.3.4.1 Ceftazidime-derived persister cells and microscopy  
In this study, B. cenocepacia and B. multivorans were exposed to 100x 
MIC of ceftazidime for 24 hours, which resulted in a 99.8 % loss of culturable 
cells for J2315, ATCC 17616, and K56-2. The persister cells were then exposed 
to insulin. Ceftazidime, a member of the cephalosporin class of antibiotics, was 
chosen as it is a clinically relevant antibiotic which is widely used in persister 
assays; it can be administered in conjunction with tobramycin to treat CF 
patients with Bcc infections. Fluorescent microscopy was used to distinguish 
insulin-bound untreated and persister cells as distinct from the total population.  
Fluorescent microscopy revealed the 100x the minimum inhibitory 
concentration (MIC) ceftazidime treated B. cenocepacia and B. multivorans 
resulted in cells that were elongated, a phenotype previously reported in other 
Gram- negative bacteria (41,219).  
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Figure 8.5. Insulin exposed control or ceftazidime-derived persister cells at 100x oil immersion 
magnification. Insulin exposed control or ceftazidime-derived persister cells, 100x oil immersion 
magnification. Images are representative of 6 fields of view. (a-b) Phase contrast FITC B. 
cenocepacia J2315 (untreated), (c-d) phase contrast and FITC B. cenocepacia J2315 ceftazidime-
derived persister cells, (e-f), phase contrast and FITC B. cenocepacia K56-2 (untreated), (g-h) phase 
contrast and FITC B. cenocepacia K56-2 ceftazidime-derived persister cells, (i-j) phase contrast and 
FITC B. multivorans ATCC 17616 (untreated), (k-l) phase contrast and FITC B. multivorans ATCC 
17616 ceftazidime-derived persister cells.  
Based on the images in Figure 8.5, B. cenocepacia K56-2 persister cells 
appear enhanced for insulin binding compared to non-persister, insulin-exposed 
controls (Figure 8.5 (e-h)).  B. cenocepacia J2315 appears moderately 
enhanced for insulin binding in persister cells compared to untreated controls 
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(Figure 8.5 (a-d)). B. multivorans ceftazidime-derived persister cells are not 
enriched for insulin binding (Figure 8.5 (i-l)).  
Whilst microscopy was useful for the study of ceftazidime-derived 
persister cells, the elongated phenotype of B. cenocepacia and B. multivorans 
made insulin binding difficult to quantify. Ceftazidime was not an ideal candidate 
for FCM and FACS-based analyses. Laser detectors would not have accurately 
visualised the chains or elongated cells as individual particles (single cells). An 
antibiotic which did not induce the elongation phenotype would enable 
quantification between untreated cells and persister cells exposed to insulin. 
Consequently, the following study utilised ciprofloxacin-derived persister cells. 
8.3.4.2 Ciprofloxacin-derived persister cells and FCM 
In order to quantify insulin-bound persister cells by FCM and FACS, 
ciprofloxacin was used to reveal persister cells of B. cenocepacia. Ciprofloxacin, 
a fluoroquinolone antibiotic, did not induce the elongated cell phenotype at high 
concentrations. However, ciprofloxacin does not cause lysis of the bacterial cell, 
resulting persister cell populations were a mix of persister cells and dead cells 
(still intact but not removed during washing steps). Consequently, the red 
fluorescent dye propidium iodide (PI) was used, which is only taken up by cells 
with damaged membranes; cells with intact membranes (live or persister cells) 
would not be stained. PI is normally used as part of a live/dead stain kit in FACS 
analysis, with SYTOX Green used to partition live cells. However, due to FITC 
and SYTOX green emission having similar wavelengths, SYTOX Green was not 
included, and selection for „live‟ cells in untreated and persister cell populations 
was based on lack of PI uptake.   
Prior to beginning persister cell and FACS analysis, the ciprofloxacin MIC 
was determined for two strains of B. cenocepacia; the clinical isolate J2315 
(used in previous studies in this chapter) and the environmental isolate MC0-3. 
Previous studies within the lab suggested MC0-3 had a higher persister cell 
frequency than other B. cenocepacia isolates. The MIC was determined using 
E-test strips for each strain and 100x the MICs were found to be 25 µg/ml for 
MC0-3 and 200 µg/ml for J2315.  
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For the ciprofloxacin persister assay, 100x was used to calculate 
ciprofloxacin-persister cell frequency. J2315 formed ciprofloxacin persister cells 
at a lower frequency of 0.002 %, while MC0-3 formed persister cells at a 
frequency of 0.0106 %. MC0-3 was used for subsequent insulin studies using 
FACS due to its higher persister cell frequency as the assessment of insulin 
binding by persister cells would likely be more robust.  
FACS analysis profiling of ciprofloxacin-derived persister cells of B. 
cenocepacia MC0-3 entailed the use of two dyes for insulin-bound and 
live/dead population separation. By selection of particles based on their 
emission in the FITC/GFP and PI emission wavelengths, quantification of live 
insulin bound persister was possible (Figure 8.6). Results in Figure 8.6(a) 
indicate the majority of cells seen by FACS analysis of persister cells were 
classified as „dead‟, based on PI staining (695/40-A on x-axis). Dead cells are 
depicted by the broad peak in the right hand side of the graph in Figure 8.6 (a). 
The y-axis depicts counts (or total cells seen by FACS) versus the x-axis, PI 
(„dead‟ cells stain) emission. Only a small population of cells had little or no 
staining by PI. This is in accordance with 24 hours of antibiotic treatment at 
100x the MIC for ciprofloxacin resulting in ~ 99.9 % cell death, with the persister 
cell frequency for MC0-3 being 0.0106% of the total population.  
 202 
 
 
 
Figure 8.6. FACS analysis profiling of insulin-exposed B. cenocepacia MC0-3 ciprofloxacin-
derived persister cells. (a) B. cenocepacia MC0-3 counts (number of total particles (cells) detected 
(y-axis)) versus 695/40-A nm (x-axis) propidium iodide (PI). (b) MC0-3 cells PI vs. FITC (B530/30-
A) emissions indicate insulin-bound live/persister cells (green population) amidst dead cells (red 
population). (c) Ciprofloxacin MC0-3 persisters exposed to FITC-insulin and PI staining for cell 
viability. Bars show percentage insulin-bound cells (relative to live cells). N=3, error bars are 
standard error (SEM).  
 
Only cells with low or no red fluorescence due to lack of uptake of PI 
were selected as live. Within the group deemed live (persisters) (Figure 8.6 (b) 
on previous page) the insulin bound FITC-bright cells were quantified, as 
depicted by the green population in the bottom of Figure 8.6 (b). The bar graph 
in Figure 8.6 (c) showed a difference between live insulin binding MC0-3 
persister cells and untreated MC0-3, but this difference was not statistically 
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significant. These data did not indicate that ciprofloxacin-derived persister cells 
were enriched for insulin binding. This observation was repeated three times on 
separate days and data presented in Figure 8.6 (c) is cumulative of three 
individual biological replicates, whilst panels (a) and (b) of the same figure are 
representative data of single biological replicates.  
Difficulties with the FACS ciprofloxacin-derived persister cell/insulin 
binding assay included live cells taking up propidium iodide stain, gauged by the 
observation that some untreated/non-persister cells exposed to PI stained 
positive with the dye, indicating PI was entering healthy cells to some extent. As 
a result, time in the presence of PI prior to FCM analysis was minimised. 
Attempts made to optimise this experiment included initially staining persisters 
with PI, isolating „live‟ persister cells, and then exposing them to insulin and a 
second round of FACS. However, the low number of persister cells in a 
population and the time taken to sort sufficient persister cells, created too long 
of processing time. The data summarised in Figure 8.6 was generated using a 
streamlined process, with PI staining directly after insulin exposure and 
immediately prior to FACS analysis to avoid uptake of the stain by any weakly 
intact persister or healthy cell membranes. Stringent gating selections were 
used to ensure live and insulin-bound cells (calculated relative to the live 
population) were not skewed.  
8.4 Discussion 
Previous reports in literature demonstrated insulin binding capabilities of 
members of the Bcc and B. pseudomallei. Insulin binding was not observed in 
P. aeruginosa (96). Bcc cause respiratory disease in CF patients, of which 
CFRD is a common comorbidity. A major risk factor for B. pseudomallei 
(causative agent of melioidosis) is diabetes (227). Whether CFRD patients may 
be equally susceptible to B. pseudomallei (or Bcc) infection is unknown. 
Alternatively, Nisr et al. suggested that microorganisms such as B. cenocepacia 
and B. multivorans could contribute to the onset of CFRD by mimicking human 
insulin receptors and binding insulin (141). Spurred on by these and previous 
observations of insulin binding in the Bcc, the present study assessed insulin 
binding in a panel of 20 strains of Burkholderia (mainly representative members 
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of the Bcc), and P. aeruginosa. Using FITC-labelled insulin in conjunction with 
different methods of analysis, 10 out of 16 Burkholderia were confirmed to bind 
insulin, whilst the remaining strains were negative for insulin binding. All four P. 
aeruginosa isolates were found to be negative or ambiguous for insulin binding 
(summarised in Table 8.1 and depicted in Figures 8.1, 8.2). It is of note that in 
the present study, the B. thailandensis E264 was recorded as insulin-binding 
positive, whilst the same strain used in the Nisr et al. study was reported as 
non-insulin binding (141). This discrepancy could be accounted for by several 
factors, one of which being that the present study only assessed E264 binding 
by quantitative plate reader assay. It would have been useful to have checked 
the E264 strain by microscopy to ensure this deviation from the Nisr et al. result 
was consistent. It is also possible that the E264 isolates could be slightly 
different, depending on where the isolates were purchased or sourced, and for 
how many passages the bacteria had been grown on between going back to 
fresh plates from freezer stocks. Indeed, another possibility is that the length of 
incubation for strains used in the Nisr et al. method is not detailed. The strains 
used in the present study were all in late stationary phase, and grown in LB (5 
g/l sodium chloride). If growth conditions differed even by a few hours 
incubation, it may have affected the insulin binding assay results.  
The observation that P. aeruginosa ATCC 27853 does not bind insulin is 
in accordance with previous insulin binding studies by Kanai et al. and Nisr et 
al., which used ATCC 27853 as a negative control. The present study 
additionally included three other P. aeruginosa strains, none of which 
definitively bound insulin. Factors for binding insulin in the Bcc are still 
undetermined, but Kanai et al. suggested factors responsible for insulin binding 
in Burkholderia are genus specific, further making Burkholderia distinct from 
Pseudomonas. Kanai et al. briefly assessed acid phosphatase activity of B. 
pseudomallei and B. cepacia. They identified a glycoprotein enzyme with 
phosphatase activity. The B. pseudomallei phosphatase was found to be more 
glycosylated than that of B. cepacia. The acid phosphatase of P. aeruginosa 
had much lower overall phosphatase activity. Differences such as these may 
explain inter- species variation, though often as shown in Table 8.1, a positive 
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and negative result was within a single species. Even B. stabilis, known for 
genomic stability, showed variation in insulin binding between two isolates 
assessed in this study. Fluorescence microscopy and FACS analysis of insulin-
bound bacteria revealed insulin-binding was species- and even strain-specific. 
The present study went on to observe that insulin is bound by only a small 
number of cells within a given population. This is a novel observation, and one 
made consistently for insulin binding strains listed in Table 8.1. Interestingly, the 
Kanai et al. study found B. pseudomallei FITC-insulin exposure revealed ill-
defined cells or cells in an aggregated mass. The present study utilised both the 
Kanai et al. and Nisr et al. protocols for insulin binding and fluorescent 
microscopy, and for both methods found insulin bound cells were distinct and 
brightly fluorescent relative to background and auto fluorescence as assessed 
by fluorescent microscopy. When high densities of insulin exposed cells were 
examined, insulin bound cells were still distinguishable.  
Using B. cenocepacia J2315 as a model organism, FACS isolation and 
re-culturing of insulin bound cells did not enrich for insulin binding. This 
indicated insulin binding was not a stable phenotype within the total bacterial 
population. Insulin-binding proteins on the bacterial cell may be subject to 
phase variation (141). This study provides results that insulin binding is only 
maintained in a minority of the cell population, but there is need for further study 
to determine specific protein/hormone interactions that are required for binding 
insulin. Nisr et al. demonstrated a role for the outer A-layer of Aeromonas 
salmonicida in insulin binding. The same study used an insulin-ligand binding 
assay that identified two putative insulin-binding proteins (IBPs), one from B. 
cenocepacia and one from B. multivorans. This suggested that surface-exposed 
proteins in these two species play a role in mammalian hormone binding. This 
could correlate with different cells able to randomly express and expose 
different surface proteins (some insulin binding specific, some not) during 
growth. The phenomenon is called phase variation, a phenotypic adaption to 
diverse environments whereby bacterial fitness and survival is improved. Phase 
variants occur by genetic or epigenetic mutation. Often, phase variants revert 
back to wild-type phenotype so can be difficult to isolate and enrich. One 
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example is from B. ambifaria AMMD, where a phase variant was able to 
produce more EPS than the wild-type (215). Members of the Bcc are reported 
to utilised phase variation, and cases have been reported that support variation 
in favour of niche adaption. The phase variants produce proteins (or do not) by 
altering surface structures, or by making one or more antigenic forms of a 
protein related to virulence (204). Other proteins not immediately related to 
virulence are also varied. This could be a relevant adaption to sense and bind 
mammalian signalling hormones once within the host.  
This study also examined insulin binding by ceftazidime- and 
ciprofloxacin-derived persister cells. In order to kill, many antibiotics require 
active targets, but persister cells evade killing by staying in a non-dividing, 
dormant, or decreased metabolic state (115). Based on the observation that a 
phenotypically distinct subpopulation of cells bound insulin, fluorescent 
microscopy of ceftazidime-derived persister cells (Figure 8.1) showed potential 
enrichment of insulin binding in B. cenocepacia K56-2. Phase variation could be 
at play during the insulin binding and persister cell assay. B. multivorans ATCC 
17616 ceftazidime-derived persister cells were not enhanced for insulin binding 
compared to controls. B. cenocepacia J2315 ceftazidime-derived persister cells 
appeared to be enriched for insulin binding relative to untreated controls. Due to 
the elongated cells phenotype, ceftazidime persister cells could not be 
quantified by FACS analysis, thus the ability of B. cenocepacia MC0-3 
ciprofloxacin-derived persister cells to bind insulin was quantified by FACS. No 
enhanced insulin binding was observed in persister cells compared to untreated 
controls (Figure 8.6). It could be reasoned that observations of potential 
enriched insulin binding in B. cenocepacia or B. multivorans ceftazidime-derived 
persister cells but not in B. cenocepacia ciprofloxacin-derived persister cells is 
possibly due to differences in the persister cells themselves. Ciprofloxacin-
derived persister cells may be a different population compared to ceftazidime-
derived persister cells due to inherent difference in the mode of action of these 
antibiotics.  
The overall clinical significance of these studies is based around the 
observation that onset of diabetes or CFRD is often followed by an overall 
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clinical decline (137). There are undefined links between diabetes, pre-
disposition to bacterial infection, and insulin. If bacteria from the soil 
environment synthesise binding or receptor proteins that mimic mammalian 
hormone binding proteins, this may be a way of sensing or signalling entrance 
to the mammalian host environment, enabling bacterial cells to signal and 
respond to the transition from the natural environment to mammalian host.  
Microorganisms in a mammalian host able to bind host insulin could potentially 
modulate levels of sugars in the host bloodstream and tissues. This may be a 
beneficial strategy for a bacterium in a nutrient deplete environment, however it 
is likely there are ample nutritional sources elsewhere in the CF host. Insulin 
binding may not benefit growth in Bcc species, but host hormone and bacterial 
interactions are not fully understood and could have ramifications for the 
pathogens phenotype and gene expression in the host environment. Nisr et al. 
suggested an auto-immune response role for insulin binding receptors, leading 
to the onset of diabetes. It is still not understood why diabetes predisposes 
individuals to contracting melioidosis, but CF patients harbouring Bcc strains 
able to bind insulin could contribute to the onset of diabetes or respiratory 
decline of CFRD.  
CFRD still requires insulin treatment to improve body mass index and 
lung function, and treatment with insulin reduces sputum culture positivity of 
respiratory pathogens (144). Treatments in the clinic are intravenous insulin, 
however interest to develop inhaled insulin still continues (111). Currently 
inhaled insulin is approved in the US and EU for type I and II diabetes. Studies 
show that 1-3 mg inhaled insulin prior to meals is as effective at controlling 
glucose levels as sub-cutaneous injection of insulin. However, inhaled insulin in 
the case of CFRD is of concern due to a 1-1.5% reduction in FEV1 in users 
(111). This decline in FEV1 is reversed by halting treatment. The better 
adherence to treatment regimen than injection of inhaled insulin may outweigh 
this drawback, however if there are insulin-based influences on Bcc and other 
bacteria residing in the CF lung, surely inhaling insulin directly into the airways 
is noteworthy and warrants further investigation.    
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If Burkholderia and Bcc members were able to modulate insulin 
availability by binding host insulin, upon treatment with insulin, existing 
pathogens in the CFRD patients‟ respiratory tract might hinder improvement of 
weight and pulmonary function usually seen in CFRD patients after treatment, 
by binding the administered insulin. Our observations were inconclusive and 
strain-dependent as to whether persister cells are enriched for insulin binding. 
And even so, it is not clear if less than 1 % of the population binding insulin (as 
our studies report) could even be biologically significant.  
The type of antibiotic administered to patients could select for different 
populations of persisters that bind insulin differently. Only two antibiotics were 
assessed in the present study. However, Burkholderia persistence has long 
been documented in melioidosis, and members of the Bcc cause chronic, 
difficult to eradicate infections in CF patients. Adaption to the human host and in 
the CF lung may or may not include the use of insulin binding proteins, but 
additional research is required to define the link between CFRD, clinical decline, 
and Bcc infection.  
Potential avenues for future research include firstly identifying insulin-
binding factors in the Bcc. Currently it has been suggested that there must be a 
specific binding motif or phospholipase activity (96,227). Secondly, identify what 
benefit binding insulin would be for the pathogen in vivo (if insulin is bound, host 
blood sugar rises potentially releasing more fuel for bacteria in tissues and 
blood stream of diabetics). Thirdly, what benefits would an environmental/soil 
dwelling organism gain if able to bind insulin. Insulin-binding may represent an 
acquired adaption by some members of Burkholderia to enhance pathogenicity 
in the human host.  
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8.5 Conclusions  
1. Although insulin binding does occur in members of the Bcc it is a sub-
population of the overall cell population that is able to bind insulin.  
 
2. Insulin binding occurs in a stochastic (random) manner. Whilst the stochastic 
manner of insulin binding appears reminiscent of persister cell phenotypes, 
studies exploring the association between persister cell and insulin binding 
phenotypes were inconclusive, and could be dependent on strain-to-strain 
variation or the antibiotic used to reveal persister cells.  
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Chapter 9: Appendix
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9.1 Primer sequences 
 
Table 9.1. Primers used for insertional mutagenesis. Crude knockout primers used for insertional inactivation with EcoRI/XbaI restriction sites to create crude 
knockout strains (CR). 
Primer Sequence 
C1576 – hecB - XbaI GTAGTTCTAGATGATGAAACGACGCACATTT 
C1576 - hecB - EcoRI GTAGTGAATTCCGATGAATACGTCCGTGATG 
C1576 – hecA - XbaI GTAGTTCTAGATCGAAAAACGACACGTTCAA 
C1576 - hecA- EcoRI GTAGTGAATTCGTCGCGATATTGTTCGAGGT 
C1576 - fim- XbaI GTAGTTCTAGATTACCGACGGCTCGATATTC 
C1576 – fim - EcoRI GTAGTGAATTCCCGTGAACAGGTTGCTGAAC 
RSF1300 (71) TAACGGTTGTGGACAACAAGCCAGGG  
hecB-Fwd-Check CATCACGGACGTATTCATCG 
hecA-Fwd-Check CGGCGTTTGACCATAGTTG 
fim-Fwd-check GGTGTCGACCTACGTGCAG 
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Table 9.2. Primer sequences used for complementation of adhesin mutants. Strains fim CR, hecB CR were complemented to make strains fim CO and hecB CO. pDA17 
primers were used to confirm insertion of inserts into vector.  
Primer Sequence 
Bmul-fim-NdeI-F GTACCATATGCGCAAGTCAATCAAGTC 
Bmul-fim-XbaI-R  GTACTCTAGATTGCGAAATTTCCTTCGTGG 
Bmul-hecB-NdeI-F GTACCATATGAAACGACGCACATTTCG 
Bmul-hecB-XbaI-R GTACTCTAGAGTAGTTCCAGTTCATTGTCG 
pDA17-Fwd TTGTTGTTGGGTAGGCAGTC 
pDA17-Rev ACCGCTTCTGCGTTCTGAT 
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Table 9.3. Primers used RT-PCR and qRT-PCR transcriptome validation. Housekeeping genes (not listed) were Bcc MLST primers for genes gapA and gyrA.   
Primer Sequence 
bceB-qPCR-Fwd cgtgacgccggtcggccggttc 
bceB-qPCR-Rev ggatttggtcaagggctaca 
hecB-qPCR-Fwd tgatgaaacgacgcacattt 
hecB-qPCR-Rev ggtggctgctccaactgac 
hecA-qPCR-Fwd gcaacaatctgaccgcaac 
hecA-qPCR-REV aggctcttgacgctaccttg 
fim-qPCR-Fwd agcagccatctgttcgtc 
fim-qPCR-REV gtagcccgcatccttgtg 
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9.2 Bacterial strains and plasmids used in this study  
Table 9.4. Bacterial strains used for insulin studies. Bcc strains, Burkholderia thailandensis and P. aeruginosa isolates used in insulin binding studies.  
Species Strain ID 
B. ambifaria AMMD 
B. anthina W92 
B. cenocepacia J2315 
B. cenocepacia MC0-3 
B. cenocepacia ATCC 17765 
B. cenocepacia K56-2 
B. cepacia ATCC 17759 
B. cepacia ATCC 25416 
B. dolosa E12 
B. multivoran C1576 
B. multivorans ATCC 17616 
B. pyrrocinia ATCC 15958 
B. stabilis  C7322 
B. stabilis  LMG 14294 
B. thailandensis E246 
B. vietnamiensis PC 259 
B. vietnamiensis  LMG 16232 
P. aeruginosa PA01 
P. aeruginosa H129 
P. aeruginosa C3425 
P. aeruginosa ATCC 27853 
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Table 9.5 Summary table of Bcc isolates used in adhesin dot-blot hybridisation. Strains are listed including their source, MLST assignment where known (ST), country 
of origin, and presence/absence of genes encoding the HecA-like, HecB-like and fimbrial usher (fim) proteins. Isolates belonging to the ST-27 outbreak strain are 
highlighted in bold. ENV, environmental isolate; CF, clinical isolate (CF); Non-CF, clinical isolate (non-CF). Where no MLST sequence type (ST) is defined, that isolate does 
not match an existing ST within the Bcc MLST database. a The inclusion of B. ambifaria MC40-6 provides an indication of the stringency of the hybridisation and washing 
procedure, as the sequence of the C1576-derived hecB-specific probe displays 83% nucleotide identity to the comparable sequence in B. ambifaria MC40-6 (gene 
BamMC406_6761). 
 
Isolate ID Species Source ST Location hecA hecB fim 
BCC0384 B. multivorans CF 15 UK - - - 
BCC0710 B. multivorans CF 15 UK - - - 
BCC0553 B. multivorans CF 16 Canada - - - 
BCC0300 B. multivorans CF 16 France - - - 
BCC0065 B. multivorans Non-CF 16 USA - - - 
E2667 B. multivorans CF 18 UK - - + 
BCC1369 B. multivorans CF 25 USA + + + 
BCC1378 B. multivorans CF 25 USA - + + 
BCC1379 B. multivorans CF 25 USA - - + 
C1574 B. multivorans CF 27 UK + + + 
C1576 B. multivorans CF 27 UK + + + 
C1578 B. multivorans CF 27 UK + + + 
C1579 B. multivorans CF 27 UK + + + 
C1581 B. multivorans CF 27 UK + + + 
C1582 B. multivorans CF 27 UK + + + 
C1591 B. multivorans CF 27 UK + + + 
C1593 B. multivorans CF 27 UK + + + 
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C1606 B. multivorans CF 27 UK + + + 
C1607 B. multivorans CF 27 UK + + + 
C1608 B. multivorans CF 27 UK + + + 
C1610 B. multivorans CF 27 UK + + + 
C1636 B. multivorans CF 27 UK + + + 
C1670 B. multivorans CF 27 UK + + + 
C1703 B. multivorans CF 27 UK + + + 
C1958 B. multivorans CF 27 UK + + + 
C1978 B. multivorans CF 27 UK + + + 
C2012 B. multivorans CF 27 UK + + + 
E3491 B. multivorans CF 27 UK + + + 
E3637 B. multivorans CF 27 UK + + + 
C1629 B. multivorans CF 27 UK + + + 
E2737 B. multivorans CF 27 UK + + + 
E247 B. multivorans CF 27 UK  + + + 
E68 B. multivorans CF 27 UK + + + 
E88 B. multivorans CF 27 UK + + + 
E4555 B. multivorans CF 27 UK + + + 
BCC1376 B. multivorans CF 179 USA  + + + 
BCC1368 B. multivorans CF 179 USA - - + 
BCC1370 B. multivorans CF 179 USA  - - + 
BCC0962 B. multivorans CF 180 Czech R. - - + 
BCC0915 B. multivorans CF 180 Czech R.  - - + 
BCC0904 B. multivorans Non-CF 180 Czech R.  - - + 
BCC0208 B. multivorans CF 189 Canada - - + 
E3814 B. multivorans CF 191 UK - - + 
BCC0087 B. multivorans CF 199 Canada - - - 
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BCC1149 B. multivorans CF 199 Canada - - - 
BCC1188 B. multivorans CF 199 Canada - - - 
E3902 B. multivorans CF 287 UK - - + 
E2791 B. multivorans CF  UK  + + + 
E3961  B. multivorans CF  UK + + + 
E1788 B. multivorans CF  UK - - + 
E277 B. multivorans CF  UK  - - + 
E2441 B. multivorans CF  UK - - + 
E2525 B. multivorans CF  Ireland - - - 
E2972 B. multivorans CF  UK - - + 
E3002 B. multivorans CF  UK  - - + 
E3218 B. multivorans CF  UK - - + 
E3318 B. multivorans CF  UK  - - + 
E3355 B. multivorans CF  UK - - + 
E3362 B. multivorans CF  UK  - - + 
E3481 B. multivorans CF  UK - - + 
E3571 B. multivorans CF  UK  - - + 
E3641 B. multivorans CF  UK - - + 
E3675 B. multivorans CF  UK  - - + 
E3756 B. multivorans CF  UK - - + 
E3762 B. multivorans CF  UK  - - + 
E3913 B. multivorans CF  UK - - + 
E3919 B. multivorans CF  UK  - - + 
E4030 B. multivorans CF  UK - - + 
E4039 B. multivorans CF  UK - - + 
E4048 B. multivorans CF  UK  - - + 
E4075 B. multivorans CF  UK - - + 
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E4079 B. multivorans CF  UK  - - + 
E4100 B. multivorans CF  UK - - + 
E4326 B. multivorans CF  UK  - - + 
E4331 B. multivorans CF  UK - - + 
E4569 B. multivorans CF  UK  - - + 
E4626 B. multivorans CF  UK - - + 
E4721 B. multivorans CF  UK  - - + 
E4730 B. multivorans CF  UK - - + 
E4731 B. multivorans CF  UK  - - + 
E4748  B. multivorans CF  UK - - + 
E4778 B. multivorans CF  UK  - - - 
J3336 B. multivorans CF  UK  - - + 
BCC0321 B. multivorans ENV 20 UK - - + 
ATCC 17616 B. multivorans ENV 21 USA - - - 
BCC0317 B. multivorans ENV 22 Canada - - + 
BCC0401 B. multivorans ENV 416 USA - - - 
BCC0487 B. multivorans ENV 416 USA - - - 
BCC0050 B. multivorans ENV 439 UK - - + 
AMMD B. ambifaria ENV 77 USA - - - 
MC40-6 a B. ambifaria ENV 136 USA - - - 
W92 B. anthina ENV 421 USA - - - 
K56-2 B. cenocepacia CF 30 Canada - - - 
ATCC 25416 B. cepacia ENV 10 USA - - - 
E12  B. dolosa CF  UK - - - 
C7322  B. stabilis CF  Canada - - - 
LMG20358 B. ubonensis ENV  299 Thailand - - - 
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Figure 9.1. Alignment of the putative 
secretion domain (‘sec’) of the 
predicted FHA outer membrane 
proteins of B. multivorans C1576 (FHA 
HecA-like & OMP 2). Outer membrane 
proteins from C1576 with the 
comparable secretion domain of known 
TpsA family proteins as described by 
Jacob-Dubuisson et al. (91). Conserved 
NPNL and NPNGI motifs are indicated by 
brackets above and below the alignment. 
The NPNL motif is conserved within the 
C1576 FHA HecA-like protein, whilst the 
NPNGI motif is conserved within the 
C1576 FHA OMP 2 protein. HecA, Erwinia 
chrysanthemi (AAN38708); FhaB, Bordetella pertussis Tohama I (NP_880571); HhdA, Haemophilus ducreyi (AAC43538); HpmA, Proteus mirabilis (P16466); ShlA, Serratia 
marcescens (P15320); HMW1, Haemophilus influenzae (AAS77299); EthA, Edwardsiella tarda (BAA21097); LspA1, Haemophilus ducreyi (NP_873911); LspA2, Haemophilus 
ducreyi (NP_873623). Numbers indicate the position relative to the starting methionine of the precursor protein. Alignment was generated using the AlignX tool of Vector 
NTI Advance 11.0 (Invitrogen).  
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Figure 9.2. Sequence alignment of representative TpsB family proteins. The alignment is centred on the conserved VRGY/F tetrad (bold) described by Delattre et al. 
(60). Alongside the HecB-like protein of B. multivorans C1576, the alignment includes: HecB, Erwinia chrysanthemi (AAC31980); EtpB, Escherichia coli (AAX13508); RscB, 
Yersinia enterocolitica (AAK77859); Hmw1B, Haemophilus influenzae (YP_249394); EthB, Edwardsiella tarda (BAA21096); ShlB, Serratia marcescens (P15321); FhaC, 
Bordetella pertussis Tohama I (NP_880575); HhdB, Haemophilus ducreyi (AAC43537). Numbers indicate the position relative to the starting methionine of the protein. 
Alignment was generated using the AlignX tool of Vector NTI Advance 11.0 (Invitrogen).  
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Figure 
9.3.  Dendrogram of representative TpsB family proteins, based either on full-length proteins (a), or on the conserved VRGY/F motif region depicted in Fig. 9.2 (b). 
Alignments and tree construction were performed using CLUSTAL and TREEVIEW respectively, revealing that the B. multivorans C1576 TpsB family protein is most closely 
related to the HecB protein of Erwinia chrysanthemi. LspB, Haemophilus ducreyi (NP_873622); HxuB, Haemophilus influenzae (P45356); HpmB, Proteus mirabilis (P16465). 
For details of other sequences, refer to legend of Fig. 9.2.
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Figure 9.4.  Dendrogram of the TPS domain of 
representative TpsA family proteins, as described by 
Mazar & Cotter (132) . Alignments and subsequent tree 
construction were performed using CLUSTAL and 
TREEVIEW respectively, revealing that the predicted 264 
kDa TpsA family protein of B. multivorans C1576 (“C1576 
HecA-like protein”) is most closely related to the HecA 
protein of Erwinia chrysanthemi. The predicted 68 kDa FHA 
family protein of C1576 (“C1576 FHA OMP 2”) is isolated. 
EtpA, Escherichia coli (YP_006203830); RscA, Yersinia 
enterocolitica (YP_001007402); HxuA, Haemophilus 
influenzae (NP_438433). For details of other sequences, refer 
to legend of Fig. 9.1. 
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9.3 Tables of differentially expressed genes from transcriptome profiling  
The following tables present selected genes, fold-changes, and annotated function to significantly differentially expressed genes from the 
ATCC 17616 microarray and RNA-seq data set. Overall, there are less differentially regulated genes in the RNA-seq data because of 
sample quality issues, and only two samples per growth conditions were used for statistical analysis. Microarray data was analysed with 
1-way ANOVA and RNA-seq was analysed with pairwise comparisons using Kals‟ test and Bonferroni post-test of FDR-adjusted p-
values. In all tables of significantly differentially expressed genes, the fold-change indicates that the gene is up or downregulated in the 
first growth condition listed, relative to the second growth condition. The fold changes were deemed significant if   > 1.5. 
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Table 9.6 Common differentially expressed genes from the mucoid microarray and RNA-seq YEM vs. YEO comparisons. Both B. multivorans ATCC 17616 and C1576 
data sets are combined to assess commonalities between EPS-inducing conditions, mannitol dosage, and strain differences of genes differentially regulated in all these 
conditions.  
ATCC 17616 and C1576  Fold change observed in strain/growth condition 
    ATCC 17616 C1576  
Locus ID Function YEF vs. YEO YEM vs. YEO 0.25 % YEM vs. YEO YEM vs. YEO 
Bmul_0305 Glutamate synthase (ferredoxin) 0.39 0.35 0.32 5.79 
Bmul_0306 glutamate synthase subunit beta 2.45 2.18 2.17 10.38 
Bmul_0321 toluene tolerance family protein 0.10 0.12 0.10 -2.99 
Bmul_0682 protease Do 0.01 0.01 0.01 -152.85 
Bmul_0683 hypothetical protein 0.06 0.07 0.07 -26.82 
Bmul_0768 hypothetical protein 0.04 0.14 0.01 -49.15 
Bmul_0888 hypothetical protein 0.00 0.00 0.01 -138.93 
Bmul_0891 hypothetical protein 2.02 2.58 1.67 4.54 
Bmul_0902 hypothetical protein 0.12 0.14 0.19 -8.67 
Bmul_1098 histidine ammonia-lyase 0.20 0.39 0.26 -6.73 
Bmul_1122 glutamine synthetase, type I 1.73 2.21 1.51 11.13 
Bmul_1141 hypothetical protein 0.28 0.31 0.34 -19.78 
Bmul_1213 hypothetical protein 0.04 0.05 0.04 -21.70 
Bmul_1335 hypothetical protein 0.06 0.10 0.10 -9.38 
Bmul_1391 PsiF repeat-containing protein 0.18 0.21 0.18 -5.20 
Bmul_1533 hypothetical protein 0.14 0.19 0.14 -5.69 
Bmul_1624 hypothetical protein 0.22 0.15 0.18 2.54 
Bmul_2210 hypothetical protein 0.07 0.09 0.11 -7.99 
Bmul_2361 hypothetical protein 0.10 0.25 0.08 -16.05 
Bmul_2447 hypothetical protein 0.08 0.07 0.09 -3.48 
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Bmul_2737 ferric uptake regulator family protein 2.86 2.53 2.67 4.28 
Bmul_3121 M48 family peptidase 1.54 1.50 4.04 18.44 
Bmul_3593 hypothetical protein 0.03 0.12 0.01 -18.18 
Bmul_3709 Hemolysin-type calcium-binding region 12.53 4.74 19.60 106.55 
Bmul_3942 hypothetical protein 0.02 0.07 0.01 -6.29 
Bmul_4183 alpha,alpha-trehalose-phosphate synthase (UDP-forming) 2.31 2.08 1.91 15.53 
Bmul_4258 hypothetical protein 0.24 0.33 0.27 -16.06 
Bmul_4377 hypothetical protein 4.67 4.83 4.99 7.72 
Bmul_4390 Crp/FNR family transcriptional regulator 0.41 0.54 0.33 67.61 
Bmul_4413 hypothetical protein 2.30 5.93 1.76 26.52 
Bmul_4458 SH3 type 3 domain-containing protein 0.23 0.29 0.34 -10.31 
Bmul_4459 hypothetical protein 0.05 0.06 0.08 -4.33 
Bmul_4475 hypothetical protein 0.06 0.06 0.08 -63.63 
Bmul_4675 hypothetical protein 0.28 0.39 0.13 -6.06 
Bmul_4829 hypothetical protein 0.10 0.08 0.06 -28.08 
Bmul_4896 glycoside hydrolase family 13 protein 5.06 4.05 5.18 10.38 
Bmul_5297 Crp/FNR family transcriptional regulator 0.22 0.17 0.05 -10.67 
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Table 9.7. Differentially expressed EPS-related genes from B. multivorans C1576 RNA-seq data. Genes listed are biosynthetic genes known to be involved in Bcc EPS 
biosynthesis. As expected, bce cluster genes are upregulated in C1576 YEM relative to YEO, and in YEM relative to non-mucoid YEM and YEG. However, the most significant 
comparisons are between YEM vs. YEO, as it is the most robust comparison where only the sugar, not the concentration of YE, is varied.  
C1576     Fold change observed in growth condition 
Locus ID 
Gene 
name/orthologue Function 
YEM vs. 
YEO 
YEM vs. non-mucoid 
YEM 
YEM vs. 
YEG 
Bmul_4377 BCAM1363 hypothetical protein 7.6 
 
19.1 
Bmul_4390 BCAM1348 Crp/FNR family transcriptional regulator 67.3 
  Bmul_4413 BCAM1321 putative polyphosphate kinase 26.0 
  Bmul_4605 bceT UDP-glucose pyrophosphorylase 53.0 36.7 50.1 
Bmul_4915 bceF exopolysaccharide tyrosine-protein kinase 12.3 
 
37.1 
Bmul_4916 bceE polysaccharide export protein 59.3 
  
Bmul_4918 bceC 
undecaprenyl-phosphate glucose 
phosphotransferase 21.5 
 
48.5 
Bmul_4919 bceB 
undecaprenyl-phosphate glucose 
phosphotransferase 28.8 25.2 42.4 
Bmul_4920 bceA mannose-1-phosphate guanylyltransferase 54.0 18.2 65.7 
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Table 9.8. Differentially expressed B. multivorans ATCC 17616 genes selected for putative or confirmed roles in Bcc EPS biosynthesis. Gene names, when available, 
are listed alongside locus ID.  
ATCC 17616     
Fold change observed in growth 
condition 
Locus ID 
Gene 
name/orthologue Function 
YEF vs. 
YEO 
YEM vs. 
YEO 
YEF vs. 
YEM 
Bmul_4920 bceA mannose-1-phosphate guanylyltransferase  2.44 3.0 
Bmul_4919 bceB undecaprenyl-phosphate glucose phosphotransferase   2.9 
Bmul_4918 bceC undecaprenyl-phosphate glucose phosphotransferase   4.1 
Bmul_4917 bceD protein tyrosine phosphatase 0.4  3.6 
Bmul_4916 bceE polysaccharide export protein 0.4  2.6 
Bmul_4915 bceF exopolysaccharide tyrosine-protein kinase 0.3  3.1 
Bmul_4914 bceG glycosyl transferase family protein 0.4  2.0 
Bmul_4913 bceH glycosyltransferase-like protein 0.2  4.9 
Bmul_4912 bceI hypothetical protein 0.4  2.5 
Bmul_4911 bceJ group 1 glycosyl transferase 0.3  4.5 
Bmul_4910 bceK group 1 glycosyl transferase 0.2  5.2 
Bmul_4611 bceO acyltransferase 0.5  3.6 
Bmul_4609 bceQ polysaccharide biosynthesis protein -  5.1 
Bmul_4608 bceR group 1 glycosyl transferase 0.4  2.0 
Bmul_2600 wcbR beta-ketoacyl synthase 0.6   
Bmul_2608 wzm ABC-2 type transporter 0.5   
Bmul_2610 wcbD lipopolysaccharide biosynthesis protein 0.3   
Bmul_2616 wcbA capsule polysaccharide biosynthesis protein 0.6   
Bmul_5217 BCAM0221 two component LuxR family transcriptional regulator 1.5 1.7  
Bmul_1956 BCAM1317 ABC transporter-like protein/ 
 
0.5  
Bmul_4413 BCAM1321 putative polyphosphate kinase 2.3 5.9 2.6 
Bmul_4408 BCAM1331 putative tyrosine-protein kinase 
 
1.8  
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Bmul_4404 BCAM1335 group 1 glycosyl transferase 1.7 2.0  
Bmul_4396 BCAM1342 sigma-54 dependent trancsriptional regulator 0.4 0.4  
Bmul_4390 BCAM1348 Crp/FNR family transcriptional regulator 0.4 0.5  
Bmul_4387 BCAM1351 TraR/DksA family transcriptional regulator 2.0 1.9  
Bmul_4381 BCAM1357 gluconate 2-dehydrogenase (acceptor) 2.2 
 
 
Bmul_4379 BCAM1359 sodium/hydrogen exchanger 3.4 1.9  
Bmul_4378 BCAM1362 peptidoglycan glycosyltransferase 2.2 
 
 
Bmul_4377 BCAM1363 hypothetical protein 4.7 4.8  
Bmul_4375 hpaR MarR family transcriptional regulator 1.9 2.0  
Bmul_4373 hpaG 
4-hydroxyphenylacetate degradation bifunctional isomerase/decarboxylase 
subunit HpaG2 0.3 
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Table 9.9 Outer membrane proteins differentially regulated in the B. multivorans ATCC 17616 microarray data. Genes encoding for outer membrane proteins such as 
porins are general down-regulated in the mucoid vs. YEO conditions, with the exception of most notably two commonly upregulated genes, opcP and an outer membrane 
efflux encoding protein. OM = outer membrane.  
ATCC 17616   Fold change observed in growth condition 
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_1937 porin 
 
0.2 
Bmul_2395 porin 0.5 0.4 
Bmul_2963 porin 0.4 0.4 
Bmul_3002 porin 0.5 0.5 
Bmul_3268 OM porin  0.2 
Bmul_3342 porin  8.4 
Bmul_3463 porin  0.4 
Bmul_3587 OM porin OpcP 1.6 1.6 
Bmul_3710  OM efflux protein 12.7 5.7 
Bmul_6034 porin  0.5 
Bmul_6067 porin  0.4 
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Table 9.10 Outer membrane proteins differentially regulated in the B. multivorans C1576.  OM = outer membrane. No other membrane protein-related genes were 
identified in C1576 growth condition comparisons of interest.  
C1576   
Fold-change in observed growth 
conditions 
Locus ID Function YEG vs. non-mucoid YEM 
Bmul_0157 aquaporin Z -13.1 
Bmul_0880 
OM porin-like 
protein 
-7.8 
Bmul_4327 porin -7.2 
 
 231 
 
Table 9.11 Upregulated transcriptional regulator genes in B. multivorans ATCC 17616. Listed are the most significantly upregulated transcriptional regulators from 
the mucoid YEF and YEM vs. YEO ATCC 17616 microarray data sets. Note this list is not inclusive of every differentially expressed transcriptional regulator in the ATCC 
17616 mucoid vs. YEO data sets, but the most upregulated for each condition and the regulators common to all mucoid vs. non-mucoid conditions. The Appendix CD 
contains the entire data set for each growth condition and differentially expressed transcriptional regulators are listed for. Asterisks (*) denotes regulator is common to all 
mucoid (including reduced YEM vs. YEO which is not shown) data sets. 
ATCC 17616   Fold change observed under each growth condition 
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_0160 transcriptional activator FlhD  2.1 
Bmul_0161 transcriptional activator FlhC  2.6 
Bmul_2015 two component transcriptional regulator 
 
5.7 
Bmul_2557* LysR family transcriptional regulator 1.7 1.9 
Bmul_2962 LysR family transcriptional regulator 4.3 
 
Bmul_3022 anti-sigma-28 factor, FlgM 
 
2.0 
Bmul_3052 two component LuxR family transcriptional regulator 4.1 4.5 
Bmul_3720 XRE family transcriptional regulator 5.7 
 
Bmul_3737 LuxR family transcriptional regulator 
 
2.7 
Bmul_3738 LuxR family transcriptional regulator 4.3 3.3 
Bmul_4418 LysR family transcriptional regulator 
 
4 
Bmul_4658 ArsR family transcriptional regulator 4 
 
Bmul_4689* TetR family transcriptional regulator 7.5 2.8 
Bmul_4903 sigma-54 dependent trancsriptional regulator 
 
3.2 
Bmul_5074* LysR family transcriptional regulator 5.8 5.4 
Bmul_5903 two component LuxR family transcriptional regulator 
 
3.2 
Bmul_6032 IclR family transcriptional regulator 4.1   
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Table 9.12 C1576 RNA-seq differentially regulated genes involved in signal transduction and transcriptional regulation. The genes listed in this table are the most 
significantly differentially expressed transcriptional regulators in the C1576 RNA-seq growth condition comparisons of interest.  
C1576   Fold change observed in growth condition 
Locus ID Function YEM vs. YEO YEG vs. non-mucoid YEM 
Bmul_0192 AsnC family transcriptional regulator 
 
-3.7 
Bmul_0236 transcription antitermination protein NusG 
 
-8.4 
Bmul_0414 DNA-binding transcriptional activator GcvA 
 
-14.5 
Bmul_1005 TetR family transcriptional regulator 
 
-5.9 
Bmul_1791 XRE family transcriptional regulator 
 
-4.1 
Bmul_2177 RNA polymerase sigma factor RpoE 
 
-5.8 
Bmul_2442 transcription antitermination protein NusB 5.4 
 Bmul_2962 LysR family transcriptional regulator 
 
-27.7 
Bmul_3031 putative transcriptional regulator 
 
-10.1 
Bmul_3128 LysR family transcriptional regulator 7.2 
 Bmul_3128 LysR family transcriptional regulator 
 
-10.7 
Bmul_3545 AraC family transcriptional regulator 76.7 
 Bmul_4270 AsnC family transcriptional regulator 
 
-8.3 
Bmul_4813 RNA polymerase sigma factor RpoD   -5.6 
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Table 9.13. B. multivorans ATCC 17616 differentially expressed motility genes. Genes related to the proteins responsible for flagella biosynthesis and chemotaxis 
pathways are the focus of this table. The flagella transcriptional regulators upregulated in YEM vs. YEO are listed in Table 9.10.  
ATCC 17616     Fold change observed in growth condition 
Locus ID Gene name  Function YEF vs. YEO YEM vs. YEO 
Bmul_0038 fliR flagellar biosynthesis protein FliR 
 
2.6 
Bmul_0040 fliP flagellar biosynthesis protein FliP 
 
10.1 
Bmul_0041 fliO flagellar biosynthesis protein FliO 0.6 
 
Bmul_0042 fliN flagellar motor switch protein FliN 2 4.2 
Bmul_0043 fliM flagellar motor switch protein FliM 
 
2.5 
Bmul_0044 fliL flagellar basal body-associated protein FliL 3.1 7.2 
Bmul_0150 fliD flagellar hook-associated 2 domain-containing protein 3.6 10.3 
Bmul_0151 fliC flagellin domain-containing protein 2.6 10 
Bmul_0162 motA flagellar motor protein MotA 3.3 9.3 
Bmul_0163 motB flagellar motor protein MotB 
 
2.1 
Bmul_0164 
 
response regulator receiver protein 
 
3.7 
Bmul_0166 cheW CheW protein 2.1 5.2 
Bmul_0167 
 
methyl-accepting chemotaxis sensory transducer 3.8 10 
Bmul_0168 
 
MCP methyltransferase, CheR-type 
 
8.5 
Bmul_0170 
 
chemotaxis-specific methylesterase 
 
4.2 
Bmul_0171 
 
response regulator receiver protein 
 
2.2 
Bmul_0172 cheZ chemotaxis regulator CheZ 
 
1.6 
Bmul_0173 
 
hypothetical protein 
 
1.6 
Bmul_0174 
 
hypothetical protein 3 2.9 
Bmul_0176 flhA flagellar biosynthesis protein FlhA 4.1 4.4 
Bmul_0178 flhG flagellar biosynthesis protein, FlhG 2.4 2.1 
Bmul_0179 
 
flagellar biosynthesis sigma factor 
 
7 
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Bmul_1733 cpaB Flp pilus assembly protein CpaB 2 1.7 
Bmul_1736 
 
Flp/Fap pilin component 
 
2.6 
Bmul_3012 
 
flagellar rod assembly protein/muramidase FlgJ 
 
2.4 
Bmul_3014 
 
flagellar basal body L-ring protein 
 
5.2 
Bmul_3015 flgG flagellar basal body rod protein FlgG 2.5 4 
Bmul_3017 flgE flagellar hook protein FlgE 
 
4.3 
Bmul_3018 
 
flagellar basal body rod modification protein 2.5 5.3 
Bmul_3019 flgC flagellar basal body rod protein FlgC 5.3 14.9 
Bmul_3059 fliS flagellar protein FliS 
 
1.9 
Bmul_3060 fliE flagellar hook-basal body complex subunit FliE 0.6 
 
Bmul_3062 
 
flagellar motor switch protein G 
 
2.7 
Bmul_3063 
 
flagellar assembly protein H 
 
5 
Bmul_3065 fliJ flagellar export protein FliJ 
 
7.2 
Bmul_4997 
 
methyl-accepting chemotaxis sensory transducer 
 
0.5 
Bmul_4998 
 
OmpA/MotB domain-containing protein 
 
0.3 
Bmul_4999   MotA/TolQ/ExbB proton channel   0.4 
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Table 9.14 Motility-related genes differentially expressed in the B. multivorans C1576 RNA-seq.  
C1576   
 
Fold change observed in growth 
condition 
Locus ID 
Gene 
name Function YEG vs. non-mucoid YEM 
Bmul_0162 motA flagellar motor protein MotA -11.9 
Bmul_0163 motB flagellar motor protein MotB -14.2 
Bmul_3010 flgK flagellar hook-associated protein FlgK -11.0 
Bmul_3362   
methyl-accepting chemotaxis sensory transducer with Pas/Pac 
sensor -14.6 
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Table 9.15 B. multivorans ATCC 17616 microarray gene expression data related to nitrogen metabolism.  
ATCC 17616 
 
Fold change observed in growth condition  
Locus ID Function YEF vs. YEO 
Bmul_4113 aerobic-type carbon monoxide dehydrogenase large subunit 0.5 
Bmul_4143 ABC-type nitrate/sulfonate/bicarbonate transport systems 0.6 
Bmul_4148 nitrite reductase (NAD(P)H), small subunit 2.3 
Bmul_4784 ABC-type nitrate/sulfonate/bicarbonate transport systems  0.5 
Bmul_5383 nitrate reductase, alpha subunit (NarG) 2.6 
Bmul_5384 nitrate reductase, beta subunit (NarH) 3.2 
    
Table 9.16 C1576 RNA-seq data set genes involved in nitrogen metabolism. Genes involved in anaerobic respiration and nitrogen assimilation are listed below.  
C1576   Fold change observed in growth condition 
Locus ID Function YEM vs. YEO 
Bmul_1212 cytochrome o ubiquinol oxidase subunit IV -14.6 
Bmul_4149 molybdopterin oxidoreductase 566.2 
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Table 9.17 Secretion-related genes differentially expressed in B. multivorans C1576 RNA-seq data. C1576 genes differentially expressed in growth conditions of 
interest were sorted based on putative involvement intracellular trafficking and secretion-related genes.  
C1576   Fold change observed in growth condition 
Locus ID Function YEG vs. non-mucoid YEM 
Bmul_0235 preprotein translocase subunit SecE -5.5 
Bmul_0269 preprotein translocase subunit SecY -6.4 
Bmul_0449 preprotein translocase subunit SecB -8.9 
Bmul_2665 preprotein translocase subunit SecY -23.9 
Bmul_2827 preprotein translocase subunit SecA -6.0 
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Table 9.18 Secretion-related genes differentially regulated in ATCC 17616. These genes were selected based on involvement with intracellular trafficking and 
secretion-related genes.  
ATCC 17616   Fold change observed for growth condition 
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_0352 type VI secretion system Vgr family protein 1.8 1.7 
Bmul_1728 type II secretion system protein 1.6 
 
Bmul_1729 type II secretion system protein 1.8 
 
Bmul_1730 type II secretion system protein E 1.5 
 
Bmul_1869 secretion protein HlyD family protein 0.1 0.2 
Bmul_2545 transport-associated protein 0.7 
 
Bmul_2585 protein TolR 
 
0.7 
Bmul_2587 translocation protein TolB 0.5 
 
Bmul_2930 type VI secretion protein 1.6 1.5 
Bmul_3711 type I secretion system ATPase 13.6 5.9 
Bmul_3750 type III secretion exporter 4.5 1.9 
Bmul_3903 type VI secretion protein 
 
1.8 
Bmul_3913 type VI secretion protein 4.9 
 
Bmul_4244 transport-associated protein 0.6 
 
Bmul_5730 type VI secretion system Vgr family protein 0.5 
 
Bmul_5888 secretion protein HlyD family protein   2.2 
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Table 9.19 B. multivorans ATCC 17616 microarray data shows genes related to antibiotic-resistance and multidrug efflux pumps.  
ATCC 17616   Fold change observed in growth condition 
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_0051 RND efflux system outer membrane lipoprotein 0.4 0.4 
Bmul_0194 beta-lactamase domain-containing protein 
 
2.2 
Bmul_0312 ABC transporter 0.5 0.5 
Bmul_1294 ABC transporter related 0.3 0.4 
Bmul_1356 ABC transporter related 1.7 
 
Bmul_1642 ABC transporter 2.3 
 
Bmul_1750 RND efflux system outer membrane lipoprotein 0.6 0.6 
Bmul_1751 efflux pump membrane protein 0.6 
 
Bmul_1768 Antibiotic biosynthesis monooxygenase 3.1 
 
Bmul_1866 RND efflux system outer membrane lipoprotein 0.3 0.5 
Bmul_1956 ABC transporter related 
 
0.5 
Bmul_2104 RND family efflux transporter MFP subunit 0.2 0.2 
Bmul_2427 ABC transporter related 0.4 
 
Bmul_2711 ABC transporter related 1.7 
 
Bmul_3313 beta-lactamase domain-containing protein 
 
0.6 
Bmul_4048 Beta-lactamase 
 
0.6 
Bmul_4052 ABC transporter related 0.4 0.4 
Bmul_4219 Antibiotic biosynthesis monooxygenase 
 
0.5 
Bmul_4303 beta-lactamase domain-containing protein 
 
2.4 
Bmul_4313 RND family efflux transporter MFP subunit 
 
0.7 
Bmul_4356 RND family efflux transporter MFP subunit 2 1.7 
Bmul_4684 RND efflux system outer membrane lipoprotein 0.3 
 
Bmul_4887 ABC transporter related 2.4 
 
Bmul_5001 ABC transporter related 0.3 0.4 
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Bmul_5647 Antibiotic biosynthesis monooxygenase 
 
0.5 
Bmul_5749 ABC-2 type transporter 2.2 
 
Bmul_5962 ABC transporter related 0.5 0.5 
Bmul_6151 RND efflux system outer membrane lipoprotein 0.6   
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Table 9.20 B. multivorans ATCC 17616 microarray data related to carbohydrate transport and metabolism.  
ATCC 17616   Fold change observed in growth condition 
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_0712 mannitol dehydrogenase domain-containing protein 3.5 
 
Bmul_2432 6-phosphogluconolactonase 4.3 
 
Bmul_2433 Glucokinase 0.5 
 
Bmul_3206 Monosaccharide-transporting ATPase 0.4 0.5 
Bmul_3245 carbon starvation protein CstA 3.6 
 
Bmul_3354 glucose-6-phosphate 1-dehydrogenase 2.1 
 
Bmul_5837 succinate dehydrogenase iron-sulfur subunit 1.9 
 
Bmul_5839 succinate dehydrogenase, hydrophobic membrane anchor protein 1.8 
 
Bmul_5840 succinate dehydrogenase, cytochrome b556 subunit 2.2 
 
Bmul_5961 Monosaccharide-transporting ATPase 0.3   
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Table 9.21 RNA-seq C1576 data summary of genes differentially expressed related to carbohydrate transport and metabolism. 
C1576 Function Fold-change in observed growth condition 
Locus ID   YEM vs. YEO YEG vs. non-mucoid YEM 
Bmul_0482 
PTS system N-acetylglucosamine-specific transporter subunit 
IIBC  
-17.7 
Bmul_0647 general substrate transporter 
 
-26.1 
Bmul_0699 sorbitol dehydrogenase 14.7 
 
Bmul_0712 mannitol dehydrogenase domain-containing protein 
 
-45.4 
Bmul_1163 phosphopyruvate hydratase 
 
-6 
Bmul_1711 ABC transporter-like protein 
 
-11.5 
Bmul_1712 monosaccharide-transporting ATPase 
 
-15.8 
Bmul_1713 periplasmic binding protein/LacI transcriptional regulator 
 
-9.9 
Bmul_2038 general substrate transporter 
 
-26.4 
Bmul_2428 
binding-protein-dependent transport systems inner membrane 
component  
-8.6 
Bmul_2429 
binding-protein-dependent transport system inner membrane 
protein  
-5.5 
Bmul_2430 extracellular solute-binding protein 
 
-7.8 
Bmul_2722 2-dehydro-3-deoxyphosphogluconate aldolase 
 
-8.5 
Bmul_2747 glyceraldehyde-3-phosphate dehydrogenase, type I 
 
-7.4 
Bmul_2784 ribokinase-like domain-containing protein 
 
-5.4 
Bmul_2968 N-acylglucosamine 2-epimerase 
 
-10.7 
Bmul_4153 major facilitator transporter 
 
-21.2 
Bmul_4154 mannonate dehydratase 
 
-48.4 
Bmul_4168 major facilitator transporter   -20.5 
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Table 9.22 B. multivorans ATCC 17616 microarray data that lists potential virulence factors. These include genes encoding for haemagglutinin-related proteins, 
phosphatases, lipases, lipoproteins, superoxide dismutases, adhesins, and phage-related genes. Motility and chemotaxis genes, as well as secretion-system related proteins 
are listed elsewhere but are also considered potential virulence factors.  
ATCC 17616   Fold change observed in growth condition  
Locus ID Function YEF vs. YEO YEM vs. YEO 
Bmul_0576 phospholipase D/Transphosphatidylase 
 
1.9 
Bmul_0753 Superoxide dismutase 2.9 2.7 
Bmul_0860 superoxide dismutase copper/zinc binding 1.7 1.6 
Bmul_1151 17 kDa surface antigen 0.1 0.1 
Bmul_1806 putative bacteriophage protein 
 
1.7 
Bmul_1815 putative bacteriophage protein 0.6 0.7 
Bmul_1914 acid phosphatase 2.0 9.3 
Bmul_1997 putative hemolysin-like protein 
 
3.0 
Bmul_2139 phospholipase C, phosphocholine-specific 
 
10.1 
Bmul_2410 lipopolysaccharide heptosyltransferase I 0.3 
 
Bmul_2496 lipopolysaccharide heptosyltransferase I 
 
2.1 
Bmul_2610 lipopolysaccharide biosynthesis protein 0.3 
 
Bmul_2951 phospholipase C, phosphocholine-specific 
 
17.2 
Bmul_3223 17 kDa surface antigen 
 
0.3 
Bmul_3271 phospholipase C, phosphocholine-specific 0.2 
 
Bmul_3329 17 kDa surface antigen 0.3 
 
Bmul_3343 YaeC family lipoprotein 1.5 1.8 
Bmul_3376 toxin ChpB 
 
0.5 
Bmul_3447 phospholipase D/transphosphatidylase 
 
7.9 
Bmul_3477 hemagluttinin domain-containing protein 0.1 0.2 
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Bmul_3522 hemagluttinin domain-containing protein 0.2 0.3 
Bmul_3709 Hemolysin-type calcium-binding region 12.5 4.7 
Bmul_4479 fimbrial biogenesis outer membrane usher protein 
 
0.2 
Bmul_4511 phospholipase/Carboxylesterase 1.7 1.6 
Bmul_4837 P2 family phage major capsid protein 2.0 4.0 
Bmul_4852 phage tail protein I 0.4 0.4 
Bmul_4860 putative phage-related tail transmembrane protein 0.3 0.4 
Bmul_4871 putative phage-encoded membrane protein 2.7 2.4 
Bmul_6272 integrase family protein 2.1 
 
Bmul_6273 hypothetical protein 2.7 
 
Bmul_6274 site-specific recombinase, phage integrase family protein 3.1   
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Table 9.23 B. multivorans C1576 RNA-seq data related to potential virulence factors. These include haemagglutinin-related proteins, phosphatases, lipases, 
lipoproteins, and adhesins. Motility and chemotaxis genes, as well as secretion-system related proteins are listed elsewhere but are also potential virulence factors. 
Including in this list are the novel adhesins discussed and characterised in Chapter 5, and screened for in the panel of isolates listed in Appendix Table 9.5. These adhesins 
are identified by bold script. Due to their absence in the genome of the environmental isolate B. multivorans ATCC 17616, adhesins were mapped to B. multivorans CGD1 
isolate and B. ambifaria MC0-40, based on NCBI BLAST searches for highest amino acid identify.   
C1576   Fold change observed in growth condition 
Locus ID Function YEM vs. YEO YEG vs. non-mucoid YEM 
Bmul_0195 rare lipoprotein A 
 
-10.9 
Bmul_0682 protease Do 8.1 
 Bmul_3252 hopanoid biosynthesis associated radical SAM protein HpnH 
 
-6.9 
Bmul_3709 hemolysin-type calcium-binding region 106.5 
 BURMUCGD1_3349 Fimbrial protein (1) 3.7 
 BURMUCGD1_3350 FimC 13.3 
 BURMUCGD1_3351 Fimbrial usher 7.0 
 BURMUCGD1_3352 Fimbrial protein (2) 4.6 
 BURMUCGD1_3353 Fimbrial protein (3) 2.5 
 MC406_6760 PPIase 1.7 
 MC406_6761 HecB-like 1.3 
 MC406_6763 FHA OMP (2) 1.7 
 MC406_6766 FHA OMP (1) 1.5   
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Table 9.24. Genes common to the Silva et al. data set. The table is not an exhaustive comparison but highlights key similarities and clusters of genes in common with the 
B. multivorans transcriptome study by Silva et al. (178). The data shown in the far right column compares differential gene expression of two clonal isolates, one mucoid 
one non-mucoid. The data presented in this table from Silva et al. simplified their findings to signify ‘D’ for gene decreased in expression or ‘U’ upregulated or enhanced in 
expression in their mucoid vs. non-mucoid isolate data. In this way, comparison between the mucoid vs. non-mucoid growth conditions explored in the present study and 
observations between the significant overlap between the two data sets can be made.  
      ATCC 17616 C1576  Silva et al.  
Locus 
Gene 
name Function  
 YEF vs. 
YEO  
  YEM vs. 
YEO 
 YEM vs. 
YEO 
  Mucoid vs. non-
mucoid 
Bmul_0042 fliN flagellar motor switch protein FliN 2.0 
  
U 
Bmul_0044 fliL flagellar basal body-associated protein FliL 3.1 
  
U 
Bmul_0159 
 
glycosyl transferase group 1 0.4 0.5 
 
D 
Bmul_0160 
 
transcriptional activator FlhD 
 
2.1 
 
U 
Bmul_0161 
 
transcriptional activator FlhC 
 
2.6 
 
U 
Bmul_0162 motA flagellar motor protein MotA 3.3 
  
U 
Bmul_0166 cheW CheW protein 2.1 
  
U 
Bmul_0167 
 
methyl-accepting chemotaxis sensory transducer 3.8 
  
U 
Bmul_0174 
 
hypothetical protein 3.0 
  
U 
Bmul_0176 flhA flagellar biosynthesis protein FlhA 2.4 
  
U 
Bmul_0305 gltB Glutamate synthase (ferredoxin) 
 
0.3 5.8 U 
Bmul_0306 gltD glutamate synthase subunit beta 2.5 2.2 10.4 U 
Bmul_0682 degP protease Do 0.01 0.01 -152.8 U 
Bmul_0712 mtlK mannitol dehydrogenase domain-containing protein 3.5 
  
U 
Bmul_1320 papA phage shock protein A, PspA 0.1 0.2 
 
D 
Bmul_2395 
 
porin 0.5 0.4 
 
U 
Bmul_2557 
 
LysR family transcriptional regulator 1.7 1.9 
 
U 
Bmul_2585 tolR protein TolR 
 
0.7 
 
D 
Bmul_2930 bcsL type VI secretion protein 1.6 1.5 
 
U 
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Bmul_3015 flgG flagellar basal body rod protein FlgG 2.5 
  
U 
Bmul_3018 
 
flagellar basal body rod modification protein 2.5 
  
U 
Bmul_3019 flgC flagellar basal body rod protein FlgC 5.3 
  
U 
Bmul_3060 fliE flagellar hook-basal body complex subunit FliE 0.6 
  
U 
Bmul_4598 fdh molybdopterin oxidoreductase Fe4S4 region 1.5 
  
D 
Bmul_4605 bceT UDP-glucose pyrophosphorylase 
  
4.3 U 
Bmul_4915 bceF exopolysaccharide tyrosine-protein kinase 0.3 
 
12.3 U 
Bmul_4916 bceE polysaccharide export protein 
  
59.3 U 
Bmul_4917 bceD protein tyrosine phosphatase 0.4 
  
U 
Bmul_4918 bceC undecaprenyl-phosphate glucose phosphotransferase 
  
21.5 U 
Bmul_4919 bceB undecaprenyl-phosphate glucose phosphotransferase 
  
28.8 U 
Bmul_4920 bceA mannose-1-phosphate guanylyltransferase   2.4 54.0 U 
 248 
 
Chapter 10: General conclusions and future work 
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10.1 Aims 
The purpose of this final chapter is to present general conclusions of each main 
body of work with respect to the main aims of the thesis and potential avenues 
for future work.  
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10.2 Summary 
The incidence of cystic fibrosis related diabetes (CFRD) is on the rise as 
patient life expectancy continues to improve. Sugars elevated in diabetics 
include glucose, fructose, and mannose. These sugars, in addition to mannitol 
(recently approved as an inhaled osmolyte for patients with cystic fibrosis) were 
the basis for this study, aimed at assessing the impact these clinically relevant 
sugars have on virulence in Burkholderia multivorans. Of these sugars, both 
mannitol and fructose induce exopolysaccharide (EPS) production, a putative 
virulence factor attributed to members of the Burkholderia cepacia complex 
(Bcc). B. multivorans is a member of the Bcc, and recent shifts in the 
epidemiology of the Bcc place B. multivorans as the dominant species in Bcc 
respiratory infections in patients with cystic fibrosis (CF). In contrast to B. 
cenocepacia, very little is known about the mechanisms of virulence in B. 
multivorans. 
Using an EPS-deficient knockout, Chapter 3 presented studies that first 
identified EPS-dependent and -independent virulence relevant phenotypes 
associated with growth on mannitol (mucoid) and mannose (non-mucoid). 
These phenotypes included mannitol enhanced invasion of alveolar epithelial 
cells, attenuation in the Galleria mellonella model of infection, increased biofilm 
formation and motility, and strain dependent enhanced adhesion to mucin. 
Crucially, including the EPS-deficient knockouts alongside B. multivorans wild-
types enabled differentiation between EPS phenotypes or those attributed to a 
broader sugar effect.  
In addition to phenotypic analysis of the B. multivorans sugar response, 
transcriptomic profiling was undertaken by microarray and RNA-seq to 
investigate the genetic basis for EPS production in two representative strains of 
B. multivorans. These studies were aimed to determine the genome-wide 
response of B. multivorans to relevant sugars. This has allowed correlation of 
gene expression changes (presented in Chapter 4) with some of the results 
from phenotypic studies (from Chapters 3 and 5) and provided insight into strain 
variation between the B. multivorans isolates in response to different sugars.   
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It was observed in both phenotypic studies and transcriptomic data that 
B. multivorans ATCC 17616 (an environmental strain) grown in mannitol 
resulted in enhanced motility relative to fructose or mannose grown cultures, in 
an EPS-independent manner. Microarray data confirmed the mannitol and 
fructose upregulated the flagella assembly and chemotaxis pathways (more so 
in mannitol than in fructose). In addition, B. multivorans C1576 (CF isolate) 
revealed the upregulation of the bce EPS cluster during growth on mannitol – 
thus confirming that although this strain is reported to produce more than one 
type of EPS (compared to ATCC 17616 which reportedly only produces 
cepacian). Interestingly, this was not the case from mannitol-or fructose-grown 
ATCC 17616, which did not enhance expression of key EPS biosynthesis genes 
following growth on these sugars.  
In Chapter 5, an observation from phenotypic studies in Chapter 3, which 
indicated the role for EPS in adherence to mucin was strain dependent, was 
further explored. EPS production positively correlated with the ability of ATCC 
17616 to adhere to mucin. The ability of the CF isolate C1576 to adhere to 
mucin was EPS independent. Whole genome sequencing of C1576 identified 
putative adhesins that were absent from ATCC 17616, namely a fimbrial locus 
and two distinct adhesins of the filamentous haemagglutinin (FHA) family. In 
Chapter 5 the present study went on to hypothesise that the presence of these 
putative adhesins in C1576 could explain the observed strain variation in 
adhesion, and went on to characterise these adhesins and assess the 
distribution within other clinical and environmental isolates of B. multivorans and 
the Bcc. Results indicated that the FHA locus was restricted to clinical B. 
multivorans isolates, and found almost exclusively in outbreak related isolates, 
whilst the fimbrial locus was widely distributed amongst clinical and 
environmental isolates. These adhesins (the first to be identified and described 
for B. multivorans) played a role in biofilm formation, adhesion to A549 human 
lung epithelial cells, and mucin. The RNA-seq dataset using mannitol-grown 
C1576 confirmed the upregulation of the three adhesins by mannitol, explaining 
the enhanced adhesion in the clinical isolate independent of EPS production.  
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Additional studies presented in Chapters 6 and 7 of this dissertation 
assessed the impact of growth on different sugars and sugar alcohols on the 
composition and biological activity of B. multivorans EPS. To carry out 
composition analysis mass spectrometry was used to compare composition of 
sugars known to be found in the Bcc cepacian repeat unit, to EPS extracts from 
ATCC 17616 and C1576 grown on mannitol or fructose. Due to technical 
difficulties with reproducibility, these composition analysis studies did not show 
any significantly altered EPS composition between strains or carbon sources. 
In Chapter 7, characterising biological activity of B. multivorans EPS was 
discussed. In iron toxicity, scavenging of reactive oxygen species (ROS) and 
desiccation protection assays, mannitol- and fructose-derived EPS resulted in 
strain-to-strain differences and variations between fructose- and mannitol-
derived EPS for both the clinical and environmental isolates. This variation in 
biological activity indicated the impact of different carbon sources on the 
biological activity of the EPS. 
Still relevant to CFRD, Chapter 8 assessed the ability of some members 
of the Bcc to bind insulin using fluorescent microscopy and fluorescent plate 
reader assays. Studies also showed using flow cytometry cell sorting and 
fluorescence microscopy that it is a small number of cells within a given 
population that bind insulin. Following fluorescence- activated cell sorting, 
insulin bound cells in repeated subculture were not enriched for insulin binding, 
and therefore these studies indicated that insulin binding occurs in a random 
subset of cells.   
Phenotypic studies have shed light on the role of EPS in virulence-
relevant assays, and linked this by transcriptomic study to highlight that sugars 
of clinical significance can alter bacterial behaviour significantly in vitro. Due to 
technical issues with reproducibility, it is inconclusive whether altering the 
carbon source that induces EPS production impacted on EPS composition, but 
it did influence biological activity of B. multivorans EPS. 
In all, this programme of study has added to the sparse knowledge base 
of B. multivorans virulence factors, including improving understanding of the 
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consequence and biological significance of EPS, identification and 
characterisation of the first adhesins described in B. multivorans. These 
adhesins were upregulated by mannitol and played a role in adhesion and 
biofilm formation, and creation of an improved method for carrying out EPS 
phenotypic studies by using an EPS deficient mutant alongside the wild-type 
strain to eliminate confusion between sugar effects versus EPS-dependent 
phenotypes.  
 
10.3 Future work  
With regards to future work leading on from studies presented in Chapter 
3, of great interest is the improvement of the macrophage assay by the creation 
of aminoglycoside-sensitive B. multivorans strains, using the elegant 
mutagenesis method described by Hamad et al. (86). Use of these antibiotic 
sensitive strains would mean fewer antibiotics (and much lower concentrations) 
required to kill off extracellular bacteria, and assurance that extracellular 
bacteria are entirely killed off.  Although efforts were made to construct 
gentamicin sensitive B. multivorans in the present study, attempts were 
unsuccessful. Preliminary trials using GFP-labelled B. multivorans and confocal 
microscopy were not carried on without gentamicin sensitive mutants. Another 
observation of interest for follow-up from data presented in Chapter 3 is the 
mannitol-enhanced survival of tobramycin-exposed biofilms. It would be 
interesting to extend this experiment to clinical isolates of B. multivorans, other 
aminoglycosides, and even other classes of antibiotics. The biofilm system used 
in Chapter 3 is a good in vitro model for studying these effects and with further 
work could define any connection between mannitol and biofilm aminoglycoside 
resistance, which could inform on antibiotics chosen to treat CF patients 
receiving mannitol therapy.  
In Chapter 4 the transcriptome profiles of two B. multivorans isolates 
indicated strain variation exists with regards to the impact of different sugar on 
the induction of EPS. Indeed, strains apparently varied in the pathways used in 
EPS production. The transcriptome studies enabled EPS regulation to be 
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assessed as well as broader impacts of different sugars on virulence relevant 
genes. Several transcriptional regulators common to both strains were 
upregulated in mucoid growth conditions would be excellent candidates for 
future mutagenesis studies to decipher EPS-regulation pathways. Study of such 
regulators would also include establishing how many of the EPS-independent 
genes or phenotypes are also controlled by these transcriptional regulators, and 
thus co-ordinately regulated in conjunction with EPS production. The 
identification and characterisation of transcriptional regulators upregulated in 
mucoid conditions would help explain the extensive overlap between the data 
set presented in Chapter 4 and mucoid/non-mucoid comparisons of B. 
multivorans clonal isolates such as those described by Silva et al. (178).  
Although the composition analysis of EPS from different carbon sources 
discussed in Chapter 6 requires different or improved methodologies to draw 
any definitive conclusions, in Chapter 7 studies of the impact of carbon source 
on EPS biological activity suggested that carbon source did impact on several 
phenotypes associated with stress survival. Thus it is clear further means to 
explore differences in the mannitol and fructose EPS composition would be 
worthwhile, using such technology as NMR to detect structural differences or 
polysaccharides other than cepacian that could influence the interaction 
between polysaccharides and host environment.  
Overall these responses to sugar and sugar alcohols are important to 
understand as they have potential influence on the course of a B. multivorans 
CF respiratory infection. As Bcc infected patients are notoriously varied in 
infection outcome, it is important to inform researchers and clinicians alike of 
the varied sugar response and significance of EPS in B. multivorans virulence.   
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